## Special Thanks to Distinguished Supporters of AACR Annual Meeting 2024

AACR gratefully acknowledges the generous support of individuals and organizations whose funding has made the AACR Annual Meeting 2024 possible.

### CURE LEVEL

*AstraZeneca*

Bristol Myers Squibb

Victoria's Secret Global Fund for Women's Cancers in Partnership with Pelotonia and AACR

### PROGRESS LEVEL

AbbVie Inc.

Daiichi Sankyo, Inc.

GSK

Merck & Co., Inc.

### PROMISE LEVEL

American Brain Tumor Association

American Cancer Society

Bayer

BeiGene

Boehringer Ingelheim

Breast Cancer Research Foundation

Cancer Research Institute

Change Our Future Fund

Eisai Inc.

Exelixis, Inc.

Fondazione Pezcoller

Genmab

Gilead and Kite Oncology

Incyte

Irving Weinstein Foundation

Janssen Pharmaceutical Companies of Johnson & Johnson

Loxo@Lilly
Ludwig Cancer Research
Novartis
Novocure
Pfizer, Inc.
Prostate Cancer Foundation
Pyxis Oncology
Sanofi
Science/AAAS
Selvita, Inc.
St. Baldrick's Foundation
Sygnature Discovery
Sylvia W. and Randle M. Kauders Foundation

## THE SCIENTIFIC PROGRAM

### Major Symposia
AstraZeneca
BeiGene
Dharma Master Jiantai Symposium
 in Biomarkers
Dharma Master Jiantai Symposium
 in Targeted Therapy

### Session
Dharma Master Jiantai Session
on Advances in Lung Cancer

### Advances in Hematological Malignancies Track
AstraZeneca

### Regulatory Science and Policy Track
Bristol Myers Squibb

## AACR AWARDS AND LECTURESHIPS

### AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
American Cancer Society

### AACR Award for Outstanding Achievement in Blood Cancer Research
AbbVie

### AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Cancer Research Institute

### AACR Gertrude B. Elion Cancer Research Award
GSK

### AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research
Loxo@Lilly

### AACR-Irving Weinstein Foundation Distinguished Lectureship
Irving Weinstein Foundation

### AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
Bristol Myers Squibb

**AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research**
St. Baldrick's Foundation

**AACR Team Science Award**
Loxo@Lilly

**Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research**
Fondazione Pezcoller

**AACR Outstanding Investigator Award for Breast Cancer Research**
Breast Cancer Research Foundation

**2024 AACR RUNNERS FOR RESEARCH 5k RUN/WALK**

**Presenting Sponsor**
AstraZeneca

**Enthusiast Sponsor**
Revolution Medicines

**AACR TRAVEL GRANTS AND SCHOLAR AWARDS**

**AACR Minority Scholar in Cancer Research Awards**
Change Our Future Fund
Gilead Sciences, Inc.
Incyte
Merck & Co., Inc.

**AACR Undergraduate Scholar Awards**
Science Translational Medicine/AAAS
Members of the AACR Science Education Committee
  Brian M. Rivers, MPH, PhD
  Kathleen W. Scotto, PhD
  John E. Leonard, MS, PhD
  Beverly D. Lyn-Cook, PhD
  Jose G. Trevino, MD

**AACR Women in Cancer Research Scholar Awards**
AstraZeneca
Gilead Sciences, Inc.
Victoria's Secret Global Fund for Women's Cancers in Partnership with Pelotonia and AACR

**Special Program for High School Students**
Change Our Future Fund

**AACR Scholar-in-Training Awards**
AbbVie Inc.
Alfred & Cathy Fraser
American Association for Cancer Research
American Brain Tumor Association
In Memory of Barbara Campbell Creighton
Breast Cancer Research Foundation
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Doreen J. Putrah Cancer Research Foundation
Fondazione Pezcoller
Gilead and Kite Oncology
Glenn Sykes
James V. Buzzitta, MD Family Fund
The John Kincade Scholarship Fund
The Estate of June L. Biedler
KidneyCAN
Ludwig Cancer Research
The Margaret Foti Foundation
Prostate Cancer Foundation
Sanofi
Sygnature Discovery
Warner Family

**AACR SCIENTIFIC WORKING GROUPS**

**AACR Cancer Immunology Working Group**
Bristol Myers Squibb

**AACR Chemistry in Cancer Research Working Group**
Selvita Inc.
Sygnature Discovery

**AACR Pediatric Cancer Working Group**
Sylvia W. and Randle M. Kauders Foundation

**AACR ANNUAL MEETING 2024 SUPPORTERS**

**AACR Advocacy Partners' Pavilion**
Pfizer, Inc.

**AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research Reception**
Loxo@Lilly

**Cancer and Biomedical Research Career Fair**
AstraZeneca

**Hotel Key Cards**
AstraZeneca

**Housing**
AstraZeneca

**Mobile Charging Stations**
Daiichi Sankyo, Inc.

**Online Registration**
AstraZeneca
Genmab

**Patient Advocacy Poster Session**
Pfizer, Inc.

**Professional Education Grants**
AbbVie
AstraZeneca
Boehringer-Ingelheim
Incyte
Merck
Novocure
AstraZeneca-Hematology
Beigine
Daiichi-Sankyo
Lilly
Novartis
Pfizer

**Seating Package**
Daiichi Sankyo, Inc.

**Scientist↔Survivor Program ®**
AbbVie
Bayer
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Exelixis, Inc.
Genmab
Janssen Pharmaceutical Companies of
        Johnson & Johnson
Loxo@Lilly
Merck & Co., Inc.
Novartis

**Women in Cancer Research Constituency Group (WICR)**
Novartis

**RESEARCH GRANTS AND FELLOWSHIPS**

AbbVie Inc.
Amgen, Inc.
AstraZeneca
Bayer
Bosarge Family Foundation
Breast Cancer Research Foundation
Bristol Myers Squibb
Cancer Research UK
Circle of Service Foundation
Conquer Cancer, the ASCO Foundation
The D-Team
Day One Biopharmaceuticals
Debbie's Dream Foundation
Exelixis, Inc.
Friends of the AACR Foundation, Party with a Purpose
Genentech, A Member of the Roche Group
Genmab
GSK
Incyte Corporation
The John and Elizabeth Leonard Family Foundation
Johnson & Johnson
KidneyCAN
Lobular Breast Cancer Alliance
Lustgarten Foundation
The Mark Foundation for Cancer Research
Merck & Co., Inc.
Mirati Therapeutics, Inc.
MPM BioImpact
Novocure
Ocular Melanoma Foundation
Pediatric Brain Tumor Foundation
Pfizer, Inc.
QuadW
The Sontag Foundation
St. Baldrick's Foundation
Stache Strong
Swim Across America
Takeda Pharmaceuticals
Triple Negative Breast Cancer Foundation

Victoria's Secret Global Fund for Women's Cancers in Partnership with Pelotonia and AACR

**SPECIAL CONFERENCE SUPPORTERS FOR 2023-2024**

AbbVie
Bayer
Boehringer Ingelheim
Bristol Myers Squibb
City of Hope
Delfi Diagnostics
Janssen
Leerink Partners
Let's Win Pancreatic Cancer
Lobular Breast Cancer Alliance (LBCA)
Loxo@Lilly
Lustgarten Foundation
Mirati Therapeutics
Novocure
Pfizer
Reaction Biology Corporation
Rivkin Center for Ovarian Cancer
Royalty Pharma
Sanofi
Sontag Foundation
Syros Pharmaceuticals
University of Miami Sylvester Comprehensive Cancer Center
Verastem Oncology

## SUSTAINING MEMBERS

### Leadership Sustaining Members

AstraZeneca

Bayer

Boehringer Ingelheim International GmbH

Bristol Myers Squibb

Genentech, A Member of the Roche Group

Loxo@Lilly

Merck & Co., Inc.

Pfizer, Inc.

Takeda Pharmaceutical

### Strategic Sustaining Members

AbbVie

Amgen, Inc.

Eisai Inc.

Gilead and Kite Oncology

GSK

Incyte Corporation

Novartis

### Major Sustaining Members

Daiichi Sankyo, Inc.

Exelixis, Inc.

Fondazione Pezcoller

Genmab

Johnson & Johnson Innovative Medicine

Jazz Pharmaceuticals

Novocure

Regeneron

Sanofi

### Associate Sustaining Members

Exact Sciences Corp

GRAIL

Karyopharm Therapeutics

QIAGEN Sciences, Inc.

Servier

Verastem Oncology

Zai Lab

# Friday, April 5, 2024

## Professional Advancement Session • 1:00 p.m.–4:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Grand Hall A - Manchester Grand Hyatt San Diego
**Grant Writing Workshop: Tips for Success from Experienced Scientists**

**Cochairs:** Oliver Bogler, Bethesda, MD; Mariana C. Stern, Los Angeles, CA; Tiffany A. Wallace, Rockville, MD; Mathias Seviiri, Herston, Queensland, Australia

**Welcome from AACR Science Education and Career Advancement Committee Chair.** Brian M. Rivers, Atlanta, GA
**Opening Remarks.** Mariana C. Stern, Los Angeles, CA

**Types of grants and how to identify them and work with funding organization.** Tiffany A. Wallace, Rockville, MD

**UK and European funding opportunities.** Lorenzo De La Rica, London, United Kingdom

**Elements of the grant.** Oliver Bogler, Bethesda, MD

**Mock grant review (R-type).** Oliver Bogler, Bethesda, MD

**Response to Summary Statement.** Shahrooz Vahedi, Bethesda, MD

**Why write a grant and how to keep going when you feel like you can't.** Robert A. Winn, Richmond, VA

**Closing Remarks and Evaluation.** Oliver Bogler, Bethesda, MD

## CME Educational Sessions • 3:00 p.m.–4:30 p.m.

Room 28, Convention Center
### Are You Targeting Your Protein?

**Chair:** Susanne Müller-Knapp, Frankfurt, Germany

**Chair Introduction.** Susanne Müller-Knapp, Frankfurt, Germany

**Choosing and using small-molecule tools to investigate protein targets.** Susanne Müller-Knapp, Frankfurt, Germany

**Combined use of orthogonal genetic and small-molecule inhibitors for biological exploration, target validation and therapeutic pathfinder studies.** Paul Workman, London, United Kingdom

**Chemical probe case studies, TAOK3 and SUV420H.** Paul Brennan, Oxford, United Kingdom

Ballroom 20 AB, Convention Center
### Determinants and Meanings of T Cell Recognition, Exhaustion, and Persistence

**Chair:** James R. Heath, Pasadena, CA

**Chair Introduction.** James R. Heath, Pasadena, CA

**T cell exhaustion and relevance in cancer immunology.** E. John Wherry, Philadelphia, PA

**Predicting the T cell characteristics of recognition, exhaustion, and persistence: Limitations and opportunities.** James R. Heath, Pasadena, CA

**Metabolic and neural regulation of immunity and cancer.** Tak W. Mak, Toronto, ON, Canada

Room 30, Convention Center
### Evolving Insights on the Microbiome in Cancer

**Chair:** Ami S. Bhatt, Stanford, CA

**Chair Introduction.** Ami S. Bhatt, Stanford, CA

**From precise microbial genomics to precision medicine.** Ami S. Bhatt, Stanford, CA

**Microbiome regulation of anti-tumor immunity through myeloid cells.** Thomas F. Gajewski, Chicago, IL

**Overcoming microbiome dependent resistance to cancer immunotherapy.** Francesca S. Gazzaniga, Boston, MA

Ballroom 6 CF, Convention Center
**Integrating Evolutionary Principles into Clinical Trial Design and Analysis**

**Chair:** Robert A. Gatenby, Tampa, FL

**Chair Introduction.** Robert A. Gatenby, Tampa, FL

**Evolutionary principles for optimizing cancer therapy and lessons learned in pilot trials.** Robert A. Gatenby, Tampa, FL

**Applying evolutionary medicine strategies in the real world.** Kenneth J. Pienta, Glen Arm, MD

**The critical role of small populations in clinical trial design.** Damon R. Reed, New York, NY


Ballroom 6 DE, Convention Center
**Measuring Structural and Social Determinants of Health in Cancer Research**

**Chair:** Salma Shariff-Marco, San Francisco, CA

**Chair Introduction.** Salma Shariff-Marco, San Francisco, CA

**The psychobiology of racism-related stress: Current research and emerging directions.** Amani Allen, Berkeley, CA

**Cancer disparities by socioeconomic deprivation and time: Analyzing persistent poverty.** Jennifer L. Moss, Hershey, PA

**Characterizing social and built environments in cancer epidemiology cohorts: Geospatial data and methods.** Salma Shariff-Marco, San Francisco, CA


Ballroom 6 B, Convention Center
**Studying the Functional Role of the Tumor Microenvironment in Cancer Disparities**

**Chair:** Melissa B. Davis, Atlanta, GA

**Chair Introduction.** Melissa B. Davis, Atlanta, GA

**The DARC side of breast cancer immunological responses.** Melissa B. Davis, Atlanta, GA

**Title to be announced.** Clayton C. Yates, Baltimore, MD

**Nativity, ancestry and TME of breast and ovarian cancers.** Sophia H. George, Miami, FL


Ballroom 20 CD, Convention Center
**What is the State of the Art in Functional Precision Medicine?**

**Chair:** Anthony Letai, Boston, MA

**Chair Introduction.** Anthony Letai, Boston, MA

**Functional precision medicine: The future is functional.** Anthony Letai, Boston, MA

**Clinical utility and accessibility of functional precision medicine for relapsed/refractory pediatric**

**and adult cancers.** Diana Azzam, Miami, FL

**Towards routine implementation of image-based single-cell functional precision medicine.** Berend Snijder, Zurich, Switzerland

## `CME` Methods Workshop • 3:00 p.m.–4:30 p.m.

Ballroom 6 A, Convention Center
**A Preview into Single-cell Data Analysis for Bench-based Scientists**

**Chair:** Roshan Sharma, New York, NY

**Chair Introduction.** Roshan Sharma, New York, NY

**Pre-processing of single-cell RNA-seq data.** Roshan Sharma, New York, NY

**Clustering and biological interpretation of single-cell RNA-seq data.** Orr Ashenberg, Cambridge, MA

## `CME` Educational Sessions • 4:45 p.m.–6:15 p.m.

Ballroom 6 A, Convention Center
**A Systems Approach to Cancer Early Detection**

**Chair:** Gerrit A. Meijer, Amsterdam, Netherlands

**Chair Introduction.** Gerrit A. Meijer, Amsterdam, Netherlands

**Fine tuning population-based screening programs, which knobs to turn?** Gerrit A. Meijer, Amsterdam, Netherlands

**Exposome, environmental risk factors, and cancer early detection.** Roel Vermeulen, Utrecht, Netherlands

**Health technology assessment in early cancer detection, putting the pieces of the puzzle in perspective.** Veerle M. Coupé, Amsterdam, Netherlands

Ballroom 6 B, Convention Center
**Chemistry to the Clinic Part 1 of 3: Targeted Protein Degraders - Delivering Degraders to the Site of Action**

**Chair:** Keith R. Hornberger, New Haven, CT

**Chair Introduction.** Keith R. Hornberger, New Haven, CT

**Strategies for PROTAC degrader oral delivery and targeting to the site of action.** Keith R. Hornberger, New Haven, CT

**Title to be announced.** Gwenn Hansen, San Francisco, CA

**Targeted PROTAC delivery: Principles of crafting PROTAC-ADCs and self-assembling PROxAb shuttles.** Marcel Rieker, Darmstadt, Germany

Ballroom 20 AB, Convention Center
**Implementing Alternative Manufacturing and Delivery Models to Improve Access to CAR-T Therapy**

**Chair:** Robert Holt, Vancouver, BC, Canada

**Chair Introduction.** Robert Holt, Vancouver, BC, Canada

**Title to be announced.** Rayne H. Rouce, Houston, TX

**The CLIC point-of-care manufacturing platform for CAR-T clinical trials in Canada.** Natasha Kekre, Ottawa, ON, Canada

**A non-profit approach to cell and gene therapy: Lowering costs to advance equity.** Rimas J. Orentas, Seattle, WA

Ballroom 20 CD, Convention Center
**Organoid Models of Human Cancer Evolution**

**Chair:** Suet Yi Leung, Pokfulam, China

**Chair Introduction.** Suet Yi Leung, Pokfulam, China

**Unraveling the role of cell-cell and cell matrix adhesion dependency in cancer evolution using human gastric organoids.** Suet Yi Leung, Pokfulam, China

**Unraveling childhood tumorigenesis using organoid technology.** Jarno Drost, Utrecht, Netherlands

**Modeling therapy resistance and metastasis using patient-derived organoids.** Karuna Ganesh, New York, NY

**CME** **Method Workshops** • 4:45 p.m.–6:15 p.m.

Room 30, Convention Center
**Characterizing Complex Structural Variation and 3D Genome Architecture**

**Chair:** Jan Korbel, Heidelberg, Germany

**Introduction.** Jan Korbel, Heidelberg, Germany

**Deciphering complex genomic rearrangement processes through systematic coupling of imaging and single-cell sequencing.** Jan Korbel, Heidelberg, Germany

**Decoding the evolutionary trajectories of complex genomic rearrangements in cancer using long-read sequencing.** Isidro Cortes Ciriano, Cambridge, United Kingdom

**Mechanisms driving complex genomic rearrangements at micronuclei.** John Maciejowski, New York, NY

Ballroom 6 CF, Convention Center
**Clinical Trial Design Workshop, Part 1: Increasing Racial and Ethnic Diversity in Clinical Trials: New Solutions for Old Problems**

**Chair:** Susan Halabi, Durham, NC

**Chair Introduction.** Susan Halabi, Durham, NC

**Exploring patient enrollment patterns and challenges in cancer clinical trials.** Susan Halabi, Durham, NC

**The ASCO TAPUR Study: How pragmatic design can improve diversity in clinical trials.** Richard L. Schilsky, La Grange, IL

**The power of asking and its impact on cancer health!** Robert A. Winn, Richmond, VA

Ballroom 6 DE, Convention Center
**How Can We Improve the Quality of Research with Antibody Reagents in Cancer Research?**

**Chair:** Aled Edwards, Toronto, ON, Canada

**Chair Introduction.** Aled Edwards, Toronto, ON, Canada

**Finding the right antibody for your cell biology application: Google is not the answer.** Aled Edwards, Toronto, ON, Canada

**Recombinant antibody approaches for dependable performance and reproducibility.** Alejandra Solache, Cambridge, United Kingdom

**Antibody identification in the scientific literature, how can RRIDs help find antibodies and their problems?** Anita Bandrowski, LaJolla, CA

# Professional Advancement Session • 5:00 p.m.–7:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall C - Manchester Grand Hyatt San Diego
**How to Design a Successful Career Path in Cancer Research: The Do's and Don'ts for Early-Stage Investigators**

**Cochairs:** Lissette Delgado-Cruzata, Bronx, NY; Christine M. Lovly, Nashville, TN; Jose G. Trevino, Gainesville, FL; SeongJun Han, Boston, MA

# Saturday, April 6, 2024

## CME Educational Sessions • 8:00 a.m.–9:30 a.m.

Ballroom 20 CD, Convention Center
**A Decade of Cancer Vaccines: Dedicated to the Memory of Harald zur Hausen**

**Chair:** Jay A. Berzofsky, Bethesda, MD

**Chair Introduction.** Jay A. Berzofsky, Bethesda, MD

**Dendritic cell vaccine successes and failures.** Lisa H. Butterfield, San Francisco, CA

**Neoantigen vaccines for cancer interception in high-risk populations.** Eduardo Vilar-Sanchez, Houston, TX

**Cancer vaccines as a key synergistic leg of the immunotherapy stool.** Jay A. Berzofsky, Bethesda, MD

Ballroom 20 AB, Convention Center
**Beyond CD8 T Cells: Targeting CD4 T Cells in Cancer**

**Chair:** Elise Alspach, St. Louis, MO

**Chair Introduction.** Elise Alspach, St. Louis, MO

**Sex based differences in regulatory CD4 T cells.** Elise Alspach, St. Louis, MO

**Targeting the tumor microenvironment with CD4+ T cells.** Joshua Veatch, Seattle, WA

**Harnessing cytotoxic CD4 T cells and their TCRs for cancer immunotherapy.** Camilla Jandus, Geneva, Switzerland

Room 31, Convention Center
**Chemo-proteomics Approaches in Drug Discovery**

**Chair:** Eric S. Fischer, Boston, MA

**Chair Introduction.** Eric S. Fischer, Boston, MA

**Chemo-proteomics strategies for the discovery of degraders.** Eric S. Fischer, Boston, MA

**Cysteine chemoproteomics to expand the scope of the druggable proteome.** Keriann Backus, Los Angeles, CA

**Proteomics to uncover the dark matter of the cancer proteome.** Alan Saghatelian, La Jolla, CA

Ballroom 6 CF, Convention Center
**Data Science Opportunities and Challenges in Biomarker-based Early Detection of Cancer**

**Chair:** Robert B. Scharpf, Baltimore, MD

**Chair Introduction.** Rob Scharpf, Baltimore, MD

**Features and data.** Paul A. Scheet, Houston, TX

**Models and prediction.** Rob Scharpf, Baltimore, MD

**Performance and populations.** Ruth D. Etzioni, Seattle, WA

Ballroom 6 A, Convention Center
**Development and Evaluation of Drug Response Predictors for Precision Oncology**

**Chair:** Benjamin Haibe-Kains, Toronto, ON, Canada

**Chair Introduction.** Benjamin Haibe-Kains, Toronto, ON, Canada

**Assembling digital tumor cells for precision oncology.** Trey Ideker, La Jolla, CA

**Bridging pre-clinical drug screening with patient molecular profiles for biomarker discovery and drug development.** R. Stephanie Huang, Minneapolis, MN

**Hallmarks of drug response models: A qualitative framework to evaluate multivariable predictive biomarkers.** Benjamin Haibe-Kains, Toronto, ON, Canada

Room 11, Convention Center
**Existing and Emerging Cohort Study Resources for Future Discoveries**

**Chair:** Mia M. Gaudet, Bethesda, MD

**Chair Introduction.** Mia M. Gaudet, Bethesda, MD

**UK Biobank: An existing cohort.** Megan Conroy, Headington, United Kingdom

**DISCERN: Triangulating data from cohort and experimental studies to identify novel causes of cancer.** Marc Gunter, London, United Kingdom

**Connect for Cancer Prevention Study: An emerging cohort.** Mia M. Gaudet, Bethesda, MD

Room 33, Convention Center
**Gene-Environment Interactions Driving Carcinogenesis**

**Chair:** Ashok R. Venkitaraman, Singapore, Singapore

**Chair Introduction.** Ashok R. Venkitaraman, Singapore, Singapore

**Molecular biologic and epidemiologic insights for preventability of colorectal cancer.** Edward L. Giovannucci, Boston, MA

**Somatic mutagenesis and gene-environment links in carcinogenesis.** Inigo Martincorena, Cambridge, United Kingdom

**Metabolic triggers in cancer evolution.** Ashok R. Venkitaraman, Singapore, Singapore

Room 30, Convention Center
**Illuminating the Genomic "Dark Matter" in Cancer: The Role of Non-Coding Elements in Cancer and Aging**

**Chair:** Laszlo G. Radvanyi, Toronto, ON, Canada

**Chair Introduction.** Laszlo G. Radvanyi, Toronto, ON, Canada

**Dissemination of retrotransposable elements in extracellular vesicles as drivers of chronic inflammation and cancer progression.** Laszlo G. Radvanyi, Toronto, ON, Canada

**Repetitive RNAs as non-coding biomarkers of cancer.** Daniel Kim, Santa Cruz, CA

**Transposable elements and immunity.** Douglas Nixon, New York, NY

Ballroom 6 B, Convention Center
**Lineage Plasticity in Tumor Evolution and Acquired Resistance**

**Chair:** Charles M. Rudin, New York, NY

**Chair Introduction.** Charles M. Rudin, New York, NY

**Lineage plasticity and resistance to targeted agents in lung cancer.** Katerina A. Politi, New Haven, CT

**Tumor escape routes from effective targeted therapies - dedifferentiation, trans-differentiation; and resulting vulnerabilities - ferroptosis.** Thomas G. Graeber, Los Angeles, CA

**Strategies to constrain lineage plasticity in lung and prostate cancer.** Charles M. Rudin, New York, NY

Room 5, Convention Center
**Team Science: How to Form and Manage a Multidisciplinary Cancer Research Team**

**Chair:** Aadel A. Chaudhuri, St. Louis, MO

**How team science led to a change in clinical practice: screening for Lynch syndrome in endometrial cancer.** Emma J. Crosbie, Macclesfield, United Kingdom

**Team science: The gynecology trainee's perspective.** Neil A. J. Ryan. United Kingdom
**Team science: The pathologist's perspective.** Ray McMahon, Macclesfield, United Kingdom
**Team science: The pathologist's perspective.** James Bolton, Macclesfield, United Kingdom
**Team science: The health psychologist's perspective.** Louise Gorman, Macclesfield, United Kingdom
**Team science: The health economist's perspective**. Katherine Payne, Macclesfield, United Kingdom
**Team science: The cytopathologist's perspective.** Durgesh Rana, Macclesfield, United Kingdom
**Team science: The cytopathologist's perspective.** Nadira Narine, Macclesfield, United Kingdom

Ballroom 6 DE, Convention Center
**Theranostics: The Nuts and Bolts**

**Cochairs:** Kayvan R. Keshari, New York, NY; Julie L. Sutcliffe, Windsor, CA

**Chair Introduction.** Kayvan R. Keshari, New York, NY

**Chemistry and biological considerations in theranostics.** Bernadette V. Marquez-Nostra, Birmingham, AL

**Radiothernostics in the clinic: Past, present, and future.** Freddy E. Escorcia, Bethesda, MD

# CME **Methods Workshops** • 8:00 a.m.–9:30 a.m.

Room 28, Convention Center
**Analytic Resources and Applications for AACR Project GENIE BPC Clinico-genomic Data**

**Chair:** Katherine Panageas, New York, NY

**Chair Introduction.** Katherine Panageas, New York, NY

**Introduction.** Alexander Paynter, Seattle, WA

**Workshop Presenter: A clinico-genomic data processing pipeline using the {genieBPC} R package.** Katherine Panageas, New York, NY

**Workshop Presenter: A clinico-genomic data processing pipeline using the {genieBPC} R package.** Samantha Brown, New York, NY

**Pan-cancer mutational signature analysis of 111,711 targeted sequenced tumors using SATS.** Bin Zhu, Bethesda, MD

Room 29, Convention Center
**Biostatistics in Clinical Trials Workshop: Out of the Rut and Beyond the Traditional, Part 1 - Design and Implementation of Novel Phase 1 and 2 Clinical Trials**

**Chair:** Wendy B. London, Boston, MA

**Introduction.** Wendy B. London, Boston, MA

**Implementation of novel dose-finding designs in early phase trials.** Nolan A. Wages, Richmond, VA

**Implementation of phase 1 that use Bayesian adaptive designs.** Wendy B. London, Boston, MA

**Trial designs in pediatric cancers and rare tumors: Constraints, opportunities, and solutions.** Lindsay A. Renfro, Los Angeles, CA

# Cancer and Biomedical Research Career Fair • 9:00 a.m.–3:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Hall F, Convention Center
**AACR Cancer and Biomedical Research Career Fair**

# CME Educational Sessions • 10:00 a.m.–11:30 a.m.

Ballroom 20 AB, Convention Center
**The Emerging Role of Liquid Biopsies in the Cancer Care Continuum**

**Chair:** Ellen Heitzer, Graz, Austria

**Chair Introduction.** Ellen Heitzer, Graz, Austria

**ctDNA-based clinical decision making in advanced cancer.** Ellen Heitzer, Graz, Austria

**ctDNA approaches for therapy response monitoring.** Valsamo K. Anagnostou, Baltimore, MD

**ctDNA as high-risk biomarker in early cancer.** Christopher Abbosh, Boston, MA

Room 5, Convention Center
**Entrepreneurship: Interacting with Regulatory Agencies**
**NOT ELIGIBLE FOR CME CREDIT**

**Chair:** William N. Hait, New Brunswick, NJ

**Panelists:**
Renu Vaish, La Jolla, CA
Levi A. Garraway, San Francisco, CA
Jeff L. Summers, Silver Spring White Oak, MD
Jeff D. Allen, Washington, DC

Ballroom 6 A, Convention Center
**Host Predisposing Stroma in Cancer Development and Progression**

**Chair:** Edna Cukierman, Philadelphia, PA

**Chair Introduction.** Edna Cukierman, Philadelphia, PA

**Role of emergency granulopoiesis in metastases.** Ilaria Malanchi, London, United Kingdom

**Mapping the spatial architecture of the TME in lung tumor evolution.** Charles Swanton, London, United Kingdom

**Utilization of geospatial data to explore the impact of the social macroenvironment on tumor microenvironment.** Shannon M. Lynch, Philadelphia, PA

Room 1, Convention Center
**Navigating Laboratory Developed Tests in Oncology: Emerging Needs and Opportunities**

**Moderator:** Anthony Letai, Boston, MA

**Panelists**:
Keith L. Ligon, Boston, MA
Bryce Portier, Stamford, CT
Sheila Walcoff, Gaithersburg, MD

Ballroom 6 DE, Convention Center
**Race, Ethnicity, and Genetic Ancestry in Research: Leveraging Value While Avoiding Harms**

**Chair:** Mindy C. Hebert-DeRouen, San Francisco, CA

**Chair Introduction.** Mindy C. Hebert-DeRouen, San Francisco, CA

**Designing research that appropriately reflects understanding of race, ethnicity, and genetic ancestry.** Mindy C. Hebert-DeRouen, San Francisco, CA

**Critically evaluating racial and ethnic categories, continental labels, and measures of genetic similarity in genomic medicine.** Alice P. Popejoy, Sacramento, CA

**Problematic assumptions about race and genetic ancestry in disease etiology, diagnostics and treatment.** Amy Non, San Diego, CA

Ballroom 6 CF, Convention Center
**The Reimagined Cell Cycle in 2024: Implications for Cancer**

**Chair:** Jan Skotheim, Stanford, CA

**Chair Introduction.** Jan Skotheim, Stanford, CA

**The G1/S transition is promoted by Rb degradation via the E3 ligase UBR5.** Jan Skotheim, Stanford, CA

**Long-term anti-proliferative effects of CDK4/6 inhibitors.** Alexis R. Barr, London, United Kingdom

**New insights into flexible cell cycle progression.** Steven D. Cappell, Bethesda, MD

Ballroom 6 B, Convention Center
**Stressing Out About Treatment Resistance: Progress and Challenges**

**Chair:** Sanjay V. Malhotra, Portland, OR

**Chair Introduction.** Sanjay V. Malhotra, Portland, OR

**Stressing YB1 to combat resistance to cancer treatment.** Sanjay V. Malhotra, Portland, OR

**Targeting ER stress to overcome resistance to cancer immunotherapy.** Juan R. Cubillos-Ruiz, New York, NY

**ADAPT: A new ARPA-H program targeting metastatic cancer evolution.** Andrea H. Bild, Monrovia, CA
Ballroom 20 CD, Convention Center
**Tumor Immunology and Immunotherapy for Non-Immunologists Session: Strategies for Enhancing Adoptive Cellular Immunotherapy and Reprogramming the Tumor Microenvironment**

**Chair:** Marco Ruella, Philadelphia, PA

**Introduction.** Marco Ruella, Philadelphia, PA
**Catch me if you can: Resistance to CART therapy.** Marco Ruella, Philadelphia, PA

**Overcoming barriers from the tumor microenvironment for effective TCR-T cell therapies.** Richard C. Koya, Saint John, IN

**Unlocking T cell potency by reprogramming the TME: Focusing on myeloid cells.** Barbara Savoldo, Chapel Hill, NC

**Uncovering hidden targets for adoptive cellular therapy in ovarian cancer.** Kunle Odunsi, Chicago, IL

Room 30, Convention Center
**Understanding and Improving Replicability in Cancer Biology**

**Chair:** Giovanni Parmigiani, Boston, MA

**Chair Introduction.** Giovanni Parmigiani, Boston, MA

**Lessons learned from a large-scale project investigating the replicability of preclinical cancer biology.** Timothy Errington, Charlottesville, VA

**Experimental design: A foundation for replicability in discovery of biomarkers for early detection of cancer.** Ann L. Oberg, Rochester, MN

**Open replicability issues in cancer research.** Giovanni Parmigiani, Boston, MA

# CME **Methods Workshops** • 10:00 a.m.–11:30 a.m.

Room 29, Convention Center
**Biostatistics in Clinical Trials Workshop: Out of the Rut and Beyond the Traditional, Part 2 - Designing Pivotal Phase 3 Trials for Regulatory Approval of New Agents or New Indications**

**Chair:** Wendy B. London, Boston, MA

**Introduction.** Wendy B. London, Boston, MA

**Multiplicity considerations in cancer research.** Frank Bretz, Basel, Switzerland

**Improved use of PROs as endpoints in clinical trials.** John Peipert, Chicago, IL

**Biomarker-driven designs.** Mary W. Redman, Seattle, WA; Susan Halabi, Durham, NC

Room 31, Convention Center
**Innovative Software Analytics for Pediatric Cancer Clinical Testing**

**Chair:** Elaine R. Mardis, Columbus, OH

**Chair Introduction.** Elaine R. Mardis, Columbus, OH

**Comparative analysis of RNA expression in the pediatric oncology clinic.** Olena M. Vaske, Santa Cruz, CA

**Using a scalable RNA-based platform as a diagnostic aid for cancer.** Adam Shlien, Toronto, ON, Canada

**The Automated Variant Analysis Toolkit: Facilitating variant classification and sign-out.** Elaine R. Mardis, Columbus, OH

Room 28, Convention Center
**Lineage Tracing in Cancer**

**Chair:** Trevor Graham, London, United Kingdom

**Chair Introduction.** Trevor Graham, London, United Kingdom

**Deciphering somatic evolution and clonal dynamics in normal tissues using whole genome sequencing data.** Raheleh Rahbari, Cambridge, United Kingdom

**Single cell mapping of phenotypes and lineages in human somatic evolution.** Anna S. Nam, New York, NY

**Fluctuating methylation for lineage tracing.** Trevor Graham, London, United Kingdom

Room 33, Convention Center
**Pathology for Cancer Researchers**

**Chair:** Angelo M. De Marzo, Baltimore, MD

**Chair Introduction.** Angelo M. De Marzo, Baltimore, MD

**Antibody validation, multiplex IHC/ in situ hybridization with image analysis for human and mouse tissues.** Angelo M. De Marzo, Baltimore, MD

**Integrating spatial transcriptomics with additional data modalities to unlock biological insights.** Ken S. Lau, Nashville, TN

**Tissue processing and process optimization for high-throughput solid-phase spatial multi-omics.** Sanja Vickovic, New York, NY

# Career Development Forum • 11:00 a.m.–3:45 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Harbor Ballroom GHI - Manchester Grand Hyatt San Diego
**Women and Power Workshop: Advancing and Securing Your Career in Science**

**Chair:** Beverly D. Lyn-Cook, Jefferson, AR
*Preregistration Required: Sign up at aacr.org/women*

# CME Educational Sessions • 12:30 p.m.–2:00 p.m.

Ballroom 6 CF, Convention Center
**Chemistry to the Clinic Part 2 of 3: Considerations in the Discovery of Small Molecules Targeting RNA**

**Chair:** Kathleen McGinness, Waltham, MA

**Chair Introduction.** Kathleen McGinness, Waltham, MA

**Discovery of RNA-targeted small molecule therapeutics.** Kathleen McGinness, Waltham, MA

**Illuminating small molecule recognition of RNAs for medicinal chemistry.** John Schneekloth, Frederick, MD

**Opportunities for targeting RNA-protein interactions for cancer drug discovery.** Amanda Garner, Ann Arbor, MI

Ballroom 6 DE, Convention Center
**Clonal Hematopoiesis: Translational and Clinical Updates and Implications**

**Chair:** Kelly Bolton, St. Louis, MO

**Chair Introduction.** Kelly Bolton, St. Louis, MO

**Clonal hematopoiesis and prevention of hematologic malignancies.** Kelly Bolton, St. Louis, MO

**Beyond the marrow: Clonal hematopoiesis in solid tumors - coincidence or consequence.** Catherine C. Coombs, Orange, CA

**Metabolism in clonal hematopoiesis: Lessons learned from AML and vice versa.** Aaron Schimmer, Toronto, ON, Canada

Room 29, Convention Center
**Dissecting the Landscape of Genotype-Matched Precision Oncology: Preclinical and Clinical Applications**

**Chair:** Valsamo K. Anagnostou, Baltimore, MD

**Chair Introduction.** Valsamo K. Anagnostou, Baltimore, MD
**Learning from real world patient data to inform precision oncology: Variant interpretation and outcome prediction.** Nikolaus Schultz, New York, NY

**Genotype-driven medicine: current standard and future perspectives for clinical care.** Christine M. Lovly, Nashville, TN

**Precision oncology decision support efforts to enhance genotype-matched medicine, challenges and opportunities.** Valsamo K. Anagnostou, Baltimore, MD

Room 33, Convention Center
**Germline Genetic Testing in Cancer: Who, What and When?**

**Chair:** Allison W. Kurian, Stanford, CA

**Chair Introduction.** Allison W. Kurian, Stanford, CA

**Clinical genetic testing, results, and management: A population-level view.** Allison W. Kurian, Stanford, CA

**Leveraging tumor genomic analysis to guide germline variant interpretation.** Michael F. Berger, New York, NY

**TP53 in germline genetic testing: From Li Fraumeni syndrome to clonal hematopoiesis.** Kara N. Maxwell, Philadelphia, PA

Ballroom 6 B, Convention Center
**The Good and the Bad of Myeloid Cells in Cancer**

**Chair:** Alberto Mantovani, Pieve Emanuele, Italy

**Chair Introduction.** Alberto Mantovani, Pieve Emanuele, Italy

**The Yin-Yang of innate immunity and inflammation in cancer.** Alberto Mantovani, Pieve Emanuele, Italy

**Myeloid-mediated T cell suppression: Vulnerabilities for therapeutic targeting.** Lisa M. Coussens, Portland, OR

**Tumor-resident myeloid cell heterogeneity as revealed by single cell sequencing.** Zemin Zhang, Beijing, China


Room 31, Convention Center
**Metabolic Dependencies and Adaptations in Cancer**

**Chair:** Cosimo Commisso, La Jolla, CA

**Chair Introduction.** Cosimo Commisso, La Jolla, CA

**Metabolic adaptations to glutamine targeting in cancer.** Cosimo Commisso, La Jolla, CA

**Determinants of cysteine essentiality in cancer.** Gina M. DeNicola, Tampa, FL

**Catabolism of extracellular GSH supplies amino acids to tumors.** Isaac Spencer Harris, Rochester, NY


Room 1, Convention Center
**Rethinking Risk and Risk Assessment for Liquid Biopsy-Based Single- and Multi-Cancer Screening**

**Moderator**: Lauren C. Leiman, Charleston, IL

**Panelists**:
Jeff D. Allen, Washington, DC
Christina A. Clarke Dur, Menlo Park, CA
Elizabeth K. O'Donnell, Boston, MA
Bree Mitchell, San Carlos, CA
Wendy Rubinstein, Rockville, MD
Victoria M. Raymond, Redwood City, CA

Room 5, Convention Center
**The Road to Entrepreneurship**
**NOT ELIGIBLE FOR CME CREDIT**

**Chair:** Michael A. Caligiuri, Duarte, CA

**Introduction.** Michael A. Caligiuri, Duarte, CA

**Getting started.** Tom Cirrito, Walnut, CA

**Entrepreneurship: Review criteria.** William N. Hait, New Brunswick, NJ

**Finding investors for your idea.** Christiana Goh Bardon, Boston, MA

Room 2, Convention Center
**Roles for Genomic Repeats and Transposable Elements in Tumor Biology and Implications for Therapy.**

**Chair:** Kathleen H. Burns, Boston, MA

**Chair Introduction.** Kathleen H. Burns, Boston, MA

**Transposable elements and the cancer epigenome.** Ting Wang, Saint Louis, MO

**The LINE-1 retrotransposon: A marker and mutator in cancers.** Kathleen H. Burns, Boston, MA

**Defining the immune phenotype of repeats in cancer.** Benjamin Dylan Greenbaum, New York, NY

Ballroom 20 AB, Convention Center
**Therapeutic and Surgical De-escalation Studies: The Next Challenge in Precision Oncology**

**Chair:** Jeanine M. Roodhart, Utrecht, Netherlands

**Chair Introduction.** Jeanine M. Roodhart, Utrecht, Netherlands

**Therapy optimization trials in early breast cancer: Chances and challenges.** Nadia Harbeck, Munich, Germany

**Utilizing ctDNA in de-escalation decisions for colorectal liver metastases.** Laleh G. Melstrom, Duarte, CA

**De-escalation studies, the next step in personalizing treatment for early stage colon cancer.** Jeanine M. Roodhart, Utrecht, Netherlands

## CME **Methods Workshops** • 12:30 p.m.–2:00 p.m.

Room 30, Convention Center
**Choosing the Right Animal Model for Your Study**

**Chair:** Nikhil S. Joshi, New Haven, CT

**Chair Introduction.** Nikhil S. Joshi, New Haven, CT

**Choosing the right mouse models for studying your question in cancer immunology.** Nikhil S. Joshi, New Haven, CT

**The A,B,Cs of modeling cancer in genetically engineered mouse models.** Cory Abate-Shen, New York, NY

**Navigating barriers and advantages of organoids as cancer models: Exploring crosstalk with animal models in cancer research.** Talya Dayton, Barcelona, Spain

Room 11, Convention Center
**Choosing and Using Antibodies for Spatial Informed Protein Expression**

**Chair:** David L. Rimm, New Haven, CT

**Chair Introduction.** David L. Rimm, New Haven, CT

**Ultra high-plex profiling of the tumor microenvironment.** Arutha Kulasinghe, Bridgeman Downs, Australia

**Choosing and using antibodies for low-plex quantitative measurement.** David L. Rimm, New Haven, CT

**Choosing and using antibodies in the clinical (CAP/CLIA) immunohistochemistry lab.** Anja C. Roden, Rochester, MN

Ballroom 20 CD, Convention Center
**Emerging Data Analysis Methods for Cancer Research**

**Chair:** Jeremy Goecks, Portland, OR

**Chair Introduction.** Jeremy Goecks, Portland, OR

**Combining spatial omics and artificial intelligence to understand therapeutic response and clinical outcome in pancreatic cancer.** Jeremy Goecks, Portland, OR

**Empowering cancer researchers: From fundamentals to AI with the Informatics Technology for Cancer Research Training Network (ITN).** Carrie Wright, Seattle, WA

**Harnessing tumor phosphoproteomics to understand kinase activities and therapeutic response.** Kristen M. Naegle, Charlottesville, VA

Room 28, Convention Center
**Implementing/Applying Technologies to Build Capacity in Low- and Middle-income Countries**

**Chair:** Kojo Elenitoba-Johnson, New York, NY

**Chair Introduction.** Kojo Elenitoba-Johnson, New York, NY

**Title to be announced.** Kojo Elenitoba-Johnson, New York, NY

**Title to be announced.** Ayman Mohamed, New Haven, CT

**Frameworks to guide the implementation of novel technologies in low resource settings.** Dianna Ng, New York, NY

# CME Special Session • 2:00 p.m.–4:00 p.m.

Ballroom 6 A, Convention Center
**Strategies to Effectively Communicate Science to the Public**

**Chair:** William G. Nelson, Baltimore, MD

**Introduction from the AACR President.** Philip D. Greenberg, Seattle, WA

**The importance of communicating science to the public.** William G. Nelson, Baltimore, MD

**Communicating to underserved communities.** Lisa A. Newman, New York, NY

**Communicating science to policy makers.** Mary C. Beckerle, Salt Lake City, UT

**Communicating science to patients and advocates.** Bianca N. Islam, Cleveland, OH

**Assisting journalists with accurate reporting.** Clifton Leaf, New York, NY

# CME Educational Sessions • 2:30 p.m.–4:00 p.m.

Room 2, Convention Center
**Cancer Phylogenetics**

**Chair:** Jeffrey Townsend, New Haven, CT

**Introduction.** Jeffrey Townsend, New Haven, CT

**What phylogenetics can tell you about cancer.** Carlo C. Maley, Tempe, AZ

**Phylogenetic inference for understanding therapeutic resistance and metastasis.** Jeffrey Townsend, New Haven, CT

**Single-cell lineage tracing reveals the origin and clonal evolution of precancerous colorectal lesions.** Zheng Hu, Shenzhen, China

Ballroom 20 CD, Convention Center
**Cell Therapies for Solid Tumors**

**Chair:** Prasad S. Adusumilli, New York, NY

**Chair Introduction.** Prasad S. Adusumilli, New York, NY

**Advances in tumor-infiltrating lymphocyte (TIL) and T cell receptor (TCR) modified cell therapy for solid tumors.** Sebastian Klobuch, Amsterdam, Netherlands

**Updates in next-generation CAR designs.** Marcela V. Maus, Boston, MA

**Tumor immune modulation: A co-requisite for successful solid tumor CAR T-cell therapy.** Prasad S. Adusumilli, New York, NY

Ballroom 6 DE, Convention Center
**Chemistry to the Clinic Part 3 of 3: From Virtual Screening to Generative Design: Digital Approaches in Cancer Drug Discovery**

**Chair:** Clara Christ, Berlin, Germany

**Chair Introduction.** Clara Christ, Berlin, Germany

**Navigating chemical space in silico: What's established, what's changed, and what's next?** Clara Christ, Berlin, Germany

**GNINA: Molecular docking and virtual screening with deep learning.** David Koes, Pittsburgh, PA

**Generative design in lead optimization.** Daniel Seeliger, Miami, FL

Room 1, Convention Center
**FDA's Project Endpoint and Overall Survival in Oncology Clinical Trials**

**Moderator**: Ruixiao Lu, San Francisco, CA
**Panelists**:
Nicole J. Gormley, Silver Spring, MD
Mary W. Redman, Seattle, WA
Steven Snapinn, Seattle, WA
Mikkael A. Sekeres, Miami, FL
Marc R. Theoret, Silver Spring, MD

Room 31, Convention Center
**Genetic Ancestry, Tumor Subtype, and Somatic Genomic Landscape**

**Chair:** Laura Fejerman, Davis, CA

**Chair Introduction .** Laura Fejerman, Davis, CA

**Genetic ancestry and breast cancer subtype-specific risk in Latin Americans.** Laura Fejerman, Davis, CA

**Genetic ancestry and somatic mutational landscape in >40,000 breast cancer patients.** Elad Ziv, San Francisco, CA

**Sequencing of tumors from patients with African ancestry reveals differences in clinically relevant alterations across common cancers.** Jian Carrot-Zhang, Cambridge, MA

Ballroom 6 CF, Convention Center
**How Do Epigenetic Modifiers Shape Immune Responses Against Cancer?**

**Chair:** Katherine B. Chiappinelli, Washington, DC

**Chair Introduction.** Katherine B. Chiappinelli, Washington, DC

**Epigenetic regulation of transposable elements to activate anti-tumor immunity.** Katherine B. Chiappinelli, Washington, DC

**Leveraging epigenetics for rational immunotherapy combination.** Rugang Zhang, Conroe, PA

**Translating epigenetic mechanisms of T cell exhaustion into durable tumor immunotherapy.** Benjamin A. Youngblood, Memphis, TN

Room 5, Convention Center
**Impact of Scientific and Technological Advances on Radiation Oncology: Challenges and Opportunities in Patient Care**

**Chair:** Aadel A. Chaudhuri, St. Louis, MO

**Chair Introduction.** Aadel A. Chaudhuri, St. Louis, MO

**Integrative liquid biopsy approaches for response and toxicity prediction.** Aadel A. Chaudhuri, St. Louis, MO
**Biological research and space health enabled by machine learning to support deep space missions: Application to radiation oncology.** Sylvain V. Costes, Washington, DC, DC

Room 11, Convention Center
**New Targets and Mechanisms of Synthetic Lethality in Cancer Therapy**

**Chair:** Thanos D. Halazonetis, Geneva, Switzerland

**Chair Introduction.** Thanos D. Halazonetis, Geneva, Switzerland

**PARP trapping is dispensable for the synthetic lethality of PARP inhibitors with homologous recombination deficiencies.** Thanos D. Halazonetis, Geneva, Switzerland

**PARG inhibitors, a new class of agents exploiting synthetic lethality in cancer.** Jasgit C. Sachdev, San Diego, CA

**Mechanisms and clinical study design to examine the synthetic lethality of WRN inhibitors with mismatch repair deficiency.** Zev A. Wainberg, Santa Monica, CA

Room 33, Convention Center
**PSA Reboot: Why Prostate Cancer Screening is Not What it Used to be and How it Has Changed**

**Chair:** Ruth D. Etzioni, Seattle, WA

**Chair Introduction.** Ruth D. Etzioni, Seattle, WA

**Seven myths about PSA and prostate cancer screening.** Andrew Vickers, New York, NY

**Do less harm: Integrating biomarkers and imaging to improve prostate cancer early detection.** Jeffrey John Tosoian, Nashville, TN

**PSA reboot: Translating from diagnostic performance to population benefit-harm.** Ruth D. Etzioni, Seattle, WA

Room 29, Convention Center
**Spontaneous Cancers of Companion Animals as Clinically Relevant Models for Advancing Human Oncology**

**Chair:** Cheryl A. London, North Grafton, MA

**Chair Introduction.** Cheryl A. London, North Grafton, MA

**Leveraging spontaneous canine cancer to rapidly assess the biologic activity of novel therapeutic combinations.** Cheryl A. London, North Grafton, MA

**Opportunities and challenges of the preclinical canine model for cellular therapy advancement.** Nicola J. Mason, Philadelphia, PA

**Evolution, aging, and cancer: How dogs can help us understand the perceived cancer epidemic.** Jaime F. Modiano, Minneapolis, MN

Ballroom 6 B, Convention Center
**Targeting Dendritic Cells in Cancer Immunotherapy**

**Chair:** Megan Ruhland, Portland, OR

**Chair Introduction.** Megan Ruhland, Portland, OR

**Androgen-mediated suppression of cDC function in tumors.** Megan Ruhland, Portland, OR

**cDC1-mediated cross-priming in cancer immunology and immunotherapy.** Ignacio Melero, Pamplona, Spain

**Impaired T cell priming in the tumor draining lymph node.** Ed Roberts, Glasgow Scotland, United Kingdom

## CME **Methods Workshops** • 2:30 p.m.–4:00 p.m.

Room 30, Convention Center
**Clinical Trial Design Workshop, Part 2: Precision Combination Therapy**

**Chair:** Elizabeth M. Jaffee, Baltimore, MD

**Chair Introduction.** Elizabeth M. Jaffee, Baltimore, MD

**Concepts in the design and analysis of COMBO MATCH.** James H. Doroshow, Bethesda, MD

**Concepts in the design of combination mutated KRAS drug studies.** Nilofer S. Azad, Baltimore, MD

**Concepts in combination precision therapy trial design.** Karen Messer, La Jolla, CA


Room 28, Convention Center
**Functional Variomics and Network Approaches in Cancer Research**

**Cochairs:** Nidhi Sahni, Houston, TX; Hannah K. Carter, San Diego, CA

**Cochair Introductions.** Nidhi Sahni, Houston, TX; Hannah K. Carter, San Diego, CA

**Functional variomics accelerates cancer research through big data-driven AI approach.** Nidhi Sahni, Houston, TX

**Interface-guided phenotyping of oncogenic coding variants in RUNX1 using SEUSS.** Hannah K. Carter, San Diego, CA

**DECIPHER: A map of highly penetrant synthetic lethal interactions in human cancers.** Trey Ideker, San Diego, CA

**Probing tumor heterogeneity through spatial genomics.** Fei Chen, Boston, MA


## CME **Awards and Lectures** • 3:00 p.m.–3:45 p.m.


Ballroom 20 AB, Convention Center
**AACR Award for Lifetime Achievement in Cancer Research**

**Chair:** Robert H. Vonderheide, Philadelphia, PA

**Award Lecture.** Steven A. Rosenberg, Bethesda, MD

## `CME` Plenary Session • 4:15 p.m.–6:15 p.m.

Hall GH, Convention Center
**Discovery Science in Early Cancer Biology and Interception**

**Chair:** Daniel D. De Carvalho, Toronto, ON, Canada

**Introduction.** Daniel D. De Carvalho, Toronto, ON, Canada

**Clonal hematopoiesis mechanisms and cancer risk.** Margaret A. Goodell, Houston, TX

**Drivers of age-related increase in breast tumorigenesis.** Kornelia Polyak, Boston, MA

**Evolution of genome instability in cancer.** Don W. Cleveland, La Jolla, CA

**DNA damage responses: Bedside to bench to bedside.** Michael B. Kastan, Durham, NC

**Wrap-up and opportunities for the future.** Daniel D. De Carvalho, Toronto, ON, Canada

## Special Session • 5:00 p.m.–7:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Harbor Ballroom DEF - Manchester Grand Hyatt San Diego
**WICR 25th Anniversary Session and Networking Reception**

**Chair:** Beverly D. Lyn-Cook, Jefferson, AR
**Speakers:**
Patricia M. LoRusso, New Haven, CT
Margaret Foti, Philadelphia, PA
Sheila K. Singh, Hamilton, ON, Canada

# Sunday, April 7, 2024

## Opening Ceremony • 8:00 a.m.–9:30 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

Hall GH, Convention Center

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science. Highlights of this year's Opening Ceremony include:

- Remarks from AACR CEO Margaret Foti and AACR President Philip D. Greenberg
- AACR Award for Lifetime Achievement in Cancer Research
- AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
- AACR Team Science Award
- AACR June L. Biedler Prizes for Cancer Journalism
- Remarks from NCI Director Kimryn Rathmell

## `CME` Opening Plenary Session • 9:30 a.m.–11:30 a.m.

Hall GH, Convention Center
**Opening Plenary Session: Inspiring Science, Fueling Progress, Revolutionizing Care**

**Cochairs:** Keith Thomas Flaherty, Boston, MA; Christina Curtis, Stanford, CA

**Introduction.** Keith Thomas Flaherty, Boston, MA; Christina Curtis, Stanford, CA

**From cell atlases to medicines.** Aviv Regev, South San Francisco, CA

**Artificial intelligence-based biomarkers in cancer histopathology.** Jakob Nikolas Kather, Dresden, Germany

**Activity-based proteomics: Cancer target and ligand discovery on a global scale.** Benjamin F. Cravatt, La Jolla, CA

**Next generation cancer therapies enabled by bioorthogonal chemistry.** Carolyn R. Bertozzi, Stanford, CA

## CME Awards and Lectures • 12:00 p.m.–12:45 p.m.

Ballroom 20 CD, Convention Center
**Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research**

**Chair:** Robert D. Schreiber, St. Louis, MO

**Funder Remarks.** Enzo Galligioni, Trento, Italy

**Telomeres and cancer: Tumor suppression and genome instability.** Titia de Lange, New York, NY

## CME Awards and Lectures • 12:45 p.m.–1:30 p.m.

Room 29, Convention Center
**AACR-Irving Weinstein Foundation Distinguished Lectureship**

**Chair:** Philip D. Greenberg, Seattle, WA

**Funder Remarks.** Steven M. Lipkin, New York, NY

**Award Lecture.** Rafi Ahmed, Atlanta, GA

## CME Clinical Trials Plenary Session • 1:00 p.m.–3:00 p.m.

Hall GH, Convention Center
**Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies**

**Cochairs:** James L. Gulley, Takoma Park, MD; Shivaani Kummar, Portland, OR

**CT001   Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups.** Sundar Jagannath, New York, NY

**Discussant.** Faith E. Davies, New York, NY

**CT002   CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study.** Samer A. Srour, Houston, TX

**Discussant.** Nicholas P. Tschernia, Bethesda, MD

**CT003   Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS).** Michael R. Migden, Houston, TX

**CT004   A single arm phase 2 study of TVEC in patients with invasive cutaneous SCC: A novel therapeutic approach for low risk tumors.** Clara Curiel-Lewandrowski, Tucson, AZ

**Discussant.** Philip A. Friedlander, Boston, MA

## NCI-NIH-Sponsored Session • 1:00 p.m.–2:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Year of Open Science: Impact of the Cancer Research Data Commons (CRDC)**

**Moderator**: Ina Felau, Bethesda, MD

**CRDC Introduction.** Anthony R. Kerlavage, Rockville, MD

**CRDC impact and success stories.** Jill Barnholtz-Sloane, Bethesda, MD

**CRDC future and lessons learned.** Erika Kim, Bethesda, MD

## CME Advances in Diagnostics and Therapeutics • 1:00 p.m.–2:30 p.m.

Room 30, Convention Center
**Designing the Next Generation of Antibody Drug Conjugates**

**Chair:** Greg Thurber, Ann Arbor, MI

**Chair Introduction.** Greg Thurber, Ann Arbor, MI

**Biology meets design: Lessons from 30 years of ADC development.** Elaine Hurt, Gaithersburg, MD

**Pharmacokinetic strategies to improve the therapeutic index of ADCs.** Joseph P. Balthasar, Lancaster, NY

**Designing clinically effective antibody drug conjugates: Role of intratumoral distribution and development of 'auto-tuning' ADCs for maximum efficacy.** Greg Thurber, Ann Arbor, MI

Ballroom 6 DE, Convention Center
**Ex Vivo Functional Diagnostics for Cancer Precision Medicine**

**Chair:** Jeffrey W. Tyner, Portland, OR

**Chair Introduction.** Jeffrey W. Tyner, Portland, OR

**Big data for functional precision medicine in AML.** Jeffrey W. Tyner, Portland, OR

**Functional precision medicine for high-risk hematological malignancies.** Caroline Heckman, Helsinki, Finland

**Convergence of systems biology and microphysiological approaches towards functional precision medicine.** Shannon M. Mumenthaler, Los Angeles, CA

Room 28, Convention Center
**Oligometastasis: Curable Metastatic State?**

**Chair:** Catherine Spina, New York, NY

**Chair Introduction.** Catherine Spina, New York, NY

**Defining the oligometastatic state: mechanisms and biological determinants.** Catherine Spina, New York, NY

**Oligometastasis: An old new way to address staging and treatment of metastatic disease.** Ralph R. Weichselbaum, Chicago, IL

**Re-examining the paradigm for local therapy in oligo- and poly-metastatic lung cancer.** John V. Heymach, Houston, TX

# CME Advances in Hematologic Malignancies • 1:00 p.m.–2:30 p.m.

Room 15, Convention Center
**Precursors to Hematologic Malignancies**

**Chair:** Irene M. Ghobrial, Boston, MA

**Chair Introduction.** Irene M. Ghobrial, Boston, MA

**Clonal hematopoiesis and myeloid cancers.** Margarete A. Fabre, Cambridge, United Kingdom

**Monoclonal B-cell lymphocytosis: A disease to be (or not to be).** Paolo Ghia, Milano, Italy

**The promise of early detection and interception in myeloma.** Irene M. Ghobrial, Boston, MA

# CME Advances in Organ Site Research • 1:00 p.m.–2:30 p.m.

Room 16, Convention Center
**Inflammatory Breast Cancer**

**Chair:** Massimo Cristofanilli, Chicago, IL

**Chair Introduction.** Massimo Cristofanilli, Chicago, IL

**Inflammatory Breast Cancer (IBC): The disease, the host and everything in between.** Massimo Cristofanilli, Chicago, IL

**Biomarkers and preclinical models to investigate biology in inflammatory breast cancer.** Marwa Manai, Belvedere, Tunisia

**Identification of novel therapeutic vulnerabilities in inflammatory breast cancer.** Nathan M. Merrill, Ann Arbor, MI

Room 17, Convention Center
**Novel Strategies for Early Detection of Ovarian Cancer**

**Chair:** Rosana Risques, Seattle, WA

**Chair Introduction.** Rosana Risques, Seattle, WA

**Circulating microRNAs in early detection of ovarian cancer and beyond!** Dipanjan Chowdhury, Boston, MA

**Advances in the detection of ovarian cancer using gynecological liquid biopsies.** Rosana Risques, Seattle, WA

**Ultrasensitive measurement of ORF1p for detecting and diagnosing ovarian cancer.** David R. Walt, Boston, MA

# CME Advances in Prevention Research • 1:00 p.m.–2:30 p.m.

Room 31, Convention Center
**Current Tools and Approaches for Studying the Role of the Microbiome in Cancer Prevention**

**Chair:** Katherine L. Cook, Winston Salem, NC

**Chair Introduction.** Katherine L. Cook, Winston Salem, NC

**Tissue-resident microbiota influence obesity-mediated breast cancer risk.** Katherine L. Cook, Winston Salem, NC

**Developing metabotherapy for human disease.** Maayan Levy, Philadelphia, PA

**A central role for the microbiome after bariatric surgery in cancer prevention.** Liza Makowski, Memphis, TN

# CME Advances in Technologies • 1:00 p.m.–2:30 p.m.

Ballroom 6 CF, Convention Center
**Unlocking Spatial Complexity: Harnessing Machine Learning for Spatial Biology Insights**

**Chair:** Raphael Gottardo, Lausanne, Switzerland

**Chair Introduction.** Raphael Gottardo, Lausanne, Switzerland

**Decoding the complexity: Navigating computational challenges and technologies in spatial biology.** Raphael Gottardo, Lausanne, Switzerland

**Forecasting immunotherapy biomarkers with spatial multi-omics.** Elana Judith Fertig, Baltimore, MD

**MOSAIC, a multi-omic spatial atlas in cancer to enable precision oncology.** Jean-Philippe Vert, Paris, France

**CME** **Major Symposia** • 1:00 p.m.–2:30 p.m.

Room 11, Convention Center
**Approaches to Improve Quality of Life and Long-term Outcomes in Cancer Survivors Across the Lifespan**

**Chair:** Kerri Winters-Stone, Portland, OR

**Introduction.** Kerri Winters-Stone, Portland, OR

**The lifetime impact of childhood cancer and therapy on quality of life and targets for intervention.** Gregory T. Armstrong, Memphis, TN

**"I felt so alone and isolated": Opportunities to improve quality of life in young adult cancer survivors.** Laura B. Oswald, Tampa, FL

**Quality over quantity: Can exercise extend healthspan in adult and older adult cancer survivors?m**Kerri Winters-Stone, Portland, OR

Ballroom 6 A, Convention Center
**Eavesdropping on the Immunosuppressive Crosstalk between the Myeloid and T Cell Compartments**

**Chair:** Stefani Spranger, Cambridge, MA

**Introduction.** Stefani Spranger, Boston, MA

**Not all T cell responses are the same: how DC shape anti-tumor immunity.** Stefani Spranger, Boston, MA

**Regulation of T cells by myeloid cells in cancer.** Dmitry I. Gabrilovich, Gaithersburg, MD

**SY37-03 Leveraging the complexities of tumor associated macrophages for effective anti-cancer therapy.** Jennifer L. Guerriero, Boston, MA

Ballroom 6 B, Convention Center
**Epigenetics and Chromatin Regulation in Cancer**

**Chair:** Cigall Kadoch, Boston, MA

**Introduction.** Cigall Kadoch, Boston, MA

**Chromatin remodeling complexes in cancer: From mechanisms to therapeutics.** Cigall Kadoch, Boston, MA

**Targeting epigenetic regulators of oncogenic transcription factors.** Arul M. Chinnaiyan, Ann Arbor, MI

**SY03-03 Thinking outside the chromosome: Interrogating epigenetic mechanisms in noncanonical chromatin species.** Yael David, New York, NY

Ballroom 20 AB, Convention Center
**Immunometabolism**

**Chair:** Greg M. Delgoffe, Pittsburgh, PA

**Introduction.** Greg M. Delgoffe, Pittsburgh, PA

**Uncovering the metabolic basis of T cell exhaustion in cancer.** Greg M. Delgoffe, Pittsburgh, PA

**Arginine links 1-carbon metabolism to histone methylation in CAR-T cells with enhanced metabolic fitness.** Roddy O'Connor, Philadelphia, PA

**System-wide factors that impact anti-tumor immunity.** Alison Epstein Ringel, Cambridge, MA

Room 5, Convention Center
**Neuronal Signaling, Unlocking a New Hallmark of Cancer**

**Chair:** Moran Amit, Houston, TX

**Introduction.** Moran Amit, Houston, TX

**The neural regulation of glioma progression.** Humsa Venkatesh, Boston, MA

**SY31-02   Nociceptor neurons control anti-tumor immunity.** Sébastien Talbot, Solna, Sweden

**SY31-03   Cancer takes a nerve: Challenges and opportunities in cancer neuroscience.** Moran Amit, Houston, TX

Room 1, Convention Center
**Perioperative Pandemonium: Trial Designs in Solid Tumors**

**Moderator**
Bernardo Haddock Lobo Goulart, Silver Spring, MD
**Panelists**:
Raymond U. Osarogiagbon, Memphis, TN
Michael Axelson, Stamford, CT
Elizabeth M. Jaffee, Baltimore, MD
Harpreet Singh, Silver Spring, MD

Room 14, Convention Center
**Socioeconomic Contributions to Cancer Health Disparities**

**Chair:** Scarlett L. Gomez, San Francisco, CA

**Introduction.** Scarlett L. Gomez, San Francisco, CA

**Multi-level socioeconomic contributions to cancer health disparities: From concept to measurement to practice.** Scarlett L. Gomez, San Francisco, CA

**SY15-02   Health insurance and outcome disparities in adolescents and young adults with cancer.** Theresa H.M. Keegan, Sacramento, CA

**Socioeconomics and breast cancer outcomes: moving beyond disparities.** Lauren E. McCullough, Atlanta, GA

Room 33, Convention Center
**Targeting Cyclin-CDKs in Cancer: The Cell Cycle Beyond CDK4/6**

**Chair:** Bruce E. Clurman, Seattle, WA

**Introduction.** Bruce E. Clurman, Seattle, WA

**Therapeutically targeting the cell cyclin in HPV+ HNSCC.** Bruce E. Clurman, Seattle, WA

**Targeting CDK2 in cancer.** Peter Sicinski, Boston, MA

**SY19-03   Mechanisms of sensitivity and resistance to CDK2 inhibitors.** Sabrina L. Spencer, Boulder, CO

**Targeting CDK1 activation in cancer.** Jordan Young, Saint-Laurent, QC, Canada

CME **Special Session** • 1:00 p.m.–2:30 p.m.

Ballroom 20 CD, Convention Center
**New Drugs on the Horizon: Part 1**

**Cochairs:** Mary M. Mader, Indianapolis, IN; Benjamin L. Ebert, Boston, MA

**Introduction.** Mary M. Mader, Indianapolis, IN

**ND01   ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors.** Jennifer Stone, 1 North Waukegan Rd., North Chicago, IL

**ND02   Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer.** Shuichan Xu, San Diego, CA

**ND03   Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor.** John E. Knox, Redwood City, CA

**ND04   Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer.** Lori S. Friedman, South San Francisco, CA

**Closing remarks.** Benjamin L. Ebert, Boston, MA

# Meet and Greet • 1:15 p.m.2:45 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Central - Booth 3737 - Halls AF, Convention Center
**Minorities in Cancer Research (MICR) Meet and Greet**

Chair: Camille C.R. Ragin, Philadelphia, PA

# Poster Sessions • 1:30 p.m.–5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

## Immunology
| | |
|---|---|
| Section 1 | Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T |
| Section 2 | Adoptive Cell Therapies 2: CAR-T Cells |
| Section 3 | Biomarkers, Immune Monitoring, and Immune Assays |
| Section 4 | Tumor-Induced Immune Suppression 1: Extrinsic Factors |
| Section 54 | Late-Breaking Research: Immunology 1 |

## Tumor Biology
| | |
|---|---|
| Section 6 | Developmental Origins and Drivers of Pediatric Cancer |
| Section 7 | Macrophages, Neutrophils, and NK Cells in Cancer |
| Section 8 | Membrane, Biophysical, and EMT Aspects of Motility/Metastasis |
| Section 9 | Organoid Models of Cancer 1 |
| Section 10 | Stem Cells in Tumor Initiation and Progression |
| Section 11 | Stroma Interactions |
| Section 12 | Tumor Adhesion |

## Molecular/Cellular Biology and Genetics
| | |
|---|---|
| Section 14 | Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 1 |
| Section 15 | Apoptosis and Ferroptosis |
| Section 16 | Cellular Stress Responses 1 |
| Section 17 | DNA Damage and Repair 1 |
| Section 18 | Metabolic Pathways 1 |
| Section 19 | microRNAs and Other Non-coding RNAs as Cancer Genes 1 |

## Chemistry
| | |
|---|---|
| Section 20 | Basic and Applied Nanotechnology and Therapeutics |
| Section 52 | Late-Breaking Research: Chemistry |

## Experimental and Molecular Therapeutics
| | |
|---|---|
| Section 21 | Cell Cycle, Transcription Regulation, and Anticancer Drug Action |
| Section 22 | Drug Resistance 1: Models |
| Section 23 | Identification of Molecular Targets |
| Section 24 | Immunotherapy |
| Section 25 | Kinase and Phosphatase Inhibitors 1 |
| Section 26 | Mechanisms of Drug Action |
| Section 27 | Novel Antitumor Agents 2 |

Section 28     Radiotherapeutic Combinations, Modifiers, Protectors, Sensitizers, and Molecular Targets
Section 29     Tumor Microenvironment
Section 53     Late-Breaking Research: Experimental and Molecular Therapeutics 1

**Prevention / Early Detection / Interception**
Section 31     Cancer Prevention
Section 32     Epidemiology

**Population Sciences**
Section 33     Cancer Disparities 1: Emerging Trends in Cancer Disparities Research
Section 34     Environmental and Occupational Risk Factors, Infection, and Aging

**Bioinformatics / Computational Biology / Systems Biology / Convergent Science**
Section 36     Application of Bioinformatics to Cancer Biology 1
Section 37     Artificial Intelligence and Machine/Deep Learning 1
Section 51     Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1

**Regulatory Science and Policy**
Section 38     Regulatory Science and Policy

**Clinical Research**
Section 39     Application of Precision Medicine for Cancer Care
Section 40     Circulating Nucleic Acids 1
Section 41     Clinical Research in Special Populations
Section 42     Diagnostic Biomarkers 1
Section 43     Early Detection Biomarkers 1
Section 44     Pediatric Sarcomas and Other Solid Tumors: Translational
Section 45     Radiation Oncology
Section 46     Spatial Proteomics and Transcriptomics
Section 47     Tumor Immune Response

# Meet and Greet • 2:00 p.m.–3:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editors-in-Chief of *Cancer Discovery*: Lewis C. Cantley, PhD and Luis A. Diaz Jr., MD**

# NCI-NIH-Sponsored Session • 2:30 p.m.–3:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Early-Onset Cancers from Etiology to Survivorship: Funding Opportunities, Resources, and Future Research Needs**

**Moderator**: Asad Umar, Rockville, MD

**Welcome and meeting overview.** Naoko Ishibe, Washington DC, DC

**Overview of early-onset cancers.** Tomotaka Ugai, Boston, MA

**Survivor's perspective.** Phuong Gallagher, Pasadena, CA

**Early-onset cancers: Portfolio analysis, funding opportunities, and NCI resources.** Anil Wali, Bethesda, MD

**Cancer Grand Challenges-PROSPECT: Pathways, risk factors, and molecules to prevent early-onset colorectal tumors.** Yin Cao, St Louis, MO

## CME Awards and Lectures • 3:00 p.m.–3:45 p.m.

Room 31, Convention Center
**AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research**

**Chair:** Manuel Hidalgo, New York, NY

**Award Lecture.** Anil K. Rustgi, New York, NY

Room 33, Convention Center
**AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship**

**Chair:** Valerie Odero-Marah, Atlanta, GA

**Award Lecture.** Camille C. R. Ragin, Philadelphia, PA

Ballroom 6 DE, Convention Center
**AACR-Princess Takamatsu Memorial Lectureship**

**Chair:** Louis M. Staudt, Bethesda, MD

**Funder Remarks.** Yoshinori Murakami, Tokyo, Japan

**Award Lecture.** Tony Hunter, La Jolla, CA

## Meet and Greet • 3:00 p.m.–4:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention*:**
**Elizabeth A. Platz, ScD, MPH**

## Major Symposium • 3:00 p.m.–4:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 1, Convention Center
**Engaging Community Members to Prioritize Research and Improve Cancer Care**

**Moderator**: Patricia Spears, Raleigh, NC

**Testing of an educational toolkit for the Community Genetic Navigation Engagement Specialists, COGENES, Training Program.** Lourdes A. Baezconde-Garbanati, Los Angeles, CA

**iCCaRE engagement of faith-based organizations to co-create and co-disseminate infographics addressing disparities in prostate cancer literacy and clinical and biospecimen studies**. James Morrison, Duarte, CA

**iCCaRE engagement of faith-based organizations to co-create and co-disseminate infographics addressing disparities in prostate cancer literacy and clinical and biospecimen studies - Researcher Perspective.** Kimlin Tam Ashing, Duarte, CA

**Pursuing leadership in literacy to ameliorate head and neck cancer disparities.** Joni D. Nelson, Charleston, SC

**Implementation of a community-based multi-component cancer screening intervention supported by a cross-sector community coalition.** Ruth Rechis, Houston, TX

## CME Special Session • 3:00 p.m.–4:30 p.m.

Ballroom 20 CD, Convention Center
**New Drugs on the Horizon: Part 2**

**Cochairs:** Lori S. Friedman, South San Francisco, CA; Hong Shen, Shanghai, China

**Introduction.** Hong Shen, Shanghai, China

**ND05   The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin's Lymphoma.** Dan Sherman, New Haven, CT

**ND06   First disclosure of AZD8421, a highly selective CDK2 inhibitor to address resistance to CDK4/6 inhibitors in breast and CCNE1-high cancers.** Christopher R. Denz, Waltham, MA

**ND07   BBO-8520, a first-in-class, direct inhibitor of KRAS$^{G12C}$ (ON), locks GTP-bound KRAS$^{G12C}$ in the state 1 conformation resulting in rapid and complete blockade of effector binding.** Pedro J. Beltran, San Francisco, CA

**ND08   M3554, a novel anti-GD2 antibody drug conjugate.** Christiane Amendt, Darmstadt, Germany

**Closing remarks.** Lori S. Friedman, South San Francisco, CA

## CME Clinical Trials Minisymposium • 3:00 p.m.–5:00 p.m.

Ballroom 20 AB, Convention Center
**Cancer Vaccines: Ready for Prime Time?**

**Cochairs:** Ecaterina Elena Dumbrava, Houston, TX; Ulka N. Vaishampayan, Ann Arbor, MI

**Introduction.** Ecaterina Elena Dumbrava, Houston, TX

**CT021   Preliminary clinical results of a therapeutic cancer vaccine PDC\*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC.** Willemijn Theelen, Amsterdam, Netherlands

**CT022   Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study .** Saurav D. Haldar, Baltimore, MD

**CT023   Prostate cancer *in situ* autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot.** Sujit S. Nair, New York, NY

**CT024   A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial.** Lindy Durrant, Oxford, United Kingdom

**CT134   Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma.** Arielle Urman, Baltimore, MD

**CT025   Personalized RNA neoantigen vaccines induce long-lived CD8[+] T effector cells in pancreatic cancer.** Vinod P. Balachandran, New York, NY

**CT026   Systemic responses to SYNC-T therapy: *In situ* personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC).** Charles J. Link, Wynnewood, PA

**Closing remarks.** Ulka N. Vaishampayan, Ann Arbor, MI

## CME Minisymposia • 3:00 p.m.–5:00 p.m.

Room 14, Convention Center
Bioinformatics, Computational Biology, Systems Biology, and Convergent Science
**Algorithms, Platforms, and Emerging Concepts**

**Cochairs:** Ben J. Raphael, Princeton, NJ; Elana Judith Fertig, Baltimore, MD

**Introduction.** Ben J. Raphael, Princeton, NJ

**1200   A novel algorithm for deconvolving cancer allele-specific clone copy number and copy number evolution.** Piotr Pawlik, London, United Kingdom

**1201   Pervasive HLA disruption fuels cancer evolution.** Clare Puttick, London, United Kingdom

**1202   Signatures of selection for biallelic inactivation in tumor suppressor genes across cancer types.** Mark R. Zucker, New York City, NY

**1203   Mushroom: A tool for identification of 3D cellular neighborhoods in multi-modal spatial datasets.** Erik Storrs, Saint Louis, MO

**1204   Neoantigen MHC presentability ratios influence the tumor microenvironment and response to immunotherapy.** Timothy J. Sears, San Diego, CA

**1205   Inferring allele-specific copy number aberrations and tumor phylogeography from spatially resolved transcriptomics.** Benjamin J. Raphael, Princeton, NJ

**1206   Three-dimensional immune atlas of pancreatic cancer precursor lesions reveals large inter- and intra-lesion heterogeneity.** Ashley L. Kiemen, Baltimore, MD

**Closing remarks.** Elana Judith Fertig, Baltimore, MD


Ballroom 6 CF, Convention Center
Clinical Research
**Biomarkers Predictive of Therapeutic Benefit**

**Cochairs:** Pashtoon Murtaza Kasi, New York, NY; Joshua LaBaer, Tempe, AZ

**Introduction.** Pashtoon Murtaza Kasi, New York, NY

**1207   Immune subtyping identifies a subset of HR+HER2- early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL.** Denise M. Wolf, San Francisco, CA

**1208   Plasma proteomics-based models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy.** Jarushka Naidoo, Dublin, Ireland

**1209   Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab.** Razelle Kurzrock, Wauwatosa, WI

**1210   High-throughput time-resolved single-cell analysis of T-cell activation.** Sheldon J. Kwok, Woburn, MA

**1211   Biomarker analysis of pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer: EAST ENERGY trial.** Kotaro Nomura, Kashiwa, Japan

**1212   Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC.** Marcelo V. Negrao, Houston, TX

**1213   Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers.** Maishara Muquith, Dallas, TX

**Closing Remarks.** Joshua LaBaer, Tempe, AZ

Room 15, Convention Center
Experimental Therapeutics
**Biological Therapeutic Agents**

**Cochairs:** Andrew J. Aguirre, Boston, MA; Piro Lito, New York, NY

**Introduction.** Andrew J. Aguirre, Boston, MA

**1214   Investigating therapeutic strategies to promote immune rejection of KRAS$^{G12C}$ inhibitor-resistant subpopulations in lung cancer.** Miriam Molina-Arcas, London, United Kingdom

**1215   DIRAS3 inhibits oncogenic RAS signaling and RAS-dependent cell growth driven by prevalent KRAS hot spot mutations.** Gamze Bildik, Houston, TX

**1216   Pan-RAS inhibition by a tumor-targeted biotherapeutic.** Greg L. Beilhartz, Toronto, ON, Canada

**1217   Defining the anti-tumor activity and immune effects of the RAS$^{MULTI}$(ON) inhibitor RMC-7977 in preclinical models of NRAS-mutant melanoma.** Larissa A. Carvalho, Tampa, FL

**1218   CDK9 inhibitors modulate the transcriptional landscape of colorectal cancer to suppress MAPK signaling and synergizes with BRAF inhibitors to treat BRAF-mutant colorectal cancer.** Chaoyuan Kuang, Bronx, NY

**1219   In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables ATAD3A gene depletion to enhance RAS-targeted therapy.** Yong Teng, Atlanta, GA

**1220   Deep mutational scanning of EGFR reveals potential domain-specific TKI sensitivities in lung cancer and glioblastoma.** Tikvah Hayes, Los Angeles, CA

**Closing remarks.** Piro Lito, New York, NY


Ballroom 6 B, Convention Center
Experimental Therapeutics
**Concurring Drug Resistance by Innovative Research**

**Cochairs:** Dihua Yu, Houston, TX; Taru E. Muranen, Boston, MA

**Introduction.** Dihua Yu, Houston, TX

**1221   Selective translational activation of PBK (PDZ- binding kinase) reveals a molecular vulnerability of drug-tolerant persister cells to targeted therapies in *EGFR*-mutant lung adenocarcinoma.** Sandra Ortiz-Cuaran, Lyon, France

**1222   Mechanisms of succinate-mediated drug resistance in ER+ breast cancer.** JENNY HOGSTROM, Boston, MA

**1223   KDM6A orchestrates NK cell response *via* CD38/48 regulation in multiple myeloma.** Jiye Liu, Boston, MA

**1224   3D models of chemotherapy- and PARPi-resistant ovarian cancer indicate essential roles for JAK/STAT signaling in mediating drug resistance.** Esther Rodman, Rochester, MN

**1225   Novel cellular barcoding to dissect melanoma heterogeneity and drug resistance.** Haiyin Li, Phialdelphia, PA

**1226   Genomically encoded lineage plasticity drives resistance to EGFR targeted therapy in lung adenocarcinoma.** Matthew Zatzman, New York, NY

**1227   Novel combination therapies to overcome non-genetic/adaptive menin inhibitor resistance in AML with MLL1r or mtNPM1.** Warren C. Fiskus, Houston, TX

**Closing Remarks.** Taru E. Muranen, Boston, MA

Room 11, Convention Center
Experimental Therapeutics
**Novel Antitumor Agents 1**

**Cochairs:** Rima S. Al-awar, Raleigh, NC; Norbert Kraut, Vienna, Austria

**Introduction.** Rima S. Al-awar, Raleigh, NC

**1228   Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models.** Nannan Zhang, Shanghai, China

**1229   BDTX-1535: A MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving molecular landscape of EGFR mutant NSCLC.** Etienne Dardenne, Cambridge, MA

**1230   MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance.** Judith S. Sebolt-Leopold, Ann Arbor, MI

**1231   First-in-class AR-V7/AR-fl small molecule molecular glue degrader for prostate cancer treatment.** CheukMan C. Au, New York, NY

**1233   Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma.** Daisuke Morishita, Fujisawa, Japan

**Closing Remarks.** Norbert Kraut, Vienna, Austria

Room 30, Convention Center
Immunology
**Tumor-Targeted Immune Cell Engagers**

**Cochairs:** David S. Hong, Houston, TX; Tanaya Shree, Portland, OR

**Introduction.** Tanaya Shree, Portland, OR

**1235   Impact of anti-CD3 and tumor-target binder affinities on *in-vitro* potency, *in-vivo* efficacy, and cytokine release.** Omar Abdelmotaleb, Schlieren, Switzerland

**1236   Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia.** Geraldine Paulus, Cambridge, MA

**1237   IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma.** Kevin C. Hart, Mountain View, CA

**1238   ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies.** Mario Perro, Epalinges, Switzerland

**1239   SAIL66, a next generation T cell engager targeting CLDN6, potentiates efficacy by binding to CD3/CD137.** Naoki Kimura, Yokohama, Kanagawa, Japan

**1240   Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel tri-specific killer engager.** Shee Kwan Phung, Minneapolis, MN

**1241   Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE).** Melissa Khaw, Minneapolis, MN

**Closing Remarks.** David S. Hong, Houston, TX

Ballroom 6 A, Convention Center
Molecular/Cellular Biology and Genetics
**Cancer Epigenetics**

**Chair:** Yael David, New York, NY

**Introduction.** Yael David, New York, NY

**1242   Foxa1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma.** Katherine Gillis, Salt Lake City, UT

**1243   Shifted mSWI/SNF complex assembly and function underlie therapeutically targetable dependencies in endometrial carcinoma.** Jessica Diane St. Laurent, Boston, MA

**1244   Exploiting the pathogenesis of endogenous retrovirus to tackle squamous cancers.** Yejing Ge, Houston, TX

**1245   The histone methyltransferase KMT2D mediates subtype-specific transcriptional regulation and therapeutic response in prostate cancer.** Srushti Kittane, Baltimore, MD

**1246   Erg-driven prostate cancer emerges from a basal subset of cells with luminal transcriptomic features.** Erik Ladewig, New York, NY

**1247   PPARsing epigenetic memory in intestinal stem cells: High-fat diet and oncogenic susceptibility.** Dominic R. Saiz, Tempe, AZ

**1248   The BRD8/p53 epigenetic switch re-establishes tumor suppression in glioblastoma.** Alea A. Mills, Cold Spring Harbor, NY

**Closing Remarks.** Yael David, New York, NY

Room 5, Convention Center
Multidisciplinary
**Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases**

**Chair:** Philippe L. Bedard, Toronto, ON, Canada

**Introduction.** Philippe L. Bedard, Toronto, ON, Canada

**1249   cBioPortal for Cancer Genomics.** Ino de Bruijn, New York, NY

**1250   Activating *PIK3CA* mutations and hedgehog signaling may confer resistance to KRAS inhibition in colorectal cancer.** Saikat Chowdhury, Houston, TX

**1251   Tobacco smoke alters the adaptive landscape of lung adenocarcinoma and influences the strength of epistatic interactions.** Krishna Dasari, New Haven, CT

**1252   AI-derived predictions improve identification of real-world cancer driver mutations.** Thinh N. Tran, New York, NY

**1253   Pan-cancer comparative and integrative analyses of driver alterations using Japanese and international genomic databases.** Sara Horie, Tokyo, Japan

**1254   Integration of human omics analysis and new syngeneic tumor organoid models reveals that aberrant RAS/PI3K crosstalk triggers refractoriness in high-grade serous carcinoma.** Tomohiro Tamura, Shinjuku, Japan

**Closing Remarks.** Philippe L. Bedard, Toronto, ON, Canada


Room 17, Convention Center
Multidisciplinary
**Genetic and Cellular Mediators of Tumor Progression**

**Chair:** Laura D. Attardi, Stanford, CA

**Introduction.** Laura D. Attardi, Stanford, CA

**1256   RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4.** Hannah N. Weinstein, San Francisco, CA

**1257   CHD5 suppresses glioblastoma by inhibiting MYC.** Xueqin Sherine Sun, Cold Spring Harbor, NY

**1258   A cholesterol metabolite can modulate neutrophil-derived extracellular vesicles to promote breast cancer cell epithelial to mesenchymal transition (EMT) and stemness.** Natalia J. Krawczynska, Urbana-Champaign, IL

**1259   HMGA1: An epigenetic gatekeeper of Wnt signals during colon tumorigenesis and regeneration.** Bailey West, Baltimore, MD

**1260   Collapse of cancer cell micronuclei from oxidative damage.** Melody Di Bona, New York, NY

**1261   *In vitro* medulloblastoma leptomeningeal metastasis models reveal adhesion signaling as a therapeutic vulnerability.** Leyre Jimenez Garcia, Columbus, OH

**1262  Comparative analysis of *TP53* alleles in pancreatic ductal adenocarcinoma.** Andy Tang, New Haven, CT

**Closing Remarks.** Laura D. Attardi, Stanford, CA

Room 28, Convention Center
Prevention, Early Detection, and Interception
**Multi-Cancer Early Detection Testing: Where Are We?**

**Cochairs:** Marie E. Wood, Aurora, CO; Wendy Rubinstein, Silver Spring, MD

**Introduction.** Marie E. Wood, Aurora, CO

**1263  Interim results from a large-scale, prospective cohort study (JINLING) for multi-cancer early detection test in average-risk asymptomatic patients.** Shanshan Yang, Nanjing, China

**1264  A targeted methylation-based multi-cancer early detection blood test preferentially detects high-grade prostate cancer and minimizes overdiagnosis.** Eric A. Klein, Menlo Park, CA

**1265  Comparison of mortality- vs. stage-based endpoints in randomized trials of cancer screening: A systematic review with implications for multi-cancer screening trials.** Hilary A. Robbins, Lyon, France

**1266  Development and performance of a multi-cancer early detection test utilizing plasma cfDNA fragmentomics: A large-scale, prospective, multicenter study.** Hua Bao, Nanjing, China

**1267  Projected impact of liquid biopsy screening strategies with high sensitivity in focused populations and high specificity in broad populations.** Peter B. Bach, Baltimore, MD

**1268  Immune activation characterization via amino acid concentration signatures for multi-cancer early detection and CDKi treatment response prediction.** Cong Tang, Lisbon, Portugal

**1269  Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection.** Mao Mao, Shenzhen, China

**Closing Remarks.** Wendy Rubinstein, Silver Spring, MD

Room 29, Convention Center
Tumor Biology
**Metastasis**

**Cochairs:** Danny R. Welch, Kansas City, KS; Leah M. Cook, Omaha, NE

**Introduction.** Danny R. Welch, Kansas City, KS

**1270  p53-R172H mutation confers gain-of-function properties and promotes metastasis in squamous cell carcinoma.** Gizem Efe, New York, NY

**1271  PMEPA1 acts as a switch to modulate cooperative cellular invasion and drive NSCLC tumor progression.** Tala O. Khatib, Atlanta, GA

**1272  Spatial profiling of human colorectal cancer brain metastasis identifies chromosomal instability with adaptive niche cellular reorganization and reprograming.** Anuja Sathe, Palo Alto, CA

**1273   Tumor progression and tumor microenvironment of pancreas cancer ascites revealed by scRNA-seq and spatial transcriptomics.** Shigeaki Umeda, New York, NY

**1274   Investigating PLOD2 as a therapeutic target to overcome metastasis in radiorecurrent prostate cancer.** Gavin Frame, Toronto, ON, Canada

**1275   *In vivo* functional CRISPR screens identifies metabolic dependencies mediating triple negative breast cancer lung metastasis.** Xiaoyong Wang, Nashville, TN

**1276   Kindlin-2: a novel target of Parkin regulating cancer metastasis.** Minjeong Yeon, Philadelphia, PA

**Closing Remarks.** Leah M. Cook, Omaha, NE

Room 16, Convention Center
Tumor Biology
**Microbes and Tumors: Time for Mechanisms**

**Cochairs:** Florencia McAllister, Houston, TX; Susan Bullman, Seattle, WA

**Introduction.** Florencia McAllister, Houston, TX

**1277   Unveiling the impact of intratumoral microbiota in the treatment efficacy of soft tissue sarcoma.** Luca Tiraboschi, Rozzano, Milan, Italy

**1278   Differential urinary microbiome and its metabolic footprint in bladder cancer patients following BCG treatment.** Xuan-Mei Piao, Cheongju, Korea, Republic of

**1280   Role of the tumor microbiome in the lung adenocarcinoma immune microenvironment through multi meta-omics analysis.** Ivania Valdés, Santiago, Chile

**1281   Antibiotics aerosolization shrinks intratumoral Tregs and impairs lung tumor growth by perturbing the taxonomic structure of tumor-associated microbiota.** Giancarla Bernardo, Milano, Italy

**1282   Gavage with *Candida albicans* leads to fungal colonization of colorectal tumors and decreased response to radiotherapy.** Dennis J. Grencewicz, Columbus, OH

**1283   Digital spatial profiling of metastatic brain tumors reveals association of the tumor microbiome with immune alterations in the tumor microenvironment.** Golnaz Morad, Houston, TX

**Closing Remarks.** Susan Bullman, Seattle, WA

## CME Clinical Trials Plenary Session • 3:30 p.m.–5:30 p.m.

Hall GH, Convention Center
**Novel Immune Checkpoint Inhibitor Combinations**

**Cochairs:** Colin D. Weekes, Boston, MA; Solange Peters, Lausanne, Switzerland

**CT006   Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial.** Jiafu Ji, Beijing, China

**Discussant.** Yelena Yuriy Janjigian, New York, NY

**CT007   Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC).** Eric S. Christenson, Baltimore, MD

**Discussant.** Michael J. Overman, Houston, TX

**CT008   A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer.** Rebecca L. Porter, Boston, MA

**Discussant.** Kathleen N. Moore, Oklahoma City, OK

**CT009   IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN).** Deborah J. Wong, Los Angeles, CA

**Discussant.** Robert L. Ferris, Pittsburgh, PA

## Meet and Greet • 4:00 p.m.–5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editor-in-Chief of *Cancer Research*: Christine Iacobuzio-Donahue, MD, PhD**

## NCI-NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Cancer Health Disparities Research Collaborations Across CRCHD and DCB**

**Moderator**: Natalia Mercer, Rockville, MD

**Overview of CRCHD and DCB collaborative research.** Natalia Mercer, Rockville, MD

**Basic research in cancer health disparities.** Tiffany A. Wallace, Rockville, MD

**Integrating health disparities into immune-oncology.** Lillian Kuo, Rockville, MD

**Administrative supplements to support cancer disparity collaborative research.** LeeAnn O. Bailey, Bethesda, MD

## Awards and Lectures • 4:15 p.m.-5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 33, Convention Center
**AACR Distinguished Public Service Award for Lifetime Achievement in Cancer Research**

**My first 50 years in cancer research: Lessons learned and potential utility for global efforts to prevent and cure cancer.** Franco Cavalli, Bellinzona, Switzerland

## CME Awards and Lectures • 4:30 p.m.-5:15 p.m.

Ballroom 6 DE, Convention Center
**AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research**

**Chair:** Suzanne L. Topalian, Baltimore, MD

**Award Lecture.** Joseph A. Sparano, New York, NY

Room 31, Convention Center
**AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research**

**Chair:** Andrew Futreal, Houston, TX

**Adaptive resistance in BRAF- and KRAS-mutated colorectal cancer.** Scott Kopetz, Houston, TX

## Professional Advancement Session • 5:00 p.m.-7:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall CD - Manchester Grand Hyatt San Diego
**Personalized Career Conversations**

**Cochairs:** Antonio T. Baines, Greensboro, NC; Melissa B. Davis, Atlanta, GA; Shiva Malek, Cambridge, MA; Katie M. Campbell, Los Angeles, CA

**CME** **Awards and Lectures** • 5:30 p.m.-6:15 p.m.

Ballroom 20 CD, Convention Center
**Presidential Address: Engineering T Cells to Eradicate Tumors - Identifying and Overcoming the Obstacles**

**Chair:** William N. Hait, New Brunswick, NJ

**Introduction.** William N. Hait, New Brunswick, NJ

**Engineering T cells to eradicate tumors: Identifying and overcoming the obstacles.** Philip D. Greenberg, Seattle, WA

# Town Meetings • 6:00 p.m.-8:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Sapphire Ballroom - Hilton Bayfront Hotel
**Artificial Intelligence for Research Enhancement in Population Sciences: A Population Sciences Working Group Town Hall Meeting**

**Cochairs:** Lorelei A. Mucci, Boston, MA; Paul A. Scheet, Houston, TX

**Connect- A new cohort to study cancer causes and prevention.** Nicolas A. Wentzensen, Bethesda, MD

**Panelists**:
Kenneth L. Kehl, Boston, MA
Juli Klemm, Rockville, MD
Yulin Hswen, San Francisco, CA
Charlotta Lindvall, San Francisco, CA, MA
Robert Scharpf, Baltimore, MD

Sapphire Ballroom - Hilton Bayfront Hotel
**Crosstalk of Immune Cells and Metabolic Pathways in the Tumor-Immune Microenvironment: A Cancer Immunology Working Group Town Hall**

**Chair:** Kunle Odunsi, Chicago, IL

**Moderator**: Marcela V. Maus, Boston, MA

**Speakers:**
Jing Chen, Chicago, IL
Greg M. Delgoffe, Pittsburgh, PA
Jeffrey C. Rathmell, Nashville, TN

Sapphire Ballroom - Hilton Bayfront Hotel
**Then and Now: Updates in Pediatric Cancer Predisposition— A Pediatric Cancer Working Group Town Hall Meeting**

**Cochairs:** E. Alejandro Sweet-Cordero, San Francisco, CA; Katherine A. Janeway, Boston, MA

**Title to be announced.** Christopher C. Porter, Atlanta, GA

**_DICER1_ testing and surveillance.** Kris Ann Schultz, Minneapolis, MN

**Identification of cancer predisposition in the era of widespread molecular testing.** Suzanne Macfarland, Philadelphia, PA

**Title to be announced.** David Malkin, Toronto, ON, Canada

**Polygenic predisposition: The curious case of Ewing sarcoma.** Logan G. Spector, Minneapolis, MN

## Special Session • 6:30 p.m.-8:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Ballroom - Omni San Diego Hotel

**Networking Hubs**

Cancercareers: Scientific Careers Resource Center
Entrepreneurship
Data Science in Cancer Research
Incorporating New Technologies into Clinical Trials
Novel Targets Enabled by Chemistry Advances

## Meet and Greet • 8:00 p.m.-9:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall B - Manchester Grand Hyatt San Diego
**AACR Associate Member Meet and Greet**

**Chair:** Katie M. Campbell, Los Angeles, CA

## AACR Annual Reception • 8:30 p.m.-11:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Seaport Ballroom - Manchester Grand Hyatt San Diego
**AACR Annual Reception, Featuring The Checkpoints**

# Monday, April 8, 2024

**CME** **Plenary Session** • 8:00 a.m.-10:00 a.m.

Hall GH, Convention Center
**Profiling Tumor Ecosystems in Native Tissue Context**

**Chair:** Christine A. Iacobuzio-Donahue, New York, NY

**Introduction.** Christine A. Iacobuzio-Donahue, New York, NY

**Spatial encoding of immune response and clinical outcome in the breast cancer tumor microenvironment.** Michael Angelo, Palo Alto, CA

**PL03-02   From microniches to single cells: Understanding the impact of intratumoral microbes on spatial and cellular heterogeneity in cancer.** Susan Bullman, Seattle, WA

**Deconvoluting the cancer ecosystem into its spatial components with a focus on breast and prostate cancer.** Joakim Lundeberg, Stockholm, Sweden

**Dissecting plasticity in tumor cell states and immuno-phenotypes in primary melanoma using 3D spatial profiling.** Peter K. Sorger, Boston, MA

**Wrap-up and opportunities for the future.** Christine A. Iacobuzio-Donahue, New York, NY

# Poster Sessions • 9:00 a.m.–12:30 p.m.

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App

**Science and Health Policy**
Section 1        Science and Health Policy

**Immunology**
Section 2        CAR-NK, NK Engagers, and NK Modulators
Section 3        Immune Checkpoints and Inhibitory Molecules 1
Section 4        Inflammation and Cancer in Metastasis
Section 5        Inflammation, Host Factors, and Epigenetic Influences on Cancer Development and Treatment
Section 52       Late-Breaking Research: Immunology 2

**Tumor Biology**
Section 6        Animal Models of Cancer
Section 7        Chemical, Environmental, and Virus-Induced Carcinogenesis
Section 8        Contributors to Metastatic Organotropism
Section 9        Immune Cells in the Tumor Microenvironment 1
Section 10       Metastasis Promoting and Suppressing Genes
Section 11       Pancreatic Cancer Microenvironment
Section 12       Tumor Evolution in Space and Time

**Molecular/Cellular Biology and Genetics**
Section 13       Cell Cycle, DNA Repair, and Telomere Biology
Section 14       Cell Signaling Components as Therapeutic Targets
Section 15       Chromatin Organization and Regulators of Chromatin Biology
Section 16       Epigenetic Targets in Oncology
Section 17       Genomic Characterization of Cancers and Cancer Subgroups
Section 18       Metabolic Pathways 2

**Chemistry**
Section 20       Lead Identification and Optimization
Section 21       Proteomics and Mass Spectrometry 1

**Experimental and Molecular Therapeutics**
Section 22       Antibody-Based Technologies and New Inhibitors
Section 23       Antibody-Drug Conjugates and Bispecific Antibodies
Section 24       Drug Resistance 2: Ras GTPase
Section 25       Kinase and Phosphatase Inhibitors 2
Section 26       Mechanisms of Drug Resistance 1
Section 27       Microenvironment, Immunity, and DNA Repair in Therapeutic Response
Section 28       New Technologies
Section 29       Novel Targets and Pathways
Section 30       Pharmacodynamic Biomarkers of Drug Response

**Prevention / Early Detection / Interception**
Section 31       Health Disparities Across the Cancer Continuum
Section 32       Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum

**Population Sciences**
Section 33     Diet, Alcohol, Tobacco Use, and Other Lifestyle Risk Factors
Section 34     Survivorship Research
Section 53     Late-Breaking Research: Population Sciences

**Bioinformatics / Computational Biology / Systems Biology / Convergent Science**
Section 35     Application of Bioinformatics to Cancer Biology 2
Section 36     Liquid Biopsy and Precision Oncology
Section 37     New Algorithms, Software, and Models

**Clinical Research**
Section 38     Antibodies 1
Section 39     Biostatistics in Clinical Trials / Surgical Oncology
Section 40     Circulating Nucleic Acids 2
Section 41     Early Detection Biomarkers 2
Section 42     Immunomodulatory Interventions and Mechanisms
Section 43     Predictive Biomarkers 1
Section 44     Predictive Biomarkers 2
Section 45     Real-World Biomarkers
Section 46     Translational Research: Imaging and Radiomics
Section 51     Late-Breaking Research: Clinical Research 1

**Clinical Trials**
Section 48     Phase I Clinical Trials 1
Section 49     Phase I Clinical Trials in Progress 1

**Science Education**
Section 47     2024 AACR Margaret Foti Undergraduate Prizes in Cancer Research

# Meet and Greet • 9:15 a.m.-10:15 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editors-in-Chief of *Cancer Immunology Research*: Robert D. Schreiber, PhD and Philip D. Greenberg, MD**

# NCI-NIH-Sponsored Session • 10:15 a.m.-11:15 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**NCI Funding Opportunities in Cancer Prevention and Interception**

**Moderator**: Robert H. Shoemaker, Boyds, MD

**Introduction.** Robert H. Shoemaker, Boyds, MD

**Discovery and development of natural products for cancer interception and prevention (DDNP-CIP) program.** Altaf Mohammed, Rockville, MD

**Cancer immunoprevention network (CIP-Net).** Lillian Kuo, Rockville, MD

**Cancer immunoprevention network (CIP-Net).** Altaf Mohammed, Rockville, MD

**PREVENT program.** Vignesh Gunasekharan, Rockville, MD

# CME Advances in Diagnostics and Therapeutics • 10:15 a.m.-11:45 a.m.

Room 16, Convention Center
**No Time to Waste: Understanding and Addressing Cancer Cachexia**

**Chair:** Mariam Jamal-Hanjani, London, United Kingdom

**Chair Introduction.** Mariam Jamal-Hanjani, London, United Kingdom

**Clinical phenotyping of cancer cachexia to guide mechanistic studies and clinical practice.** Mariam Jamal-Hanjani, London, United Kingdom

**The role of lipid metabolism in driving cancer cachexia.** Salvador Aznar-Benitah, Barcelona, Spain

**The role of inflammatory signaling in cancer cachexia and its therapeutic potential.** Marcus DaSilva Goncalves, New York, NY

# CME Advances in Hematologic Malignancies • 10:15 a.m.-11:45 a.m.

Room 15, Convention Center
**Relapse after Allogeneic Bone Marrow Transplant**

**Chair:** Luca Vago, Milan, Italy

**Chair Introduction.** Luca Vago, Milan, Italy

**Mechanisms of leukemia immune escape and relapse: From biology to precision medicine (and back).** Luca Vago, Milan, Italy

**An analytic framework for the prediction of GvL minor Histocompatibility Antigens to prevent or treat post-transplant relapse.** Nicoletta Cieri, Boston, MA

**Modulation of T-cell functions to facilitate GVL after allogeneic hematopoietic stem cell transplantation.** Takanori Teshima, Sapporo, Japan

## CME Advances in Organ Site Research • 10:15 a.m.-11:45 a.m.

Room 14, Convention Center
**Emerging Non-invasive Tests for Colorectal Cancer Screening: Potential Opportunities and Pitfalls**

**Chair:** Samir Gupta, San Diego, CA

**Chair Introduction.** Samir Gupta, San Diego, CA

**Emerging fecal tests for colorectal cancer screening.** Folasade P. May, Los Angeles, CA

**Emerging blood tests for colorectal cancer screening.** Rachel Issaka, Seattle, WA

**Non-invasive tests for colorectal cancer screening: potential opportunities and pitfalls.** Samir Gupta, San Diego, CA

## CME Advances in Technologies • 10:15 a.m.-11:45 a.m.

Ballroom 6 CF, Convention Center
**Systematic Functional Approaches for Understanding and Targeting Cancer**

**Chair:** Francisca Vazquez, Cambridge, MA

**Chair Introduction.** Francisca Vazquez, Cambridge, MA

**DepMap: Mapping the landscape of cancer vulnerabilities.** Francisca Vazquez, Cambridge, MA

**A multiplex prime-editing framework for identifying drug resistance mutations at scale.** Alice Berger, Seattle, WA

**NG03  Functional and computational approaches to uncover selection advantages of cancer aneuploidy.** Alison M. Taylor, New York, NY

**Single-cell Phenoscaping of Tumor Microenvironment Organoids.** Chris Tape, London, United Kingdom

## CME Advances in the Science of Cancer Disparities • 10:15 a.m. -11:45 a.m.

Room 31, Convention Center
**Molecular Profiling in Breast Cancer and Racial/Ethnic Minorities: Dedicated to the Memory of Edith P. Mitchell**

**Chair:** John D. Carpten, Duarte, CA

**Chair Introduction.** John D. Carpten, Duarte, CA

**NG02   Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.** Kara N. Maxwell, Philadelphia, PA

**Disparities in breast cancer biomarker testing.** Gregory A. Vidal, Germantown, TN

**Reassessing the biology of breast cancer through the lens of African ancestry and health equity.** Clayton C. Yates, Baltimore, MD

**Interrogating the tumor and immune microenvironment of triple negative breast cancer in a diverse cohort.** John D. Carpten, Duarte, CA

## CME Major Symposia • 10:15 a.m.-11:45 a.m.

Ballroom 6 A, Convention Center
**AACR-Bayard D. Clarkson Symposium: Cellular Plasticity in Tumor Development, Metastasis and Response to Therapy**

**Chair:** Frederic J. de Sauvage, South San Francisco, CA

**Introduction.** Frederic J. de Sauvage, South San Francisco, CA

**Identifying the mechanisms promoting cellular plasticity during the early steps of prostate and breast cancer initiation.** Cedric Blanpain, Bruxelles, Belgium

**Dissecting plasticity during colorectal cancer progression.** Karuna Ganesh, New York, NY

**Colorectal cancer stem cells in metastasis and resistance to KRAS inhibitors.** Frederic J. de Sauvage, South San Francisco, CA

Ballroom 6 DE, Convention Center
**Advances in Pediatric Cancer: Mechanisms, Vulnerabilities, and Translation**

**Chair:** Paul A. Northcott, Memphis, TN

**Introduction.** Paul A. Northcott, Memphis, TN

**Developmental vulnerabilities underlying medulloblastoma pathogenesis.** Paul A. Northcott, Memphis, TN

**Identification of novel osteosarcoma subtypes based on epigenetic and genomic analysis.** Eric Alejandro Sweet-Cordero, San Francisco, CA

**Learning from pediatric genomes to improve clinical decision making.** Elli Papaemmanuil, New York, NY

Room 28, Convention Center
**Chromatin and Cancer: From Mechanisms to Therapy**

**Chair:** Elisa Oricchio, Lausanne, Switzerland

**Introduction.** Elisa Oricchio, Lausanne, Switzerland

**SY05-01   Targeting chromatin adaptor proteins in cancer.** Yadira Soto-Feliciano, Cambridge, MA

**Modulation of 3D chromatin structures to support tumor evolution.** Elisa Oricchio, Lausanne, Switzerland

**SY05-03   Circular extrachromosomal DNA promotes tumor heterogeneity and enhancer rewiring.** Lukas Chavez, La Jolla-, CA

Room 5, Convention Center
**FDA Center for Tobacco Products' Priorities to Reduce Tobacco Use and Support the Cancer Moonshot**

**Moderator**: Brian A. King, Silver Spring, MD

**Panelists**:
Suchitra Krishnan-Sarin, New Haven, CT
Carol McGruder, San Diego, CA

Room 17, Convention Center
**Radiation Induced Tumor Metabolic Rewiring Modulates Therapeutic Responses**

**Chair:** Erina Vlashi, Los Angeles, CA

**Introduction.** Erina Vlashi, Los Angeles, CA

**Metabolic crosstalk between radiation therapy and lactate in adenocarcinomas.** Aparna H. Kesarwala, Atlanta, GA

**Glioblastomas rewire glucose and serine metabolism to resist radiation therapy.** Erina Vlashi, Los

Angeles, CA

**Fatty acid metabolism as a barrier to anti-tumor immunity against irradiated glioblastoma.** Claire Isabelle Vanpouille-Box, New York, NY

Room 29, Convention Center
**RNA Modifications in Malignancy**

**Chair:** Howard Y. Chang, Stanford, CA

**Introduction.** Howard Y. Chang, Stanford, CA

**Harnessing circular RNA for cancer immunotherapy.** Howard Y. Chang, Stanford, CA

**SY11-02   Small molecule inhibitors of RNA modifying enzymes as precision cancer therapeutics.** Robert A. Copeland, Lexington, MA

**RNA modifying enzymes in leukemogenesis.** Kathy Liu, Philadelphia, PA

**Cell surface glycoRNA biology in cancer.** Ryan Flynn, Boston, MA

Room 11, Convention Center
**Surgical Innovations in Breast Cancer**

**Chair:** Oluwadamilola M. Fayanju, Philadelphia, PA

**Introduction.** Oluwadamilola M. Fayanju, Philadelphia, PA

**What the future of breast surgical oncology may look like.** Oluwadamilola M. Fayanju, Philadelphia, PA

**Transformational potential of selective elimination of breast cancer surgery among patients with exceptional responses to neoadjuvant systemic therapy.** Henry Kuerer, Houston, TX

**Single port robotic nipple sparing mastectomy: Initial outcomes, challenges, and potential.** Deborah Farr, Dallas, TX

Room 33, Convention Center
**Targeting the Mitotic Cell Cycle: Emerging Strategies**

**Chair:** Toru Hirota, Tokyo, Japan

**Introduction.** Toru Hirota, Tokyo, Japan

**SY22-01   A strategy to intervene mitotic kinases to induce mitotic catastrophe in cancer cells.** Toru Hirota, Tokyo, Japan

**Centrosome-perturbing agents as potential therapeutics targeting cancer cell division.** Arshad Desai, San Diego, CA

**Cdk4/6 inhibitors dysregulate cell size to impair mitotic fidelity in cancer cells.** Adrian Saurin, Dundee, United Kingdom

Room 30, Convention Center
**The Growing Impact of Obesity on Cancer and Cancer Immunotherapy Outcomes**

**Chair:** William J. Murphy, Sacramento, CA

**Introduction.** William J. Murphy, Sacramento, CA

**SY38-01   Diverse effects of obesity on cancer immunology and therapy: Both the good and the bad.** William J. Murphy, Sacramento, CA

**SY38-02   Clinical investigations of obesity in cancer: BMI and other confounders.** Sai Yendamuri, Buffalo, NY

**Obesity and melanoma: The literplay of host and tumor metabolism.** Jennifer McQuade, Houston, TX

Room 1, Convention Center
**Trading Places: Regulator as Patient, Patient as Regulator**

**Moderator**: Richard Pazdur, Silver Spring, MD

**Panelists**:
Joshua Donaldson, Silver Spring, MD
Leslie Doros, Silver Spring, MD
Lola A. Fashoyin-Aje, Silver Spring, M
Gwynn Ison, Silver Spring, MD
Steven Lemery, Silver Spring, MD

Ballroom 6 B, Convention Center
**Understanding and Predicting Tumor Evolution**

**Chair:** Andrea Sottoriva, Milan, Italy

**Introduction.** Andrea Sottoriva, Milan, Italy

**Mutation and selection in the hematopoietic hierarchy.** Thomas Hofer, Heidelberg, Germany

**Darwinian evolution of the epigenome and non-Darwinian cell plasticity in cancer.** Andrea Sottoriva, Milan, Italy

**NG01   Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.** Kathleen Houlahan, Stanford, CA

**SY02-03   Stochastic modeling of clonal evolution in carcinogenesis.** Kit Curtius, La Jolla, CA

**CME** **Special Session** • 10:15 a.m.-11:45 a.m.

Ballroom 20 CD, Convention Center
**New Drugs on the Horizon: Part 3**

**Cochairs:** Michelle R. Arkin, San Francisco, CA; Ingo Hartung, Darmstadt, Germany

**Introduction.** Michelle R. Arkin, San Francisco, CA

**ND09   Actinium-225 -PSMA-Trillium (BAY 3563254): Preclinical evaluation and clinical imaging study of a novel 225Ac-labeled PSMA-targeting small molecule triad for the treatment of mCRPC.** Sabine Zitzmann-Kolbe, San Francisco, CA, Germany

**ND10   NST-628 is a novel, potent, fully brain-penetrant MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers.** Klaus P. Hoeflich, Cambridge, MA

**ND11   Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase.** Shota Kikuchi, San Diego, CA

**ND11   Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase.** Piergiorgio Pettazzoni, Basel, Switzerland

**ND12   Discovery of PF-07220060, a potent and selective CDK4 inhibitor.** Lars Anders, San Diego, CA

**ND12   Discovery of PF-07220060, a potent and selective CDK4 inhibitor.** Gary Gallego, New York, NY

**Closing remarks.** Ingo Hartung, Darmstadt, Germany

**CME** **Major Symposium** • 10:15 a.m.-12:00 p.m.

Hall GH, Convention Center
**Presidential Select Symposium: Cancer Immunotherapy - Where Do We Go from Here?**

**Chair:** Philip D. Greenberg, Seattle, WA

**Introduction.** Philip D. Greenberg, Seattle, WA

**Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures.** James P. Allison, Houston, TX

**Cancer vaccines and understanding and promoting immunogenicity.** Nir Hacohen, Boston, MA

**Decoding and reprogramming T cell circuits with CRISPR.** Alexander Marson, San Francisco, CA

**CD4 T cells: Empowering CD8 T cells to eliminate tumors.** Andrea Schietinger, New York, NY

## CME Clinical Trials Plenary Session • 10:15 a.m.-12:15 p.m.

Ballroom 20 AB, Convention Center
**Advances in Targeted Therapy**

**Chair:** Ryan B. Corcoran, Boston, MA

**CT011   The PARTNER trial: Neoadjuvant olaparib in germline BRCA mutated breast cancer (gBRCA); "gap"' scheduling with carboplatin and paclitaxel, a step closer to cure.** Jean E. Abraham, Cambridge, United Kingdom

**CT012   PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC).** Karen Pinilla, Cambridge, United Kingdom

**Discussant.** Hope S. Rugo, San Francisco, CA

**11:10 a.m.   CT013   KRYSTAL-1: Pooled phase 1/2 efficacy and safety of adagrasib (MRTX849) in combination with cetuximab in patients with metastatic colorectal cancer (CRC) harboring a KRAS$^{G12C}$ mutation.** Scott Kopetz, Houston, TX

**Discussant.** Alex A. Adjei, Cleveland, OH

**CT014   PETRA: first-in-human Phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with *BRCA1/2*, *PALB2* or *RAD51C/D* mutations.** Timothy A. Yap, Houston, TX

**Discussant.** Patricia M. LoRusso, New Haven, CT

## Meet and Greet • 11:30 a.m.-12:20 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editor-in-Chief of *Molecular Cancer Research*: Massimo Loda, MD**

## NCI-NIH-Sponsored Session • 12:00 p.m.-1:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Review and Funding of Foundational Cancer Biology Research at NIH & NCI**

**Moderator**
Daniel L. Gallahan, Bethesda, MD

**Introduction.** Daniel L. Gallahan, Bethesda, MD

**Overview of NCI grants processes and policy updates.** Shannon Hughes, Bethesda, MD

**Overview of NIH grant review and policy updates.** Amy Rubinstein, Bethesda, MD

## Meet and Greet • 12:30 p.m.-1:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 4043 - Hall AF
**Meet the Editors-in-Chief of *Blood Cancer Discovery*: Riccardo Dalla-Favera, MD and Kenneth C. Anderson, MD**

## Special Session • 12:30 p.m.-1:45 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room 5, Convention Center
**AACR Annual Business Meeting of Members**

**AACR Chief Executive Officer.** Margaret Foti, Philadelphia, PA
**AACR President.** Philip D. Greenberg, Seattle, WA
**AACR Past President.** Lisa M. Coussens, Portland, OR
**AACR Treasurer.** William N. Hait, New Brunswick, NJ

## CME Advances in Diagnostics and Therapeutics • 12:30 p.m.-2:00 p.m.

Room 29, Convention Center
**Chemical Biology Approaches to Tackle Undruggable Targets**

**Chair:** Daniel K. Nomura, Berkeley, CA

**Chair Introduction.** Daniel K. Nomura, Berkeley, CA

**Reimagining druggability using chemoproteomic platforms.** Daniel K. Nomura, Berkeley, CA

**An 'omics approach to drug discovery.** Liron Bar-Peled, Boston, MA

**Proteome-wide ligand and target discovery in cells.** Christopher Parker, San Diego, CA

## CME Advances in Hematologic Malignancies • 12:30 p.m.-2:00 p.m.

Room 14, Convention Center
**Ongoing Advances in the Understanding and Treatment of Acute Myeloid Leukemia**

**Chair:** Omar Abdel-Wahab, New York, NY

**Chair Introduction.** Omar Abdel-Wahab, New York, NY

**AML: Ongoing advances and increasingly individualized treatment options.** Courtney D. Dinardo, Houston, TX

**NG05   Epitope editing enables targeted immunotherapy of acute myeloid leukemia.** Gabriele Casirati, Boston, MA

**Novel immunotherapy targets for the treatment of myeloid neoplasms.** Omar Abdel-Wahab, New York, NY

**Pre-leukemic mutations and leukemia stem cells in human AML.** Ravindra Majeti, Stanford, CA

# ⬛CME Advances in Organ Site Research • 12:30 p.m.-2:00 p.m.

Room 15, Convention Center
**Advances and Challenges in Therapy for Malignant Glioma**

**Chair:** Sean E. Lawler, Providence, RI

**Chair Introduction.** Sean E. Lawler, Providence, RI

**Recent clinical advances in the treatment of gliomas.** Patrick Y. Wen, Boston, MA

**Pre-clinical modeling of drug delivery and immunotherapies in glioblastoma.** Sean E. Lawler, Providence, RI

**Epigenetic reprogramming of the DNA repair machinery and hematopoiesis in mutant IDH1 gliomas.** Maria G. Castro, Ann Arbor, MI

Ballroom 6 A, Convention Center
**Translational and Clinical Advances in Pancreatic Cancer**

**Chair:** Diane M. Simeone, San Diego, CA

**Chair Introduction.** Diane M. Simeone, San Diego, CA

**The PRECEDE Study: A platform for risk modeling and early detection of pancreatic adenocarcinoma.** Diane M. Simeone, San Diego, CA

**Plasma whole genome sequencing for the detection of pancreatic cancer.** Faiyaz Notta, Toronto, ON, Canada

**Therapeutic exploitation of homologous recombination deficiency in pancreatic cancer.** Talia Golan, Tel Hashomer, Israel

## CME Advances in Population Sciences • 12:30 p.m.-2:00 p.m.

Room 31, Convention Center
**Progress Since COVID-19 on Cancer Prevention Rates**

**Chair:** John M. Carethers, La Jolla, CA

**Chair Introduction.** John M. Carethers, La Jolla, CA

**COVID-19 pandemic effects on cancer screening rates and predictions for future missed cancers.** Alpa V. Patel, Atlanta, GA

**Racial inequities in recovery rates for CRC screening and findings post-pandemic.** Hassan Ashktorab, Washington, DC

**Post-COVID-19 pandemic cancer screening rates and mitigation factors employed to potentially boost rates.** John M. Carethers, La Jolla, CA

## CME Advances in Technologies • 12:30 p.m.-2:00 p.m.

Ballroom 20 CD, Convention Center
**Novel Experimental Models for Functional Precision Genomics**

**Chair:** Alice Soragni, Los Angeles, CA

**Chair Introduction.** Alice Soragni, Los Angeles, CA

**Organoid human immunity model in motion.** Anne Rios, Utrecht, Netherlands

**Heterogeneity and genetic diversity in patient-derived organoid models from rare benign and malignant tumors.** Alice Soragni, Los Angeles, CA

**A living tumor organoid biobank for dependency mapping.** Mathew Garnett, Cambridge, United Kingdom

## CME Major Symposia • 12:30 p.m.-2:00 p.m.

Room 28, Convention Center
**Addressing Shared Risk Factors for Cancer, Cardiovascular Disease and Metabolic Disease**

**Chair:** Michael N. Pollak, Montreal, QC, Canada

**Introduction.** Michael N. Pollak, Montreal, QC, Canada

**Anti-obesity drugs: Can we add cancer risk reduction to the benefits in cardiovascular disease and diabetes?** Michael N. Pollak, Montreal, QC, Canada

**Biology of nicotine addiction that underlies the global disease burden attributable to tobacco.** Scott Vrieze, Minneapolis, MN

**Optimal dietary patterns for prevention of cancer, diabetes and heart disease.** Edward L. Giovannucci, Boston, MA

Ballroom 20 AB, Convention Center
**Cancer Epigenome Analysis for Novel Diagnostic Markers and Therapeutic Strategies**

**Chair:** Bing Ren, La Jolla, CA

**Introduction.** Bing Ren, La Jolla, CA

**Identifying, modeling and targeting epigenetic cancer drivers.** Bradley E. Bernstein, Boston, MA

**Single-cell and 3D genomics: new methods and applications to cancer.** Christina Leslie, New York, NY

**Epigenome analysis of tumor heterogeneity and evolution.** Bing Ren, La Jolla, CA

Ballroom 6 DE, Convention Center
**Communication between DNA Damage and Immune Responses in Cancer**

**Chair:** Roger A. Greenberg, Philadelphia, PA

**Introduction.** Roger A. Greenberg, Philadelphia, PA

**Innate immune sensing of DNA damage during cancer initiation and therapy.** Gaorav Gupta, Chapel Hill, NC

**RNA-mediated genome instability and immune signaling.** Karlene A. Cimprich, Stanford, CA

**NG04 Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in small cell lung cancer.** Israel Cañadas, Philadelphia, PA

**Inflammatory signaling in homologous recombination deficient ovarian cancer.** Roger A. Greenberg, Philadelphia, PA

Room 1, Convention Center
**Disparities in Pediatric Oncology**

**Moderator**: Alejandro Sweet-Cordero, San Francisco, CA

**Panelists**:
Lena Winestone, San Francisco, CA
Justine Kahn, New York, NY
Puja Umaretiya, Dallas, TX
M. Paula Aristizabal, San Diego, CA

Martha Donoghue, Silver Spring, MD

Ballroom 6 B, Convention Center
**Neoadjuvant Therapies**

**Chair:** Kelly K. Hunt, Houston, TX

**Introduction.** Kelly K. Hunt, Houston, TX

**Neoadjuvant therapy in breast cancer: Endpoints, targets and future directions.** Kelly K. Hunt, Houston, TX

**Getting a head start with neoadjuvant therapy in melanoma.** Georgia Beasley, Durham, NC

**Progress in neoadjuvant therapy for soft-tissue sarcoma.** Jonathan C. Trent, Miami, FL

Hall GH, Convention Center
**New Models of CAR-T Cells**

**Chair:** Marcela V. Maus, Boston, MA

**Introduction.** Marcela V. Maus, Boston, MA

**Safe and effective targeting of T cell malignancies with CAR T.** Rayne H. Rouce, Houston, TX

**TEAMS of CAR-T cells in cancer.** Marcela V. Maus, Boston, MA

**New approaches to enhance CAR-T cell efficacy for solid cancers.** Crystal L. Mackall, Stanford, CA

Ballroom 6 CF, Convention Center
**Somatic Evolution in Normal Tissues: Causes and Consequences - Dedicated to the Memory of Judith Campisi**

**Chair:** James V. DeGregori, Aurora, CO

**Introduction.** James V. DeGregori, Aurora, CO

**SY36-01   Somatic evolution, cancer, and our inevitable decline with age: Inextricably linked.** James V. DeGregori, Aurora, CO

**Somatic mutation and clonal selection in normal tissues.** Inigo Martincorena, Cambridge, United Kingdom

**Clonal Hematopoiesis: Somatic mutation in hematopoietic stem cells and the impact of environmental stress on clonal competition.** Katherine King, Houston, TX

Room 33, Convention Center
**Targeting Aberrant Transcription in Pediatric Cancer**

**Chair:** Claudia Kleinman, Montreal, QC, Canada

**Introduction.** Claudia Kleinman, Montreal, Q, Canada

**Identifying aberrant transcription in the era of big data.** Claudia Kleinman, Montreal, QC, Canada

**NG06   Tracing the developmental origins of group 3 medulloblastoma.** Olivier Saulnier, Paris, France

**From oncogenic chimeric transcription factors to immune targets.** Olivier Delattre, Paris, France

**Aberrant transcription as a therapeutic target in pediatric brain tumors.** Pratiti Bandopadhayay, Boston, MA

## CME **Awards and Lectures** • 12:15 p.m.-3:15 p.m.

Ballroom 6 A, Convention Center
**NCI Director's Address and Fireside Chat**

**Introduction.** Philip D. Greenberg, Seattle, WA

**NCI Director's Address.** W. Kimryn Rathmell, Bethesda, MD

## Special Session • 12:30 p.m.-2:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 30, Convention Center
**Convergence Research: Deciphering Tumor Microenvironment Interactions and Therapeutic Responses with Cutting-Edge Multi-Organ Organoids and Multi-Omics: A SU2C Session**

**Chair:** Arnold J. Levine, Princeton, NJ

**Introduction.** Arnold J. Levine, Princeton, NJ

**Understanding and manipulating immune modulation by the microbiome.** Michael Fischbach, Princeton, NJ, CA

**Oxygen gradient influences invasion and polarity in organoid models of colorectal cancer.** Scott R. Manalis, Boston, MA

**Disentangling tumor and environmental contributions to colorectal cancer progression.** Karuna Ganesh, New York, NY

**Q&A.** Arnold J. Levine, Princeton, NJ

## Meet and Greet • 1:30 p.m.-2:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editor-in-Chief of *Clinical Cancer Research*: Keith T. Flaherty, MD**

## NCI-NIH-Sponsored Session • 1:30 p.m.-2:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**NCI Funding Opportunities and Grant Writing Strategies for New and Early-Stage Investigators**

**Moderators**
Sundar Venkatachalam, Bethesda, MD
Morgan O'Hayre, Bethesda, MD

**Grant mechanisms and funding opportunities.** Sundar Venkatachalam, Bethesda, MD

**Grant writing strategies.** Morgan O'Hayre, Bethesda, MD

**Peer review process/updates.** Lambratu Rahman Sesay, Bethesda, MD

**NCI research resources.** Christophe Marchand, Rockville, MD

## Poster Sessions • 1:30 p.m.–5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App

**Survivorship**
Section 1      Advocates Poster Session 1
Section 37     Advocates Poster Session 2

**Immunology**
Section 2      Antibody-Drug Conjugates
Section 3      Epigenetic Regulation of Tumor Immunity
Section 4      Immune Checkpoints and Inhibitory Molecules 2
Section 5      Innate Immunity in Cancer
Section 6      Single Target and Bispecific Antibodies

**Tumor Biology**
Section 7      Biomarkers and Expression Differences in Metastatic Progression
Section 8      Cancer Stem Cells and Their Microenvironment
Section 9      Microbiome and Cancer
Section 10     Modeling Cancer in Mice
Section 11     Pediatric Cancer Genomics and Epigenomics
Section 12     Radiation Science
Section 13     The Tumor Microenvironment as a Drug Target
Section 54     Late-Breaking Research: Tumor Biology 1

**Molecular/Cellular Biology and Genetics**
Section 14     Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 2
Section 15     Cellular Stress Responses 2
Section 16     microRNA- and Other Non-coding RNA-Based Translational Medicine
Section 17     New Insights into Tumor Suppressor Genes

Section 18     Oncogenic Transcription Factors
Section 19     Signaling Pathways That Regulate Metabolism 1
Section 53     Late-Breaking Research: Molecular/Cellular Biology and Genetics 1

**Chemistry**
Section 20     High-Throughput Screening and New Assay Technology

**Experimental and Molecular Therapeutics**
Section 21     Antibody-Drug Conjugates
Section 22     Cancer Biology and Metastasis
Section 23     Cancer Immunotherapy and Drug Delivery
Section 24     Epigenetic Targets
Section 25     Immune Modulators and Antisense Molecules
Section 26     Mechanisms of Drug Resistance 2
Section 27     Molecular Glues
Section 28     Novel Antitumor Agents 3
Section 29     Novel Therapeutics
Section 52     Late-Breaking Research: Experimental and Molecular Therapeutics 2

**Prevention / Early Detection / Interception**
Section 30     Animal and Cellular Models of Cancer Prevention and the Study of
               Biological/Biochemical Mechanisms
Section 31     Cancer Control and Survivorship

**Population Sciences**
Section 32     Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biologic
               Effects, and Prognosis
Section 33     Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers

**Bioinformatics / Computational Biology / Systems Biology / Convergent Science**
Section 34     Application of Bioinformatics to Cancer Biology 3
Section 35     Artificial Intelligence and Machine/Deep Learning 2
Section 36     Database Resources, Statistical Methods, and Other Tools

**Endocrinology**
Section 38     Molecular, Preclinical, and Clinical Endocrinology 1

**Clinical Research**
Section 39     Adoptive Cellular Therapy 1
Section 40     Biomarkers in Clinical Trials
Section 41     Circulating Nucleic Acids 3
Section 42     Circulating Tumor Cells 1
Section 43     Combination Immunotherapies
Section 44     Diagnostic Biomarkers 2
Section 45     Metastasis Biomarkers
Section 46     Outcome Investigation with Real World Data
Section 47     Tumor Immune Response 2

**Clinical Trials**
Section 48     First-in-Human Phase I Clinical Trials 1
Section 49     Phase 0 and Phase I Clinical Trials
Section 50     Phase I Clinical Trials in Progress 2

**Meet and Greet** • 2:30 p.m.-3:30 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room 26, Convention Center
**Meet the Research Grant Reviewers**

Christine M. Lovly, Nashville, TN
Sandeep Burma, San Antonio, TX

CME **Major Symposium** • 2:30 p.m.-4:00 p.m.

Room 1, Convention Center
**In the Eye of the Beholder: Equipoise in Cancer Clinical Trials**

**Moderator**
Paz Joan Vellanki, Silver Spring, MD

**Speakers:**
Jeevan Puthiamadathil, Silver Spring, MD
George D. Demetri, Boston, MA
Kathryn A. Gold, San Diego, CA

**Panelists**:
Chi Song, Silver Spring, MD
Paz Joan Vellanki, Silver Spring, MD
Dafydd Gwyn Bebb, Waltham, MA
James Pantelas, San Carlos, CA

CME **Clinical Trials Minisymposium** • 2:30 p.m.-4:30 p.m.

Hall GH, Convention Center
**Advances in Immunotherapy**

**Cochairs:** Alice Y. Ho, Boston, MA; Isaac Chan, Baltimore, MD

**Introduction.** Alice Y. Ho, Boston, MA

**CT029   Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial.** Jian Guan, Houston, TX

**CT030   Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity.** Yongwoo David Seo, Houston, TX

**CT031   A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer.** Zev A. Wainberg, Los Angeles, CA

**CT032   Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202).** Atsushi Horiike, Tokyo, Japan

**CT033   Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort.** Antoine Italiano, Bordeaux, France

**CT034   Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC).** Ernest Nadal, Barcelona, Spain

**CT035   Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial.** Crescens Tiu, Sutton, United Kingdom

**Closing remarks.** Isaac Chan, Baltimore, MD


## CME Late-Breaking Minisymposium • 2:30 p.m.-4:30 p.m.

Room 16, Convention Center
**Minisymposium: Late-Breaking Research**

**Cochairs:** Teresa A. Zimmers, Portland, OR; Priscilla K. Brastianos, Boston, MA

**Introduction.** Priscilla K. Brastianos, Boston, MA

**LB231  The mutagenic forces shaping the genomic landscape of lung cancer in never smokers.** Marcos Diaz-Gay, San Diego, CA

**LB232  Implementation of population-based risk assessment for hereditary cancer in primary care: Results from the Early Detection of Genetic Risk (EDGE) Trial.** Elizabeth M. Swisher, Seattle, WA

**LB233  Single-cell transcriptional analysis of embryonic melanoblasts pinpoints embryonic cell states that underlie targeted therapy and immune checkpoint blockade resistance.** Vishaka Gopalan, Bethesda, MD

**LB234  Identifying cancer vulnerabilities associated with changes in chromatin accessibility by simultaneously profiling hundreds of cancer cell lines with ATAC-seq.** Patricia Borck, Cambridge, MA

**LB235  Prrx1 regulates acinar cell plasticity via TGFβsignaling in pancreatic acinar-to-ductal metaplasia.** Noriyuki Nishiwaki, New York, NY

**LB236  Metabolically armed CD19 CAR-T cells for safe and effective treatment of relapsed or refractory CD19+ B cell hematological malignancies at extremely low doses.** Jingjing Ren, Shenzhen, China

**LB237  PVRL2 suppresses antitumor immune responses through PVRIG- and TIGIT-independent pathways.** Jiuling Yang, San Francisco, CA

**Closing remarks.** Teresa A. Zimmers, Portland, OR

**CME Minisymposia** • 2:30 p.m.-4:30 p.m.

Ballroom 20 AB, Convention Center
Bioinformatics, Computational Biology, Systems Biology, and Convergent Science
**Multi-omic Analysis and Translational Research**

**Chair:** Sohrab Shah, New York, NY

**Introduction.** Sohrab Shah, New York, NY

**3872   Multi-ancestral origins of colorectal lesions.** Ryan O. Schenck, Palo Alto, CA

**3873   Understanding spatial organization of cellular plasticity in pancreatic ductal adenocarcinoma.** Izabella Zamora, Cambridge, MA

**3874   Adaptive heterogeneity enables the survival of residual malignant PDAC cells in response to RAS-GTP inhibition.** Lorenzo Tomassoni, New York, NY

**3875   Glioblastoma mutational profiles drive cancer cell signaling and immune evasion.** Maryam Pourmaleki, New York, NY

**3876   A spatial transcriptomic study of a triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) model of residual disease refractory to conventional chemotherapy.** Qian Zhu, Houston, TX

**3877   Multi-modal analysis of paracrine signaling in group 3/4 medulloblastoma.** Bohyeon Yu, San Francisco, CA

**3878   Therapy-associated remodeling of pancreatic cancer revealed by single-cell spatial transcriptomics and optimal transport analysis.** JINGYI CAO, Boston, MA

**Closing remarks.** Sohrab Shah, New York, NY


Room 11, Convention Center
Chemistry
**Identification, Optimization, and Characterization of Protein Degraders and Inhibitors**

**Cochairs:** Keith R. Hornberger, New Haven, CT; Alex Gregory Waterson, Nashville, TN

**Introduction.** Keith R. Hornberger, New Haven, CT

**3879   Development of potent, highly selective and efficacious SMARCA2 degraders.** Lin Yang, Ann Arbor, MI

**3880   LYTAC targeting galectin-1 to enhance radioimmunotherapy of cancers in the upper aerodigestive tract.** Yuyan Jiang, Stanford, CA

**3881   Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression.** Haibin Zhou, Ann Arbor, MI

**3882   Targeted degradation of undruggable proteins using a novel heterobifunctional proteomimetic platform.** Max Wang, Evanston, IL

**3883   Cryo-EM-guided enhancement of target selectivity of a novel p97 inhibitor for treating multiple myeloma and acute myeloid leukemia.** Jason Crawford, Burnaby, BC, Canada

**3884   Artificial intelligence (AI)-enabled discovery of GLX1546, a novel and potent inhibitor of ULK1/2 kinases and autophagy.** Chengtao Li, Beijing, China

**3885   A ubiquitin-specific proximity labeling method to study drug-induced ubiquitylation.** Hai-Tsang Huang, Cambridge, MA

**Closing Remarks.** Alex Gregory Waterson, Nashville, TN


Ballroom 6 CF, Convention Center
Clinical Research
**Application of Real-World Evidence to Cancer Care**

**Chair:** Kenneth L. Kehl, Boston, MA

**Introduction.** Kenneth L. Kehl, Boston, MA

**3886   Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines.** Alyssa Obermayer, Tampa, FL

**3887   The origins and clinical impact of extrachromosomal DNA across 39 cancers.** Chris Bailey, London, United Kingdom

**3888   *TOP1* mutations mediate cross resistance to ADCs in metastatic breast cancer.** Rachel Occhiogrosso Abelman, Boston, MA

**3889   Genomic landscape of gynecologic cancers with poor prognosis in Japan, an analysis of the national database of comprehensive genomic profiling tests.** Qian Xi, Tokyo, Japan

**3890   Comprehensive molecular and immunological characterization of early-onset esophagogastric cancer.** Lawrence W. Wu, New York, NY

**3891   Early real-world experience with repeat multi-cancer early detection (MCED) testing.** Ora K. Gordon, Los Angeles, CA

**3892   Systematic generation of a clinicogenomic harmonized oncologic real-world dataset (MSK-CHORD).** Christopher J. Fong, New York, NY


Ballroom 6 B, Convention Center
Clinical Research
**Early Detection and Progression Biomarkers**

**Cochairs:** David L. Rimm, New Haven, CT; Muhammed Murtaza, Madison, WI

**Introduction.** David L. Rimm, New Haven, CT

**3893   A multimodal spatial-omics atlas of lung precancer and progression to adenocarcinoma.** Ansam Sinjab, Houston, TX

**3894   The temporal influence of the tumor microenvironment in response to checkpoint

**blockade.** Noah F. Greenwald, Palo Alto, CA

**3895   Prognostic significance of blood-based multi-cancer detection in cell-free DNA: 4-year outcomes analysis.** Charles Swanton, London, United Kingdom

**3896   Time to diagnosis analysis using miRNA-based ovarian cancer prediction models.** James Webber, Boston, MA

**3897   Isolation and molecular characterization of exosomes from glioblastoma patients using a microfluidic device after ultrasound-based opening of the blood-brain barrier.** Abha Kumari, Ann Arbor, MI

**3898   SJPedPanel: A pan-cancer gene panel for childhood malignancies.** Pandurang Kolekar, Memphis, TN

**3899   An exosome-based liquid biopsy for non-invasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter and prospective study.** Caiming Xu, Monrovia, CA

**Closing Remarks.** Muhammed Murtaza, Madison, WI

Room 30, Convention Center
Experimental Therapeutics
**Drug Discovery 1: New Targets and Approaches**

**Cochairs:** Sharon Pitteri, Palo Alto, CA; Tanya Ivanova Stoyanova, Los Angeles, CA

**Introduction.** Sharon Pitteri, Palo Alto, CA

**3900   A high-throughput platform identifies novel drug combinations towards acute myeloid leukemia therapy.** Anthony R. Soltis, Boston, MA

**3901   Therapeutic targeting of LGR5-positive cancer stem cells.** Stephen B. Howell, La Jolla, CA

**3902   The Nanoprimer: A significant opportunity to boost the efficacy of cancer therapies.** Julie Devallière, Paris, France

**3903   Discovery of ULBP6 as a novel immuno-oncology target using pleiotropic signals from 23andMe's genetic and health survey database.** Kim Gerrick, South San Francisco, CA

**3904   Multiplexed flow cytometry based immunophenotyping paired with functional *ex vivo* (MFLEX) drug profiling informs potential efficacy of therapeutic agents in acute myeloid leukemia.** Reecha Shah, South San Francisco, CA

**3905   Targeting RNA demethylase ALKBH5 blocks growth and improves therapy response in osteosarcoma.** Daisy Medina, San Antonio, TX

**3906   *Ex vivo* breast tumors for understanding the patient specific tumor microenvironment remodeling and drug responses.** Elizabeth Martin, Portland, OR

**Closing Remarks.** Tanya Ivanova Stoyanova, Los Angeles, CA

Ballroom 6 DE, Convention Center
Experimental Therapeutics
**Novel Molecular Targets and Biomarkers**

**Cochairs:** Benjamin L. Ebert, Boston, MA; Alice P. Chen, Bethesda, MD

**Introduction.** Benjamin L. Ebert, Boston, MA

**3907   Novel public and tumor-wide neoantigens arising from clonal aberrant splicing events drive tumor-specific T-cell responses across diverse cancer types.** Darwin Kwok, San Francisco, CA

**3908   DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2.** Jennifer B. Castro, Lexington, MA

**3909   PARG inhibitor sensitivity is correlated with accumulation of single strand DNA gaps in preclinical models of ovarian cancer.** Ramya Ravindranathan, Boston, MA

**3910   The Atlas of Blood Cancer Genomes: A resource for therapeutic and biomarker development.** Jennifer Shingleton, Durham, NC

**3911   A FGFR-p53 developmental signaling axis drives progression of salivary cancer.** Julia M. Billington, Tampa, FL

**3912   ATM and PARP combined inhibition demonstrate synergistic antitumor efficacy in osteosarcoma models.** Sona N. Kocinsky, Memphis, TN

**3913   Molecular mechanism of action and targets of glucocorticoids in lymphoma therapy.** Jaewoo Choi, Bethesda, MD

**Closing Remarks.** Alice P. Chen, Bethesda, MD

Ballroom 20 CD, Convention Center
Immunology
**Immune Targets and Therapies**

**Cochairs:** Sophie E. Lucas, Brussels, Belgium; Taha Merghoub, Jersey City, NJ

**Introduction.** Taha Merghoub, Jersey City, NJ

**3914   IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target.** X. Shirley Liu, Cambridge, MA

**3915   BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models.** Dhan Chand, Lexington, MA

**3916   TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy.** Ayushi Patel, New York, NY

**3917   A CXCR4 partial agonist TFF2-MSA improves anti-PD-1 immunotherapy in advanced gastric cancer by selectively targeting PMN-MDSC.** Jin Qian, New York, NY

**3918   Targeting MARCO in combination with anti-CTLA4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming.** Hidenori Takahashi, Tampa, FL

**3919 Targeting tissue-resident macrophage progenitors by anti-IL34 restores anti-tumor immunity and suppresses tumor growth.** Hui Chen, San Diego, CA

**3920 BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment.** Tsuri Peretz, Misgav Industrial Park, Israel

**Closing Remarks.** Sophie E. Lucas, Brussels, Belgium

Room 28, Convention Center
Immunology
**Understanding and Targeting Pathogenic Inflammation in Solid Tumors**

**Cochairs:** Katelyn T. Byrne, Portland, OR; Mara H. Sherman, New York, NY

**Introduction.** Mara H. Sherman, New York, NY

**3921 The aged tumor microenvironment limits CD8[+] T cell control of cancer.** Alex C.Y. Chen, Boston, MA

**3922 Quaking modulates anti-tumor immunity by regulating antigen processing and presentation in dendritic cells.** Yating Li, Houston, TX

**3923 Targeting immunosuppressive TREM2[+]tumor associated macrophages in prostate cancer.** Alex J. Lee, Baltimore, MD

**3924 Dual COX-2/sEH inhibition enhances immunotherapy and chemotherapy to induce bladder cancer regression.** Kimberly Lupita Vazquez, Boston, MA

**3925 Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity.** Seunghyun Lee, St. Louis, MO

**3926 ARF6-dependent endocytic trafficking of the interferon-gamma receptor drives adaptive immune resistance and response to immune checkpoint blockade.** Allie H. Grossmann, Salt Lake City, UT

**3927 Metabolic inhibition of BATF2 dampens type-I interferon-mediated immune sensing of cancer.** Wang Gong, Ann Arbor, MI

**Closing Remarks.** Katelyn T. Byrne, Portland, OR

Room 31, Convention Center
Molecular/Cellular Biology and Genetics
**Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Heterogeneity**

**Cochairs:** Gayathri Devi, Durham, NC; Jovanny Zabaleta, New Orleans, LA

**Introduction.** Gayathri Devi, Durham, NC

**3928 Genomic landscape and estimation of immune infiltration of soft tissue sarcoma histology subtypes from the ORIEN network.** Alex C. Soupir, Tampa, FL

**3929 Comparative genomics of breast cancer in indigenous African and western populations first results from the E-Predict study.** Smiths Sengkwawoh Lueong, Essen, Germany

**3930   The therapeutic implications of consensus genomic subtypes of gastric adenocarcinoma.** Yun Seong Jeong, Houston, TX

**3931   Breast cancer genomic architecture contributes to immune escape across metastasis.** Lise Mangiante, Stanford, CA

**3932   Multi-omics characterization of molecular features and global-local genomic ancestry analysis of colorectal cancer in Hispanic-Latinos.** Enrique I. Velazquez Villarreal, Los Angeles, CA

**3933   Comprehensive molecular characterization of mitochondrial mutational landscape across the evolution of lung adenocarcinoma.** Alka Singh, Chicago, IL

**3934   Smoking's influence on divergent paths to lung cancer.** Edward James Evans, Aurora, CO

**Closing Remarks.** Jovanny Zabaleta, New Orleans, LA

Room 33, Convention Center
Molecular/Cellular Biology and Genetics
**Novel Mechanisms of Oncogenesis and New Therapeutic Targets**

**Cochairs:** Karen M. Cichowski, Boston, MA; Martin McMahon, Salt Lake City, UT

**Introduction.** Karen M. Cichowski, Boston, MA

**3935   Involvement of nanoscale physical communication in obesity-associated breast cancer severity.** Tanmoy Saha, Cambridge, MA

**3936   Altered endosomal pH regulation: molecular mechanisms of oncogenesis and therapeutic dependencies.** Higinio Dopeso, New York, NY

**3937   Investigating the role of fibulin 3 in pancreatic tumorigenesis.** Hyemin Song, La Jolla, CA

**3938   A novel mouse model reveals potential therapeutic strategies for RIT1-driven lung adenocarcinomas.** Alessandro Mauro Mozzarelli, New York, NY

**3939   Ror2, a novel key regulator driving cell fate decisions throughout pancreatic tumor progression.** Simone Benitz, Detroit, MI

**3940   Nuclear translocation of HER3 promotes breast cancer progression and dissemination recruiting immune cells via CXCL1 and CXCL8.** Tasneem Cheytan, Heidelberg, Germany

**3941   Wild-type KRAS dosage in mutant KRAS lung cancer: Implications for tumorigenesis and therapeutic response.** Tonci Ivanisevic, Leuven, Belgium

**Closing Remarks.** Martin McMahon, Salt Lake City, UT

Room 14, Convention Center
Population Sciences
**Cancer Disparities Research**

**Cochairs:** Salma Shariff-Marco, San Francisco, CA; Diana Redwood, Anchorage, AK

**Introduction.** Diana Redwood, Anchorage, AK

**3942   Mailed at-home self-sampling for HPV testing increases screening participation among under-screened patients in a U.S. safety net health system: Results of the PRESTIS trial.** Trisha L. Amboree, Houston, TX

**3943   Refined race and ethnicity categories for an EHR-based cohort to study disparities in liver cancer risk.** Mindy C. DeRouen, San Francisco, CA

**3944   Addressing stomach cancer disparities by assessing *Helicobacter pylori* infections among American Indian adults from the Navajo Nation.** Dornell Pete, Seattle, WA

**3945   The development of a culturally adapted tobacco prevention curriculum for LGBTQ+ youth across California: Formative research.** Bonnie Halpern-Felsher, Palo Alto, CA

**3946   Weaving equity into the fabric of health: A deep dive into race, social determinants of health and facility type in pancreatic adenocarcinoma care.** Christopher Wu, Birmingham, AL

**3947   Non-BRCA variants in hereditary breast and ovarian cancer patients in the Northern Mexico population.** Carlos H. Burciaga-Flores, Monterrey, Mexico

**3948   HPV45 and HPV52 prevalence, within-type variants, and precancer/cancer risks differ by race/ethnicity.** Aimee J. Koestler, Rockville, MD

**Closing remarks.** Salma Shariff-Marco, San Francisco, CA

Room 15, Convention Center
Tumor Biology
**Genetic Drivers and Therapeutic Achilles' Heels of Childhood Cancers**

**Cochairs:** Sarah K. Tasian, Philadelphia, PA; Theodore W. Laetsch, Philadelphia, PA

**Introduction.** Theodore W. Laetsch, Philadelphia, PA

**3949   SMARCAL1 is a novel synthetic lethal target in ALT+ osteosarcoma and neuroblastoma.** Lillian M. Guenther, Memphis, TN

**3950   Dedifferentiation unveils origin of Ewing sarcoma.** Utkarsh Kapoor, Vienna, Austria

**3951   Timing the development of chemoresistance in relapsed pediatric cancer.** Sasha Blay, Toronto, ON, Canada

**3952   Multiomic single-cell tumor evolution models of minimal residual disease in pediatric B-cell acute lymphoblastic leukemia.** Steven M. Foltz, Philadelphia, PA

**3953   BET inhibitor increases DNA damage, modulates Wnt signaling, and suppresses osteosarcoma growth in naïve and metastatic disease models.** Niknam Riyahi, Indianapolis, IN

**3954  Increased mosaic chromosomal alterations among survivors of childhood acute myeloid leukemia.** Xijun Zhang, Memphis, TN

**3955  A proteogenomic study of high-grade glioma among adolescents and young adults.** Nicole Tignor, New York, NY

**Closing Remarks.** Sarah K. Tasian, Philadelphia, PA

## CME Special Session • 2:30 p.m.-4:30 p.m.

Room 29, Convention Center
**AACR-JCA Joint Session: Novel Molecular Drivers of Gastroesophageal Cancers and Evolving Biomarker Driven Therapies**

**Cochairs:** Elena Elimova, Toronto, ON, Canada; Tatsuhiro Shibata, Tokyo, Japan

**Introduction.** Elena Elimova, Toronto, ON, Canada

**Molecular genetic analysis of gastric cancer.** Tatsuhiro Shibata, Tokyo, Japan

**ERBB2 addiction in gastroesophageal cancer: Unveiling innovations, navigating challenges, and charting future frontiers.** Yelena Yuriy Janjigian, New York, NY

**Emerging targets for gastro-esophageal cancer: CLDN18.2 and FGFR2.** Kohei Shitara, Chiba, Japan

**The role of immunotherapy in the management of gastroesophageal cancers and biomarkers that predict response.** Elena Elimova, Toronto, ON, Canada

**Closing Remarks.** Tatsuhiro Shibata, Tokyo, Japan

## CME Awards and Lectures • 3:00 p.m.-3:45 p.m.

Room 17, Convention Center
**AACR-Women in Cancer Research Charlotte Friend Lectureship**

**Chair:** Carmen E. Guerra, Philadelphia, PA

**Award Lecture.** Elizabeth L. Travis, Houston, TX

## NCI-NIH-Sponsored Session • 4:00 p.m.-5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room 2, Convention Center
**From Lab to Market: Funding and Transition Support for Early-Stage Oncology Startups from National Cancer Institute**

**Moderator**: Monique Pond, Bethesda, MD

**Speakers:**
Nathan G. Dolloff, Charleston, SC
Connor Barth, Portland, OR

## CME Awards and Lectures • 4:45 p.m.-5:30 p.m.

Ballroom 20 AB, Convention Center
**AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research**

**Chair:** Michael A. Caligiuri, Duarte, CA

**Award Lecture.** Chi Van Dang, New York, NY

## CME Special Session • 4:45 p.m.-5:30 p.m.

Ballroom 6 DE, Convention Center
**AACR-ASCO Joint Session: Strategies for Detecting Minimal Residual Disease (MRD) and How to Apply It in the Clinic**

**Cochairs:** Philip D. Greenberg, Seattle, WA; Lynn M. Schuchter, Philadelphia, PA

**Welcome and introductory remarks from the AACR President.** Philip D. Greenberg, Seattle, WA

**Welcome and introductory remarks from the ASCO President.** Lynn M. Schuchter, Philadelphia, PA

**Progress in MRD assessment in solid tumors and the path to high value clinical applications.** Luis A. Diaz, New York, NY

**Technical and clinical considerations for assessing MRD using circulating tumor DNA.** Maximilian Diehn, Stanford, CA

**Strategies to therapeutically target dormant and reactivated MRD to prevent cancer recurrence: Challenges and opportunities.** Angela M. DeMichele, Philadelphia, PA

## CME Awards and Lectures • 5:00 p.m.-5:45 p.m.

Room 28, Convention Center
**AACR Award for Outstanding Achievement in Chemistry in Cancer Research**

**Chair:** Daniel K. Nomura, Berkeley, CA

**Award Lecture.** Nathanael S. Gray, Boston, MA

Ballroom 6 A, Convention Center
**AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology**

**Chair:** Ignacio Melero, Pamplona, Spain

**Funder Remarks.** Jill O'Donnell-Tormey, New York, NY

**Award Lecture.** Gordon J. Freeman, Boston, MA

## CME Meet-the-Expert Sessions • 5:00 p.m.-5:45 p.m.

Ballroom 6 CF, Convention Center
**Circulating Tumor DNA to Enable Interception of Molecular Residual Disease in Solid Tumors**

Lillian L. Siu, Toronto, ON, Canada

Room 15, Convention Center
**Identifying and Measuring Gender Inequities in Science and Medicine**

Jennifer Rubin Grandis, San Francisco, CA

Room 29, Convention Center
**Myeloma as a Paradigm for Developing Novel Therapies Targeting Tumor in its Microenvironment**

Kenneth C. Anderson, Boston, MA

Ballroom 6 B, Convention Center
**Improving Cancer Detection with Nanotechnology**

Sangeeta N. Bhatia, Cambridge, MA

# CME Forums • 5:00 p.m.-5:45 p.m.

Room 30, Convention Center
**Breaking the Obesity-Cancer Link: The Role of New Weight Loss Drugs**

**Chair:** Stephen D. Hursting, Chapel Hill, NC

**Chair Introduction.** Stephen D. Hursting, Chapel Hill, NC

**What is a body weight "set point" and how can we change it?** Randy Seeley, Ann Arbor, MI

**Nutrient-stimulated hormone-based therapies for the treatment of obesity: Sparks from the pipeline.** Ania Jastreboff, New Haven, CT

Room 31, Convention Center
**Financial Hardship following Cancer Diagnosis: Opportunities for Improving Care and Patient Outcomes**

**Chair:** Robin Yabroff, Atlanta, GA

**Introduction: Overview of medical financial hardship following cancer diagnosis.** Robin Yabroff, Atlanta, GA

**Considerations and strategies for addressing financial toxicity.** Matthew P. Banegas, San Diego, CA

**Mitigating financial toxicity through legal protections and patient and provider education.** Joanna Fawzy Doran, Chicago, IL

Room 33, Convention Center
**Optimizing Cancer Care in Low Resource Settings**

**Chair:** Timothy R. Rebbeck, Boston, MA

**Chair Introduction.** Timothy R. Rebbeck, Boston, MA

**Assessing readiness for clinical cancer research in low- and middle-income countries.** Jennifer Dent, Seattle, WA

**Adapted technologies and therapies for cancer care in low resource settings.** Wilfred Ngwa, Baltimore, MD

**Framework for resource stratification in cancer care: The National Comprehensive Cancer Network experience.** Thomas W. Flaig, Aurora, CO

Hall GH, Convention Center
**Optimizing Cancer Vaccines through Advances in Immunogenomics and Immunopeptidomics**

**Chair:** Nina Bhardwaj, New York, NY

**Chair Introduction.** Nina Bhardwaj, New York, NY

**Improvement of tumor neoantigen detection by high field asymmetric waveform ion mobility (mass) and spectroscopy (FAIMS).** Robert D. Schreiber, St. Louis, MO

**Dark antigens: A new class of tumor-specific targets for immunotherapy.** Sebastian Amigorena, Paris, France

**Predictability and co-evolution of neoantigens and T-cell receptors.** Benjamin D. Greenbaum, New York, NY

## CME Special Session • 5:00 p.m.-5:45 p.m.

Ballroom 20 CD, Convention Center
**The Nature of Cancer: Lessons Learned from Tumors with Simple Genomes**

**Chair:** Charles W. Roberts, Memphis, TN

**Chair Introduction.** Charles W. Roberts, Memphis, TN

**Insights into the nature of cancer.** Charles W. Roberts, Memphis, TN

**Goldilocks: Not just a children's tale.** Kimberly Stegmaier, Boston, MA

**The genesis of cancer: Lessons from pediatrics.** Stefan M. Pfister, Heidelberg, Germany

## CME Awards and Lectures • 5:30 p.m.-6:15 p.m.

Room 14, Convention Center
**AACR Award for Outstanding Achievement in Basic Cancer Research**

**Chair:** Jonathan Chernoff, Jenkintown, PA

**Award Lecture.** Sarah-Maria Fendt, Leuven, Belgium

Room 17, Convention Center
**AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research**

**Chair:** Jonathan Chernoff, Jenkintown, PA

**Job's Dilemma for the Genome: Why Bad Things Happen to Good Chromosomes.** David Pellman, Boston, MA

# Professional Advancement Session • 5:30 p.m.-7:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Ballroom C - Omni San Diego Hotel
**Productive Peer Review: Improving Science While Avoiding Common Pitfalls**

**Moderators:**
Christine A. Iacobuzio-Donahue, New York, NY
Christine M. Lovly, Nashville, TN

# Town Meetings • 5:30 p.m.-7:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall B - Manchester Grand Hyatt San Diego
**MICR Town Hall Meeting**

**Chair:** Camille C. R. Ragin, Philadelphia, PA

Sapphire Ballroom - Hilton Bayfront Hotel
**Losing our Inhibitions – Is (Protein) Degradation Preferred?: A Chemistry in Cancer Research Working Group Town Hall Meeting**

**Cochairs:** Mary M. Mader, Indianapolis, IN; Lori S. Friedman, South San Francisco, CA

**Moderator**: Katrina L. Jackson, Watertown, MA

**Speakers:**
Laura La Bonte, Cambridge, MA
Owen Wallace, Boston, MA
Harald Weinstabl, Vienna, Austria

Sapphire Ballroom - Hilton Bayfront Hotel
**Perspectives in Cancer Prevention: Global and Early Detection Approaches: A Cancer Prevention Working Group Town Hall - Dedicated to the Memory of David S. Alberts**

**Cochairs:** Adriana Albini, Milano, Italy; Marcia R. Cruz-Correa, San Juan, PR

**CPWG Working Group Overview.** Adriana Albini, Milano, Italy; Marcia R. Cruz-Correa, San Juan, PR

**Title to be announced.** Philip E. Castle, Rockville, MD

**Precision prevention through population risk stratification and lifestyle medicine.** Olufunmilayo I. Olopade, Chicago, IL
**Moderator**
Adriana Albini, Milano, Italy

**Round table discussion on global perspectives: nobody left behind**
**Panelists**:
Kevin Darryl Cassel, Honolulu, HI

Philip E. Castle, Rockville, MD
Graham A. Colditz, St. Louis, MO
Olufunmilayo I. Olopade, Chicago, IL
Mariana C. Stern, Los Angeles, CA

# Professional Advancement Session • 6:30 p.m.-8:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall A - Manchester Grand Hyatt San Diego
**Navigating The Path to a Successful Career in Cancer Research**

**Cochairs:** Brian M. Rivers, Atlanta, GA; Andrea Hayes-Dixon, Washington, DC, DC; Kristin Ann Altwegg, Gaithersburg, MD

**Moderator**
Jose G. Trevino, Richmond, VA

**Table 1: Putting Yourself on the Map: Strategies to Increase Your Visibility and Expand the Impact of your Research.** Clayton C. Yates, Baltimore, MD

**Table 2: How NCI Supports Cancer Researchers in Training and in the Early Phase of Their Independent Careers.** Oliver Bogler, Bethesda, MD

**Table 3: How to Set Up a Lab and Management of Resources and Personnel.** Wayne D. Bowmen, Providence, RI

**Table 4: Physician-scientists: Leveraging Your Training and Carving Out Your Niche/The Physician-Scientist.** John M. Carethers, La Jolla, CA

**Table 5: Becoming an Effective Peer Reviewer: Improving the Quality of Articles and Cultivating Career Development.** Elizabeth A. Platz, Baltimore, MD

**Table 6: Conducting International Research: Things to Look out for and Pitfalls to Avoid.** Folakemi T. Odedina, Jacksonville, FL

**Table 7: What to Look for in a Good Mentor: Help I've Outgrown My Mentor.** Danny R. Welch, Kansas City, KS

**Table 10: Careers in Cancer: Government - FDA.** Beverly D. Lyn-Cook, Jefferson, AR

**Table 11: Career Objectives and Survival Skills-Graduate Students.** Christopher Sistrunk, Duarte, CA

**Table 13: Careers in Biotech.** Francesco Caiazza, San Francisco, CA

**Table 14: Effective Management, Communication, and Negotiation Skills.** Rick A. Kittles, Duarte, CA

**Table 15: Navigating from Postdoc to Independent Investigator.** Lloyd C. Trotman, Cold Spring Harbor, NY

**Table 17: Embracing Diversity in Cancer Research.** Luis G. Carvajal-Carmona, Davis, CA

**Table 18: Building Effective Collaborations / Working Effectively in a Team.** Quyen T. Nguyen, La Jolla, CA

**Table 19: Negotiating for Job Offers, Salaries, and Promotion.** Chanita Hughes Halbert, Los Angeles, CA

**Table 20: Career Transitioning: From Undergraduate to Graduate Student.** Kristin Ann Altwegg, Gaithersburg, MD

**Table 21: Career Objectives and Survival Skills for Postdoctoral Fellows.** Andreana N. Holowatyj, Nashville, TN

**Table 22: Fostering community Engagement and Patient Education.** Kimlin T. Ashing, Duarte, CA

**Table 24: Careers in Industry.** Lori S. Friedman, South San Francisco, CA

**Table 25: Careers in Cancer: Academia.** Jennie L. Williams, Stony Brook, NY

**Table 28: How to Advance from Poster to Paper: Challenges of Publishing in Peer Reviewed Journals with High Impact Factor.** Sandra Demaria, New York, NY

# Tuesday, April 9, 2024

CME **Plenary Session** • 8:00 a.m.-10:00 a.m.

Hall GH, Convention Center
**Evolution of the Genome, Microenvironment, and Host through Metastasis**

**Chair:** Cyrus M. Ghajar, Seattle, WA

**Introduction.** Cyrus M. Ghajar, Seattle, WA

**Insights into the invisible phase of systemic cancer: Genomic evolution and phenotypic plasticity of the metastatic seed.** Christoph A. Klein, Regensburg, Germany

**Charting the awesome power of plasticity during metastasis.** Dana Pe'er, New York, NY

**Metastasis aggressiveness: A function of metabolite signaling.** Sarah-Maria Fendt, Leuven, Belgium.

**Multi-organ systemic therapies to combat metastatic disease and its complications.** David C. Lyden, New York, NY

**Panel discussion.**

**Closing remarks.** Cyrus M. Ghajar, Seattle, WA

# Professional Advancement Session • 8:30 a.m.-2:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall C - Manchester Grand Hyatt San Diego
**Special Program for High School Students "The Conquest of Cancer and the Next Generation of Cancer Researchers"**

**Chair:** Brian M. Rivers, Atlanta, GA

**Welcome.** Brian M. Rivers, Atlanta, GA

**Understanding Cancer.** Jose G. Trevino, Richmond, VA

**Keys to Cancer Prevention.** Chanita Hughes Halbert, Los Angeles, CA
**Why Cancer Research Needs You!** Greisha L. Ortiz Hernandez, Duarte, CA

**Special Remarks from AACR President.** Philip D. Greenberg, Seattle, WA

# Meet and Greet • 9:30 a.m.-10:30 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editor-in-Chief of *Molecular Cancer Therapeutics*: Beverly A. Teicher, PhD**

# Poster Sessions • 9:30 a.m.–12:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App

**Immunology**
Section 1     Adaptive Immunity in Tumors
Section 2     Adoptive Cell Therapies 3: CAR-T Cells
Section 3     Combination Approaches
Section 4     Immune Modulation with Cytokines
Section 5     Vaccines, Antigens, and Antigen Presentation 1

**Tumor Biology**
Section 7     Detection, Treatment, and Prevention of Metastasis
Section 8     In Vivo Imaging and Anatomical and Molecular Pathology
Section 9     In Vivo Imaging and Humanized Models
Section 10    Models to Study Immune Cells in the Tumor Microenvironment
Section 11    Organoid Models of Cancer 2
Section 12    The Extracellular Matrix in Cancer
Section 13    Tumor Evolution Models and Technologies
Section 54    Late-Breaking Research: Tumor Biology 2

**Molecular/Cellular Biology and Genetics**
Section 14    Autophagy and Other Forms of Cell Death
Section 15    Characterization of Mutational Processes and Drivers in Cancer Development and Evolution
Section 16    Deregulated Signaling in Tumor Development and Progression
Section 17    Epigenetics and Cancer Biology
Section 18    Metabolomics
Section 19    Signaling Pathways That Regulate Metabolism 2
Section 53    Late-Breaking Research: Molecular/Cellular Biology and Genetics 2

**Chemistry**
Section 20    Drug Design and in Silico Screening
Section 21    Targeted Protein Degradation

**Experimental and Molecular Therapeutics**
Section 22    DNA Reactive Agents
Section 23    Drug Combinations
Section 24    HDAC and Methyltransferase Inhibitors

Section 25    Mechanisms of Drug Resistance and Novel Combinations
Section 26    Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Section 27    New Compounds and Drug Targets
Section 28    New Targets, Technologies, and Drug Delivery Systems
Section 29    Other Cellular Mechanisms for Anticancer Drug Action
Section 30    Reversal of Drug Resistance 1
Section 52    Late-Breaking Research: Experimental and Molecular Therapeutics 3

**Prevention / Early Detection / Interception**
Section 31    Biomarkers and Molecular Targets for Cancer Prevention
Section 32    Population-Based Screening

**Population Sciences**
Section 33    Cancer Disparities 2: Survivorship Research Addressing Cancer Disparities
Section 34    Descriptive Epidemiology and Statistical and Epidemiological Methodology

**Bioinformatics / Computational Biology / Systems Biology / Convergent Science**
Section 35    Application of Bioinformatics to Cancer Biology 4
Section 36    Artificial Intelligence and Machine/Deep Learning 3
Section 37    Integrative Computational Approaches 1 / Analytic Pipeline Optimization
Section 51    Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

**Clinical Research**
Section 38    Artificial Intelligence and Data Science on Real World Data
Section 39    Chemotherapy, Radiation, and Vaccine Mediated Immunity
Section 40    Circulating Nucleic Acids 4
Section 41    Molecular Biology in Clinical Oncology: Genetics and Beyond
Section 42    Novel Immunotherapies and Immune Modulation
Section 43    Pediatric CNS Tumors, Leukemia, and Neuroblastoma: Translational
Section 44    Predictive Biomarkers 3
Section 45    Predictive Biomarkers 4
Section 46    Prognostic Biomarkers 1

**Clinical Trials**
Section 48    First-in-Human Phase I Clinical Trials 2
Section 49    Phase II Clinical Trials 1
Section 50    Phase III Clinical Trials

# NCI-NIH-Sponsored Session • 10:15 a.m.-11:15 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**NCI Network: Participant Engagement and Cancer Genome Sequencing (PE-CGS) Community Health Educator Supplement Program**

**Moderator**: LeeAnn O. Bailey, Bethesda, MD

**Introduction.** LeeAnn O. Bailey, Bethesda, MD

**Strengthening Hispanic/Latino osteosarcoma patient engagement in genomic sequencing studies.** Timothy R. Rebbeck, Boston, MA

**Increasing cancer genetic education and research engagement among Latino communities: The community genetic navigation engagement specialists (CoGENES) training program.** Mariana C. Stern, Los Angeles, CA

**Conducting community cafes to enhance cancer genetic research and referral approaches for black Americans.** Erin Linnenbringer, St. Louis, MO

**Optimizing engagement of Latino communities to promote equity in low grade glioma genomic research.** Elizabeth B. Claus, New Haven, CT

# CME Advances in Diagnostics and Therapeutics • 10:15 a.m. -11:45 a.m.

Room 29, Convention Center
### Drugging Transcription Factors

**Chair:** Angela N. Koehler, Cambridge, MA

**Chair Introduction.** Angela N. Koehler, Cambridge, MA

**Attenuating oncogenic transcription.** Angela N. Koehler, Cambridge, MA

**Targeted degradation of transcription factors.** Benjamin L. Ebert, Boston, MA

**Drugging notorious oncogenic transcriptional drivers: The helicon solution.** Gregory L. Verdine, Cambridge, MA

Room 11, Convention Center
### Radiotheranostics: A Paradigm-Shifting Therapy

**Cochairs:** Julie Sutcliffe, Sacramento, CA; Kayvan R. Keshari, New York, NY

**Chair Introduction.** Kayvan R. Keshari, New York, NY

**avb6-integrin targeted radioligand therapy: Bench to bedside.** Julie L. Sutcliffe, Windsor, CA

**Priming anti-cancer immunity with radioligand therapy.** David R. Piwnica-Worms, Houston, TX

**Title to be announced.** Jeevan Virk, Geneva, Switzerland

## CME Advances in Hematologic Malignancies • 10:15 a.m.-11:45 a.m.

Room 15, Convention Center
**Immune Microenvironment in Hematologic Malignances**

**Chair:** Ioannis Aifantis, New York, NY

**Chair Introduction.** Ioannis Aifantis, New York, NY

**Mapping the interactions between tumor:immune system in myeloid leukemia.** Iannis Aifantis, New York, NY

**Immune dysfunction in myelodysplastic syndrome at disease initiation and progression.** Simona Colla, Houston, TX

**Pathogenic interactions in the immune microenvironment of myeloproliferative neoplasms.** Simón Méndez-Ferrer, Cambridge, United Kingdom

## CME Advances in Organ Site Research • 10:15 a.m.-11:45 a.m.

Ballroom 6 CF, Convention Center
**Unwrapping Heterogeneity in Pancreatic Cancer**

**Chair:** Jen Jen Yeh, Chapel Hill, NC

**Chair Introduction.** Jen Jen Yeh, Chapel Hill, NC

**3D genomic mapping reveals multifocality of human pancreatic precancers.** Laura Delong Wood, Baltimore, MD

**NG08   Dissecting and quantifying pancreatic cancer plasticity using single-cell multiomics, lineage tracing and functional genomics reveals novel mediators of therapy resistance.** Arnav Mehta, Boston, MA

**Mechanisms of resistance to KRAS inhibition in pancreatic cancer.** Andrew J. Aguirre, Boston, MA

**Beyond tumor heterogeneity.** Jen Jen Yeh, Chapel Hill, NC

Room 28, Convention Center
**Updates from SABCS 2023**

**Cochairs:** Carlos L. Arteaga, Dallas, TX; Virginia G. Kaklamani, San Antonio, TX

**Introduction.** Carlos L. Arteaga, Dallas, TX

**Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: An exploratory analysis of CheckMate 7FL.** Sherene Loi, Melbourne, Australia

**Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer.** Christopher J. Lord, London, United Kingdom

**Novel mechanisms of CDH1 inactivation in breast invasive lobular carcinoma unveiled by the integration of artificial intelligence and genomics.** Fresia Pareja, New York, NY

**Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers.** Nolan Priedigkeit, Boston, MA

**Closing remarks.** Virginia G. Kaklamani, San Antonio, TX

Room 17, Convention Center
**Uveal Melanoma: Elucidating the Adjuvant Window of Therapeutic Opportunity**

**Chair:** J. William Harbour, Dallas, TX

**Chair Introduction.** J. William Harbour, Dallas, TX

**How canonical genetic aberrations in uveal melanoma suppress the tumor immune microenvironment.** J. William Harbour, Dallas, TX

**Liquid biopsy in uveal melanoma: Are we there yet?** Elin S. Gray, Joondalup, Australia

**Unraveling the enigma of uveal melanoma dormancy in the liver.** Julio A. Aguirre-Ghiso, New York, NY

## CME Advances in Population Sciences • 10:15 a.m.-11:45 a.m.

Room 14, Convention Center
**Early-onset Cancers: Challenges and Opportunities for Prevention and Treatment**

**Chair:** Yin Cao, St Louis, MO

**Chair Introduction.** Yin Cao, St Louis, MO

**Charting the path forward to combat early-onset cancers: Global trends and prevention.** Yin Cao, St Louis, MO

**Early-onset breast cancer: What we have learned from enriched cohorts that may inform the global trends.** Mary Beth Terry, New York, NY

**Young-onset colorectal cancer: Summary of evidence and implications for treatment and research.** Kimmie Ng, Boston, MA

**Panelist.** Jane C. Figueiredo, Los Angeles, CA

## CME Advances in Technologies • 10:15 a.m.-11:45 a.m.

Ballroom 20 CD, Convention Center
**Frontiers in Computational Oncology: Harnessing Multimodal Data for Biological Insight**

**Chair:** Sohrab Shah, New York, NY

**Chair Introduction.** Sohrab Shah, New York, NY

**Multimodal integration at the level of real world patient data and single cells.** Sohrab Shah, New York, NY

**Multimodal artificial intelligence-based biomarkers in precision oncology.** Jakob Nikolas Kather, Dresden, Germany

**Integrating radiology in multi-omic models.** Mireia Crispin-Ortuzar, Cambridge, United Kingdom

## CME Major Symposia • 10:15 a.m.-11:45 a.m.

Room 33, Convention Center
**Antigen Discovery and Validation for Cancer Vaccines**

**Chair:** James R. Heath, Pasadena, CA

**Introduction.** James R. Heath, Pasadena, CA

**SY41-01   Selection of targeted neoantigens for personalized cancer vaccines.** Derin Keskin, Boston, MA

**Transcriptional programs of tumor-specific CD4, CD8 and Treg cells.** Drew M. Pardoll, Baltimore, MD

**SY41-02   Experimental methods for high throughput discovery and validation of tumor antigens.** James R. Heath, Seattle, WA

Ballroom 6 A, Convention Center
**Biomarkers in the Post-TCGA Era: Where Are We Now?**

**Chair:** Lipika Goyal, Stanford, CA

**Introduction.** Lipika Goyal, Stanford, CA

**Biomarkers for optimal precision therapy in gastroesophageal cancers.** Lipika Goyal, Stanford, CA

**Biomarkers for optimal precision therapy in gastroesophageal cancers.** Harshabad Singh, Boston, MA

**Moving beyond TCGA: The pursuit of clinical useful biomarkers in urothelial carcinoma.** Petros Grivas, Seattle, WA

Room 30, Convention Center
**Crosstalk within the Tumor Ecosystem**

**Chair:** Mara H. Sherman, New York, NY

**Introduction.** Mara H. Sherman, New York, NY

**Decoding and rewiring cancer-lymphocyte interactions.** Livnat Jerby, Stanford, CA

**What determines oncogenic competence?** Richard M. White, Oxford, United Kingdom

**NG07   Association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors.** Claire Elizabeth Thomas, Seattle, WA

**Mechanisms and consequences of tumor stromal evolution.** Mara H. Sherman, New York, NY

Ballroom 20 AB, Convention Center
**Dharma Master Jiantai Symposium in Targeted Therapy: T Cell-based Therapies for Solid Tumors**

**Chair:** Aude G. Chapuis, Seattle, WA

**Introduction.** Aude G. Chapuis, Seattle, WA

**Unlocking new avenues to overcome efficacy challenges of TCR T-based strategies.** Aude G. Chapuis, Seattle, WA

**T cell signaling biology inspires unique CAR engineering.** Robbie G. Majzner, Palo Alto, CA

**Enhancing the effector functions of CAR T cells for the treatment of solid tumors.** Avery D. Posey, Philadelphia, PA

Room 1, Convention Center
**Diversity Plans in Action: FDA, Industry, and Community Perspectives**

**Panelist**: Phyllis Jehne Pettit Nassi, Salt Lake City, UT

**Speakers:**
Asma Dilawari, Silver Spring, MD
Bea Lavery, San Francisco, CA
Camille A. Pope, Birmingham, AL
Angeloe Burch, Durham, NC

Ballroom 6 B, Convention Center
**Harnessing Altered Metabolism for Novel Cancer Therapies**

**Chair:** M. Celeste Simon, Philadelphia, PA

**Introduction.** M. Celeste Simon, Philadelphia, PA
**Serine metabolism in cancer.** Gina M. DeNicola, Tampa, FL

**SY21-02   Coenzyme Q-dependent metabolism: Lessons from structure-function studies of DHODH.** Julie-Aurore Losman, Boston, MA

**Metabolism based therapies for liver cancer.** M. Celeste Simon, Philadelphia, PA

Ballroom 6 DE, Convention Center
**Health Behavior Practices after Cancer Diagnosis to Deter Cancer Progression and Death - Evidence, Gaps, and Solutions**

**Chair:** June M. Chan, San Francisco, CA

**Introduction.** June M. Chan, San Francisco, CA

**SY08-01   Does exercise or fitness deter cancer progression after diagnosis?** June M. Chan, San Francisco, CA

**The role of diet in reducing risk of recurrence and mortality in cancer survivors: evidence and research gaps.** Marjorie L. McCullough, Atlanta, GA

**Improving diet quality and increasing physical activity in cancer survivors: Successes, challenges, and next steps.** Karen M. Basen-Engquist, Houston, TX

Room 31, Convention Center
**Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances**

**Chair:** Danette L. Daniels, Cambridge, MA

**Introduction.** Danette L. Daniels, Cambridge, MA

**SY12-01   Targeting validated but un-drugged oncogenes with small molecule protein degraders.** Nello Mainolfi, Cambridge, MA

**Targeting chromatin regulatory cancer drivers with degraders.** Steven F. Bellon, Cambridge, MA

**NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma.** Gwenn Hansen, San Francisco, CA

**Monovalent degraders of SMARCA2/A4 acting through recruitment of the FBXO22 CRL complex.** Elisia Villemure, South San Francisco, CA

Room 16, Convention Center
**The Microbiome and Treatment Response to Cancer Therapy**

**Chair:** Marcel R.M. van den Brink, Los Angeles, CA

**Introduction.** Marcel R.M. van den Brink, Los Angeles, CA

**Microbes, Metabolites and Modulation of Immunotherapy.** Kathy McCoy, Calgary, AB, Canada

**Microbiome and cancer treatment toxicities.** Rob Jenq, Houston, TX

**The role of the intestinal microbiome in cancer immunotherapy.** Marcel R.M. van den Brink, Los Angeles, CA

# CME Clinical Trials Plenary Session • 10:15 a.m.-12:15 p.m.

Hall GH, Convention Center
**Biomarkers: Quantifying Pharmacodynamic Modulation**

**Cochairs:** Nilofer S. Azad, Baltimore, MD; Ryan J. Sullivan, Boston, MA

**CT016   Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of entinostat in combination with nivolumab.** Marina Baretti, Baltimore, MD

**Discussant.** Evanthia T. Roussos Torres, Los Angeles, CA

**CT017   FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed.** Pasi A. Jänne, Boston, MA

**Discussant.** Marina Chiara Garassino, Milano, Italy

**CT018   *TMPRSS2-ERG* and *RB1* as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).** Josep M. Piulats, Barcelona, Spain

**Discussant.** Rahul R. Aggarwal, San Mateo, CA

**CT019   Biological mechanisms underlying objective responses in recurrent GBM patients treated with sequential bortezomib and temozolomide: An interim analysis of NCT03643549 Phase IB/II trial.** Mohummad Aminur Rahman, Bergen, Norway

**Discussant.** Nader Sanai, Phoenix, AZ

## Meet and Greet • 11:30 a.m.-12:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editors-in-Chief of *Cancer Prevention Research*: Raymond N. DuBois, MD, PhD and Nickolas Papadopoulos, PhD**

## CME Awards and Lectures • 12:00 p.m.-12:30 p.m.

Room 5, Convention Center
**AACR Gertrude B. Elion Cancer Research Award Lecture: Mechanisms of Gene Regulation by Chromatin Adaptors in Development and Disease**

**Moderator**: Geeta Sharma, Cambridge, MA

**Mechanisms of gene regulation by chromatin adaptors in development and disease.** Yadira Marie Soto-Feliciano, Cambridge, MA

## CME Advances in Technologies • 12:15 p.m.-2:00 p.m.

Room 29, Convention Center
**Mutational Processes in Cancer: From Replication Stress to Complex Genomic Rearrangements**

**Chair:** Samuel Aparicio, Vancouver, BC, Canada

**Chair Introduction.** Samuel Aparicio, Vancouver, BC, Canada

**Replication stress as a driver of cancer genome evolution.** Sarah McClelland, London, United Kingdom

**NG10   Evolutionary dynamics of whole-genome doubling in ovarian cancer.** Ignacio Vazquez-Garcia, New York, NY

**Understanding complex structural variant mutational processes in cancer through long molecule genome profiling.** Marcin Imielinski, New York, NY

**Single cell origins and consequences of gene dosage mutations.** Samuel Aparicio, Vancouver, BC, Canada

## NCI-NIH-Sponsored Session • 12:30 p.m.-1:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Intramural and Extramural Training and Career Development Awards and Opportunities**

**Moderator**: Oliver Bogler, Bethesda, MD
**Introduction.** Oliver Bogler, Bethesda, MD

**Training at NCI: Opportunities to advance your research career.** Joanne D'Silva, Rockville, MD

**NCI fellowship funding opportunities for predocs and postdocs.** Hana M. Odeh, Rockville, MD

**NCI career development award funding opportunities: Tips for early career stage investigators.** Michael K. Schmidt, Bethesda, MD

# CME Advances in Diagnostics and Therapeutics • 12:30 p.m.-2:00 p.m.

Ballroom 6 CF, Convention Center
**Advances in T-cell Bispecific Approaches Targeting Solid Tumors**

**Chair:** Teemu T. Junttila, South San Francisco, CA

**Chair Introduction.** Teemu T. Junttila, South San Francisco, CA

**Overcoming challenges in T cell bispecific antibody targeting of solid tumors.** Teemu T. Junttila, South San Francisco, CA

**DLL3 T cell engagers bite SCLC.** Luis G. Paz-Ares, Madrid, Spain

**Tumor-targeted costimulation via CD28 bispecific antibodies.** Dimitris Skokos, New York, NY

Ballroom 20 AB, Convention Center
**KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology**

**Chair:** Kevan Michael Shokat, San Francisco, CA

**Chair Introduction.** Kevan Michael Shokat, San Francisco, CA

**Expanding K-Ras covalent chemistry for targeting K-Ras (G12D).** Kevan Michael Shokat, San Francisco, CA

**Title to be announced.** Sandra B. Gabelli, Lansdale, PA

**Discovery of RMC-6236, a tri-complex RAS (ON)multi-selective inhibitor.** Elena S. Koltun, Redwood City, CA

# CME Advances in Hematologic Malignancies • 12:30 p.m.-2:00 p.m.

Room 14, Convention Center
**Dissecting the Heterogeneity of Lymphoid Malignancies to Improve Precision Therapy**

**Chair:** Margaret A. Shipp, Boston, MA

**Chair Introduction.** Margaret A. Shipp, Boston, MA

**Biological heterogeneity of follicular lymphoma: Are there opportunities for precision care?** Jessica Okosun, London, United Kingdom

**New insights into diffuse large B-cell lymphoma Heterogeneity: Biological and clinical implications.** Sandrine Roulland, Marseille, France

**Precision immunotherapy in Hodgkin Lymphoma: New insights into mechanisms of response and resistance to checkpoint blockade.** Margaret A. Shipp, Boston, MA

# CME Advances in Organ Site Research • 12:30 p.m.-2:00 p.m.

Ballroom 6 A, Convention Center
**Dharma Master Jiantai Advances in Lung Cancer Research Session: Deciphering Lung Cancer in Non-smokers - Dedicated to the Memory of Richard H. Creech**

**Chair:** Tony S. Mok, Shatin, NT, Hong Kong

**Chair Introduction.** Tony S. Mok, Shatin, NT, Hong Kong

**Screening for early stage lung cancer among never smoker: Can we? Should we?** Elaine Shum, New York, NY

**Tackling drug resistance to molecular targeted therapy for never smoker.** Tony S. Mok, Shatin, NT, Hong Kong

**Rational approach to development of Immunotherapy for never smoker.** A. McGarry Houghton, Seattle, WA

# CME Advances in Prevention Research • 12:30 p.m.-2:00 p.m.

Room 33, Convention Center
**From Precursors to Prevention: How Research into Cancer Precursor Lesions Creates Prevention Opportunities**

**Chair:** David G. Huntsman, Vancouver, BC, Canada

**Chair Introduction.** David G. Huntsman, Vancouver, BC, Canada

**From fallopian tube precursors to opportunistic salpingectomy, a population based prevention program.** David G. Huntsman, Vancouver, BC, Canada

**Understanding evolutionary trajectories of Barrett's to intercept oesophageal cancer.** Rebecca C. Fitzgerald, Harston, United Kingdom

**When you come to a fork in the road, take it: Navigating the diverse evolutionary paths from precursor lesions to melanomas.** Boris C. Bastian, San Francisco, CA

# **CME** Advances in Technologies • 12:30 p.m.-2:00 p.m.

Room 30, Convention Center
**Accelerating Precision Oncology through AI: Impact of Computational Pathology and Generative AI on Personalized Medicine**

**Chair:** Tamara Jamaspishvili, Syracuse, NY

**Chair Introduction.** Tamara Jamaspishvili, Syracuse, NY

**Precision in pixels: Revolutionizing pathology practices and improving patient care.** Tamara Jamaspishvili, Syracuse, NY

**Solving fundamental cancer problems with AI.** Amber L. Simpson, Kingston, ON, Canada

**Title to be announced.** Thomas J. Fuchs, New York, NY

Ballroom 20 CD, Convention Center
**New Liquid Biopsy Technologies for Detection and Characterization of Cancer**

**Chair:** Victor E. Velculescu, Baltimore, MD

**Chair Introduction.** Victor E. Velculescu, Baltimore, MD

**Title to be announced.** Daniel D. De Carvalho, Toronto, ON, Canada

**Circulating DNA topology as an approach for cancer detection: Advances in fragmentomics.** Alain R. Thierry, Montpellier, France

**Early detection of cancer using cell-free DNA fragmentomes.** Victor E. Velculescu, Baltimore, MD

# **CME** Advances in the Science of Cancer Disparities • 12:30 p.m.-2:00 p.m.

Room 31, Convention Center
**Oncologic Anthropology: Impact of Genetic Ancestry and Social Determinants of Health on Breast Cancer Risk**

**Chair:** Lisa A. Newman, New York, NY

**Chair Introduction.** Lisa A. Newman, New York, NY

**Genetic ancestry and breast cancer risk.** Melissa B. Davis, Atlanta, GA

**Models for quantifying socioeconomic status.** Lauren E. McCullough, Atlanta, GA

**Role of allostatic load and epigenetics in breast cancer disparities.** Samilia Obeng-Gyasi, Columbus, OH

## [CME] Major Symposia • 12:30 p.m.-2:00 p.m.

Ballroom 6 B, Convention Center
**Advancing Cellular Therapies for Childhood Solid Malignancies: Dedicated to the Memory of Sharon B. Murphy**

**Chair:** John M. Maris, Philadelphia, PA

**Introduction.** John M. Maris, Philadelphia, PA

**Discovery and development of highly tumor specific immunotherapy targets for childhood cancers.** John M. Maris, Philadelphia, PA

**Interleukin-15 to enhance CAR expressing effector cell therapies.** Andras A. Heczey, Houston, TX

**Improving the "fitness" of cellular therapies to enhance activity against pediatric solid tumors.** Julie R. Park, Memphis, TN

Room 28, Convention Center
**Cancer Dormancy: From Basic Biology to Clinical Reality**

**Chair:** Mikala Egeblad, Cold Spring Harbor, NY

**Introduction.** Mikala Egeblad, Cold Spring Harbor, NY

**SY34-01   Plasticity, dormancy, and glycosylation of circulating tumor cell clusters in response to therapy.** Huiping Liu, Chicago, IL

**SY34-02   Age-related and organ-specific host mosaicism as a driver of dormant cancer cell awakening.** Julio A. Aguirre-Ghiso, New York, NY

**Neutrophils connect systemic responses with the local microenvironment to promote metastasis from disseminated cancer cells after chronic stress exposure.** Mikala Egeblad, Cold Spring Harbor, NY

Ballroom 6 DE, Convention Center
**CDK4/6 Inhibitors: Not Just for Breast Cancer Anymore**

**Chair:** Geoffrey I. Shapiro, Boston, MA

**Introduction.** Geoffrey I. Shapiro, Boston, MA

**Bridging the gap: Exploring CDK4/6 inhibitors for a deeper understanding of senescence-based therapy in dedifferentiated liposarcoma.** Andrew Koff, New York, NY

**Augmentation of CD8 T cell memory via CDK4/6 inhibition can be sequentially combined with PD-1 blockade to avoid toxicities.** Stephanie K. Dougan, Boston, MA

**Combined inhibition of CDK4/6 and signal transduction: activity beyond ER+ breast cancer.** Geoffrey I. Shapiro, Boston, MA

Hall GH, Convention Center
**Discovering and Broadening the Therapeutic Modalities of Immune Therapy**

**Chair:** F. Stephen Hodi, Boston, MA

**Introduction.** F. Stephen Hodi, Boston, MA

**Improved understanding of antigen presentation machinery for therapies.** F. Stephen Hodi, Boston, MA

**Getting T and NK cells to collaborate in an MHC-I heterogeneous microenvironment.** Justin Micah Balko, Nashville, TN

**Using archetypes and machine learning to discover novel immune pathways for tumor elimination.** Matthew F. Krummel, San Francisco, CA

Room 1, Convention Center
**Putting the Precision Back in Precision Oncology**

**Chair:** Christy L. Osgood, Silver Spring, MD

**Panelists**:
Flora Mulkey, Silver Spring, MD
Francesco Pignatti, London, United Kingdom
Michael Fusco, Silver Spring, MD
Manju George, Omaha, NE
Vassiliki Karantza, Rahway, NJ
Andrew J. Mckenzie, Nashville, TN

# Meet and Greet • 1:30 p.m.-2:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 4043 - Hall AF
**Meet the Editors-in-Chief of *Cancer Research Communications*: Elaine R. Mardis, PhD and Lillian L. Siu, MD**

# Poster Sessions • 1:30 p.m.–5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App

**Immunology**
Section 1          Adoptive Cell Therapies 4
Section 2          Immune Modulating Effects of Chemotherapy and Other Agents
Section 3          Immune Modulation Employing Agonist or Co-Stimulatory Approaches

Section 40    Adoptive Cellular Therapy 2
Section 41    Antibodies 2
Section 42    Pediatric Clinical Research and Late Effects
Section 43    Predictive Biomarkers 5
Section 44    Predictive Biomarkers 6
Section 45    Profiling Cancer with Real-World Evidence
Section 46    Targeting Kinase and ERK Pathways
Section 47    Tumor Microenvironment and Cancer Immunity
Section 51    Late-Breaking Research: Clinical Research 2

**Clinical Trials**
Section 48    Phase II Clinical Trials 2
Section 50    Phase II and Phase III Clinical Trials in Progress

# NCI-NIH-Sponsored Session • 2:30 p.m.-3:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**Building on the Power of Data and Community**

**Moderator**: Gregory Reaman, Bethesda, MD

**Introduction.** Gregory Reaman, Bethesda, MD

**Molecular characterization initiative (MCI): Update and feedback on expanding to other cancers.** Malcolm A. Smith, Bethesda, MD

**Framework for a CCDI coordinated pediatric and young adult rare cancer initiative.** Brigitte C. Widemann, Bethesda, MD

**CCDI data echo system: Tools and resources.** Subhashini Jagu, Rockville, MD

**Integrating proteogenomic approaches: Pioneering pediatric brain cancer treatment from discovery to clinical trials.** Ana I. Robles, Rockville, MD

# CME Major Symposium • 2:30 p.m.-4:00 p.m.

Room 1, Convention Center
**The Cancer Moonshot: Challenges to Fulfilling the Vision of the National Cancer Plan - Dedicated to the Memory of Senator Dianne Feinstein**

**Moderator**: Roy S. Herbst, New Haven, CT

**Speakers:**
W. Kimryn Rathmell, Bethesda, MD
Patricia M. LoRusso, New Haven, CT
Elizabeth M. Jaffee, Baltimore, MD
Bianca N. Islam, Cleveland, OH
Danielle Carnival, Washington, DC

## CME Clinical Trials Minisymposium • 2:30 p.m.-4:30 p.m.

Hall GH, Convention Center
**Novel Agents and Emerging Therapeutic Strategies**

**Cochairs:** S. Percy Ivy, Bethesda, MD; Alison Schram, New York, NY

**Introduction.** S. Percy Ivy, Bethesda, MD

**CT037   A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.** Paolo Strati, Houston, TX

**CT038   Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study.** Jordi Rodon, Houston, TX

**CT039   Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study.** Francis Mussai, Welwyn Garden City, United Kingdom

**CT040   First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer.** Lyudmila Bazhenova, San Diego, CA

**CT042   NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations.** Timothy A. Yap, Houston, TX

**CT044   A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients.** Nader Sanai, Phoenix, AZ

**CT043   Safety and preliminary efficacy of AZD1390 + radiation therapy (RT) for glioblastoma (GBM).** Jonathan T. Yang, New York, NY

**Closing remarks.** Alison Schram, New York, NY

## CME Minisymposia • 2:30 p.m.-4:30 p.m.

Ballroom 20 AB, Convention Center
Bioinformatics, Computational Biology, Systems Biology, and Convergent Science
**Computational Approaches to Precision Medicine**

**Chair:** Christopher J. Kemp, Seattle, WA

**Introduction.** Christopher J. Kemp, Seattle, WA

**6543   A map of osteosarcoma cell architecture reveals convergence of pediatric cancer mutations on protein assemblies.** Mengzhou Hu, La Jolla, CA

**6544   Targeting resistance mechanisms to AR-targeted therapy in prostate cancer through inhibition of CREBBP/EP300.** Bonnie V. Dougherty, Chicago, IL

**6545   Reversing lineage plasticity and drug resistance in lethal prostate cancer.** Alessandro Vasciaveo, New York, NY

**6546   Spatial immunology landscapes that correlate with survival in triple negative breast cancer.** Ali Foroughi pour, Farmington, CT

**6547   Dysregulated FGFR3 signaling alters immune landscape in bladder cancer and presents therapeutic possibilities.** Daniel R. Bergman, Baltimore, MD

**6548   Leveraging compact feature sets for TCGA-based molecular subtype classification on new samples.** Kyle Ellrott, Portland, OR

**6549   Mechanistic models of tumor and patient heterogeneity explain and predict clinical outcomes of large B-cell lymphoma (LBCL) treatment.** Amy E. Pomeroy, Chapel Hill, NC

**Closing Remarks.** Christopher J. Kemp, Seattle, WA


Ballroom 20 CD, Convention Center
Immunology
**<span style="color:green">Immuno-oncology</span>**

**Cochairs:** Cassian Yee, Houston, TX; Evan W. Newell, Seattle, WA

**Introduction.** Cassian Yee, Houston, TX

**6550   Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma.** Katie M. Campbell, Los Angeles, CA

**6551   Comprehensive genomic and transcriptomic analyses capture the effects of epigenetic therapy priming on immune checkpoint blockade response in non-small cell lung cancer.** Blair V. Landon, Baltimore, MD

**6552   Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors.** Ryan J. Sullivan, Boston, MA

**6553   Targeting macrophages and regulatory T cells improves response to chemotherapy in high-grade serous ovarian cancer.** Samar Elorbany, London, United Kingdom

**6554   Lurbinectedin induces multimodal immune activation and augments the anti-tumor immune response in small-cell lung cancer.** Subhamoy Chakraborty, New York, NY

**6555   scRNAseq and TCR repertoire analysis identifies immune correlates of response to combined BRAF/MEK/PD1 inhibition in a phase 2 trial.** Hongcheng Yao, Boston, MA

**6556   Targeting mesenchymal tumor cell-intrinsic factors sensitizes refractory tumors to immune checkpoint blockade therapy.** Kimaya M. Bakhle, Ithaca, NY

**Closing Remarks.** Evan W. Newell, Seattle, WA

Ballroom 6 CF, Convention Center
Clinical Research
**Liquid Biopsy**

**Cochairs:** Klaus Pantel, Hamburg, Germany; Catherine Alix-Panabieres, Montpellier, France

**Introduction.** Klaus Pantel, Hamburg, Germany

**6557   Longitudinal cell-free tumor load dynamics represent an early endpoint for immunotherapy response in non-small cell lung cancer.** Lavanya Sivapalan, Baltimore, MD

**6558   Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patients.** Christoffer Gebhardt, Hamburg, Germany

**6559   Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study.** Carmen Rubio Alarcon, Amsterdam, Netherlands

**6560   Cell-free RNA analysis for non-invasive cancer detection and characterization.** Monica C. Nesselbush, Stanford, CA

**6561   Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.** Sabine Kasimir-Bauer, Essen, Germany

**6562   Comprehensive liquid biopsy: Multi-analyte evaluation of cellular and plasma components of blood in prostate cancer from a single blood collection tube.** Jon Ladd, Seattle, WA

**6563   PSMA-based detection and global proteome-based analysis of circulating tumor cells in castration resistant prostate cancer patients.** Justin M. Drake, Minneapolis, MN

**Closing Remarks.** Catherine Alix-Panabieres, Montpellier, France


Ballroom 6 A, Convention Center
Clinical Research
**Novel Approaches for Targeted Therapies**

**Cochairs:** Aaron N. Hata, Charlestown, MA; Yonina Robbie Murciano-Goroff, New York, NY

**Introduction.** Aaron N. Hata, Charlestown, MA

**6564   SOS1 inhibitor treatment improves response to Venetoclax in acute myeloid leukemia.** Kaja Kostyrko, Vienna, Austria

**6565   Improving survival of atypical teratoid/rhabdoid tumor orthotopic xenografts through the combination of PI3K inhibitor paxalisib and nucleoside analog gemcitabine.** Tyler Findlay, Baltimore, MD

**6566   Clinical evaluation of functional combinatorial precision medicine platform to predict treatment outcomes and enhance combination therapy design in soft tissue sarcomas.** Edward Kai-Hua Chow, Singapore, Singapore

**6567   Affinity and cooperativity modulate ternary complex formation to drive degradation of SMARCA2.** Dane Mohl, Thousand Oaks, CA

**6568** *PTCH1* **loss-of-function alterations: Mutational landscape and therapeutic outcomes to hedgehog pathway inhibitors in non-canonical histologies.** Antoine Desilets, New York, NY

**6569   KLIPP: Precision targeting of cancer with CRISPR.** Mats Ljungman, Ann Arbor, MI

**6570** *HLA* **genotyping and HLA-based clinical trial matching using MSK-IMPACT, a targeted next-generation sequencing assay.** Monica F. Chen, New York, NY

**Closing Remarks.** Yonina Robbie Murciano-Goroff, New York, NY

Room 5, Convention Center
Endocrinology
**Molecular, Preclinical, and Clinical Endocrinology 3**

**Cochairs:** Clodia Osipo, Maywood, IL; Carol A. Sartorius, Aurora, CO

**Introduction.** Clodia Osipo, Maywood, IL

**6571   O-GlcNAc sites on progesterone receptor are critical for its ligand independent repression of interferon signaling in breast cancer.** Harmony Ivanna Saunders, Kansas City, KS

**6572   Screening of drug library targeting neural signaling identifies cholecystokinin B receptor as a potential therapeutic target in small cell lung cancer.** Masakatsu Tokunaga, Tokyo, Japan

**6573   Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in adrenocortical carcinoma.** Nai-Yun Sun, Bethesda, MD

**6574   UCHL1 is a molecular indicator and a therapeutic target for neuroendocrine carcinomas.** Tanya Ivanova Stoyanova, Los Angeles, CA

**6575   Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response.** Dannielle Upton, Sydney, Australia

**6576   Discovery of potent and selective novel small molecule drugs to target estrogen receptor mutants in endocrine-resistant breast cancer.** Murugesan Palaniappan, Houston, TX

**4:05 PM   6577   Chemoproteomic evaluation of PROTACs targeting estrogen receptor alpha for ER+ breast cancer.** Zachary Sandusky, Boston, MA

**Closing Remarks.** Carol A. Sartorius, Aurora, CO

Room 30, Convention Center
Experimental Therapeutics
**Drug Discovery 2: New Therapies**

**Cochairs:** Sanjay V. Malhotra, Portland, OR; Marco Gerlinger, London, United Kingdom

**Introduction.** Sanjay V. Malhotra, Portland, OR

**6578   N17465, a systemically deliverable elastase, attenuates tumorigenesis and stimulates anti-tumor immunity.** Ravindra Gujar, San Diego, CA

**6579   DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models.** Kohei Takano, Tokyo, Japan

**6580   A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models.** Zhu Chen, Seattle, WA

**6581   DX126-262 combined with chemotherapy (Cisplatin and 5-Fu) demonstrates promising antitumor efficacy in HER2-positive gastric cancer.** Robert Y. Zhao, Hangzhou City, China

**6582   Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors.** Romain Remark, Marseille, France

**6583   Developing a selective cancer chemotherapy by small molecule-based targeting of PCNA protein.** John J. Perry, Duarte, CA

**6584   Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiveness in the setting of anti-PD-1 acquired resistance in cancer.** George Fromm, Durham, NC

**Closing Remarks.** Marco Gerlinger, London, United Kingdom


Ballroom 6 DE, Convention Center
Experimental Therapeutics
**Novel Antitumor Agents 5**

**Cochairs:** Methvin Isaac, Toronto, ON, Canada; Liliana Attisano, Toronto, ON, Canada

**Introduction.** Liliana Attisano, Toronto, ON, Canada

**6585   Combination RAS$^{G12C}$(ON) and RAS$^{MULTI}$(ON) inhibition overcomes resistance and prolongs durability in preclinical models of mutant KRAS$^{G12C}$-driven cancers.** Xing Wei, Redwood City, CA

**6586   ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models.** Anneleen Daemen, South San Francisco, CA

**6587   Discovery of molecular glue of FBXW7:MYC interaction using small molecule microarray.** Shenghao Guo, Cambridge, MA

**6588   Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile.** Maria Ahn, Cambridge, United Kingdom

**6589   Discovery of potent and selective pan-TEAD autopalmitoylation inhibitors for the treatment of Hippo-pathway altered cancers.** Jacob A. Gordon, Boston, MA

**6590   Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells.** Gabriele Picco, Hinxton, United Kingdom

**Closing Remarks.** Methvin Isaac, Toronto, ON, Canada

Ballroom 6 B, Convention Center
Immunology
**New Insights for Therapies Modulating Antitumor T-Cell Responses**

**Cochairs:** Michael A. Curran, Houston, TX; Mario Sznol, New Haven, CT

**Introduction.** Mario Sznol, New Haven, CT

**6592   Deciphering the effects of age on T cell immunity and immunotherapy.** SeongJun Han, Boston, MA

**6593   Rejuvenation of tumor-infiltrating lymphocytes (TIL): A novel strategy to revitalize TIL antitumor function for cell therapy.** Raul Vizcardo, South San Francisco, CA

**6594   4-1BB: A double-edged sword for T cells.** Liping Yang, Frederick, MD

**6595   HDAC8 targeting impairs Foxp3+Treg cell function and promotes anti-tumor immunity.** Wayne W. Hancock, Philadelphia, PA

**6596   BRMS1 downregulation alters the tumor microenvironment and induces immunotherapy resistance in lung adenocarcinoma.** Manendra B. Lankadasari, New York, NY

**6597   CD40 agonism induces CD4 T cell mediated rejection of major histocompatibility complex class I deficient pancreatic tumors.** Margaret E. Haerr, Portland, OR

**6598   Inhibition of cGAS as a strategy to restore anti-tumor immunity response to STING agonist in chromosomally unstable tumors.** Christy Hong, New York, NY

**Closing Remarks.** Michael A. Curran, Houston, TX


Room 31, Convention Center
Molecular/Cellular Biology and Genetics
**Chromatin and Transcriptional Regulatory Mechanisms in Cancer**

**Cochairs:** Rosalie C. Sears, Portland, OR; Jeremy N. Rich, Pittsburgh, PA

**Introduction.** Jeremy N. Rich, Pittsburgh, PA

**6599   3D genomic analysis reveals novel enhancer hijacking mechanisms caused by complex structural alterations that drive oncogene overexpression.** Katelyn L. Mortenson, Salt Lake City, UT

**6600   Investigating molecular regulators of a dual identity state in lung adenocarcinoma.** Gabriela Fort, Salt Lake City, UT

**6601   Menin drives oncogenesis in Ewing sarcoma cells by activating transcription of key metastatic factors.** Katherine A. Braun, Seattle, WA

**6602   Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.** Lanbo Xiao, Ann Arbor, MI

**6603   A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers**

**enzalutamide resistance in prostate cancer.** Sayanika Dutta, Lubbock, TX

**6604   Spatial transcriptomics delineates tumor heterogeneity in NACT triple-negative breast cancer.** Isobelle Wall, London, United Kingdom

**6605   Understanding the role of sumoylated Etv1 in mammary oncogenesis.** Zhijie Li, Iowa City, IA

**Closing Remarks.** Rosalie C. Sears, Portland, OR

Room 28, Convention Center
Molecular/Cellular Biology and Genetics
**Metabolism and Cancer**

**Cochairs:** Gina M. DeNicola, Tampa, FL; Christina G. Towers, La Jolla, CA

**Introduction.** Gina M. DeNicola, Tampa, FL

**6606   *HK2* is conditionally essential for growth in human cancer cells.** Kimberly S. Huggler, Madison, WI

**6607   Serine depletion promotes antitumor immunity through mitochondrial DNA-mediated cGAS/STING1 activation.** David C. Montrose, Stony Brook, NY

**6608   Therapeutic enzyme depletion of L-serine for the treatment of serine auxotrophic tumors.** Vipin Rawat, Chicago, IL

**6609   NRF2/ACSS2 axis regulates alcohol-induced metabolic reprogramming in esophageal squamous epithelial cells.** Zhaohui Xiong, Camden, NJ

**6610   Metabolic patterns of pancreatic cancer cachexia: Cross-tissue lipid networks predict cachexia progression.** Deepti Mathur, Boston, MA

**6611   Unbiased functional genetic screens reveal essential RNA modifications in human cancer and drug resistance.** Michaela Frye, Heidelberg, Germany

**6612   Therapy-resistant endocycling cancer cells alter mitochondrial structure and metabolism to survive therapeutic stress.** Melvin Li, Baltimore, MD

**Closing Remarks.** Christina G. Towers, La Jolla, CA

Room 11, Convention Center
Population Sciences
**Molecular Epidemiology**

**Cochairs:** Iona C. Cheng, San Francisco, CA; Shaneda Warren Andersen, Nashville, TN

**Introduction.** Shaneda Warren Andersen, Nashville, TN

**6613   Understanding the causes of head and neck cancer using mutational signature analysis.** Laura Torrens, Lyon, France

**6614   Integrating single-cell RNA-seq and large genome-wide association study data to identify colorectal cancer cell-of-origin populations.** Xingyi Guo, Brentwood, TN

**6615   Reduced penetrance *BRCA1* and *BRCA2* pathogenic variants in clinical germline genetic testing.** Alvaro N. Monteiro, Tampa, FL

**6616   Polygenic risk score associated with risk of upgrading and tumor features in a prospective cohort of prostate cancer patients on active surveillance.** Louisa B. Goss, Seattle, WA

**6617   Oral microbiome and subsequent risk for head and neck squamous cell cancer development.** Soyoung Kwak, New York, NY

**6618   Pleiotropic GATA3 locus is associated with multiple childhood cancers: harnessing the existing data from the St. Jude Lifetime Cohort and the Childhood Cancer Survivor Study for genetic etiology research.** Cheng Chen, Shanghai, China

**6619   Dynamic prediction with repeated mammogram images improves 5-year breast cancer risk performance.** Shu Jiang, St. Louis, MO

**Closing Remarks.** Iona C. Cheng, San Francisco, CA

Room 33, Convention Center
Tumor Biology
**Nonclinical Models of Cancer**

**Cochairs:** Corinne Mary Linardic, Durham, NC; Helen M. Piwnica-Worms, Houston, TX

**Introduction.** Helen M. Piwnica-Worms, Houston, TX

**6620   PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant disease.** Amanda L. Rinkenbaugh, Houston, TX

**6621   Development of a melanocyte lineage-specific knockout system in zebrafish.** Sarah Perlee, New York, NY

**6622   Identification of early oncogenic lesions following concomitant Vhl and Pbrm1 loss in the murine kidney.** Joanna Lima, Oxford, United Kingdom

**6623   Ala59 mutants of KRAS cooperate with Nf1 loss to enhance colon tumorigenesis.** Christian William Johnson, Boston, MA

**6624   MYC promotes lobuloalveologenesis and mammary tumorigenesis in male mice.** Emilia M. Pulver, Amsterdam, Netherlands

**6625   Development of novel mixed-cell models to capture heterogeneity in castration-resistant prostate cancer.** Sampreeti Jena, Minneapolis, MN

**6626   Functional and molecular interrogation of a high-plasticity cell state in lung cancer.** Jason Earl Chan, New York, NY

**Closing remarks.** Corinne Mary Linardic, Durham, NC

Room 14, Convention Center
Tumor Biology
**The Microenvironment: Beyond Surrounding the Tumor**

**Cochairs:** Tracy McGaha, Toronto, ON, Canada; Jennifer Bailey-Lundberg, Houston, TX

**Introduction.** Jennifer Bailey-Lundberg, Houston, TX

**6628   Mapping the spatial and molecular determinants of macrophage heterogeneity in breast cancer.** Nir Ben Chetrit, New York, NY

**6627   Boosting macrophage-specific BCAA oxidation enhances immune activation within the tumor microenvironment and diminishes tumor growth in pancreatic cancer.** Gauri Mirji, Philadelphia, PA

**6629   Cancer-associated nerves regulate anti-tumor immunity in pancreatic cancer.** Ruiyuan Xu, Beijing, China

**6630   Non-cell-autonomous cancer progression from chromosomal instability.** Jun Li, New York, NY

**6631   Aging influences the pancreatic ductal adenocarcinoma tumor immune microenvironment to promote features of immunosuppression.** Daniel J. Zabransky, Baltimore, MD

**6632   Adipocyte death drives dormant breast cancer cell reactivation.** Xiaoyu Yuan, St. Louis, MO

**6633   Tracking cell-cell interactions using intercellular barcode transfer.** Neil Q. Tay, San Francisco, CA

**Closing Remarks.** Tracy McGaha, Toronto, ON, Canada

CME **Awards and Lectures** • 3:00 p.m.-3:45 p.m.

Room 29, Convention Center
**AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention**

**Chair:** Jesse Nodora, La Jolla, CA

**Funder Remarks.** Joanne Elena, La Jolla, CA

**Award Lecture.** Timothy R. Rebbeck, Boston, MA

Room 16, Convention Center
**AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research**

**Chair:** Elizabeth R. Lawlor, Seattle, WA

**Toward the Total Cure of Childhood Acute Lymphoblastic Leukemia.** Ching-Hon Pui, Memphis, TN

## CME NCI-NIH-Sponsored Session • 4:00 p.m.-5:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**NCI Division of Cancer Prevention Research Resources, Funding Opportunities, and Research Workforce Activities**

**Moderator**: Shanen M. Sherrer, Bethesda, MD

**Introduction.** Jessica M. Faupel-Badger, Rockville, MD

**NCI DCP support and resources for preclinical research.** Shanen M. Sherrer, Bethesda, MD

**NCI DCP support and resources for preclinical research.** Jessica M. Faupel-Badger, Rockville, MD

**NCI DCP support and resources for clinical research.** Brandy Heckman-Stoddard, Rockville, MD

**Symptom science and DCP workforce initiatives.** Brandy Heckman-Stoddard, Rockville, MD

**Symptom science and DCP workforce initiatives.** Jessica M. Faupel-Badger, Rockville, MD

**Symptom science and DCP workforce initiatives.** Shanen M. Sherrer, Bethesda, MD

## CME Awards and Lectures • 4:30 p.m.-5:15 p.m.

Room 29, Convention Center
**AACR Award for Outstanding Achievement in Blood Cancer Research**

**Chair:** Faith E. Davies, New York, NY

**Award Lecture.** Owen N. Witte, Los Angeles, CA

## CME Meet-the-Expert Session • 5:00 p.m.-5:45 p.m.

Ballroom 6 DE, Convention Center
**A Multitarget FIT for Inexpensive Large Scale Early Detection of Colorectal Cancer**

Gerrit A. Meijer, Amsterdam, Netherlands

## Career Development Forum • 5:00 p.m.-6:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall A - Manchester Grand Hyatt San Diego
**Minorities in Cancer Research Professional Development Forum "What do you need to become a successful scientist while overcoming challenges?"**

**Cochairs:** Tiffany A. Wallace, Rockville, MD; Melissa B. Davis, Atlanta, GA

## CME Forums • 5:00 p.m.-6:30 p.m.

Room 33, Convention Center
**Can Trust in Science Help Us Decrease Cancer Health Care Disparities and Increase Clinical Trials Participation?**

**Cochairs:** Jesse Nodora, La Jolla, CA; Stacey J. Adam, North Bethesda, MD

**Introduction.** Jesse Nodora, La Jolla, CA

**Communicating with all patients: Building trust.** Patricia Spears, Raleigh, NC

**Participation of diverse populations in clinical trials: Understanding social drivers of health and mistrust.** Marcia R. Cruz-Correa, San Juan, PR

**Remarks and introduction for discussion.** Stacey J. Adam, North Bethesda, MD

**Panelist.** Allison Rosen, Houston, TX

Ballroom 6 B, Convention Center
**Lifestyle Choices, the Food Environment, and Health Equity Impact Cancer Prevention and Control - But Are There Solutions? And What Are the Opportunities for Future Research?**

**Chair:** Wendy Demark-Wahnefried, Birmingham, AL

**Chair Introduction.** Wendy Demark-Wahnefried, Birmingham, AL

**Overview of the growing problem of obesity, poor diet and physical inactivity in the U.S. and its impact on cancer incidence and mortality.** Linda Nebeling, Rockville, MD

**An upstream equity and community-centered approach to cancer prevention: Taxing soda distributors in Berkeley, CA.** Xavier Morales, Oakland, CA

**Harnessing the internet with theory-driven, scalable interventions to reach cancer survivors and other high risk populations.** Wendy Demark-Wahnefried, Birmingham, AL

**Recap of challenges and opportunities for funding.** Linda Nebeling, Rockville, MD

Ballroom 6 A, Convention Center
**Mechanisms of Resistance: Why Have We Failed to Turn Cold Tumors Hot?**

**Chair:** Thomas F. Gajewski, Chicago, IL

**Chair Introduction.** Thomas F. Gajewski, Chicago, IL

**Expanding immunotherapy efficacy by understanding mechanism of response versus resistance.** Thomas F. Gajewski, Chicago, IL

**HEVs and tertiary lymphoid structures implementing immune responses in cancer.** Gabriele Bergers, Leuven, Belgium

**Myeloid cell mediated extrinsic immune resistance in HPV-induced cancers.** Sjoerd H. Van Der Burg, Leiden, Netherlands

Ballroom 6 CF, Convention Center
**Opportunities and Challenges in Leveraging Real-World Data to Accelerate Evidence Generation**

**Chair:** Fabrice Andre, Villejuif, France

**Chair Introduction.** Fabrice Andre, Villejuif, France

**Building and exploiting academic molecular databases (including AACR Project GENIE).** Fabrice Andre, Villejuif, France

**Leveraging clinico-genomics databases for R&D.** Marc Hafner, South San Francisco, CA

**What is the guidance of the FDA on the use molecular data to generate RWE.** Paul G. Kluetz, Silver Spring, MD

**Large language models for whole of PubMed dependent cancer data contextualization and hypothesis/experiment formulations.** Garry Nolan, Stanford, CA

Room 30, Convention Center
**Using Small-Molecule Inhibitors in Cancer Research and Drug Discovery: How Can We Maximize Their Value?**

**Chair:** Paul Workman, London, United Kingdom

**Setting the scene: Promise, perils, and panaceas?** Paul Workman, London, United Kingdom

**Blueprint for chemical probes in cancer biology: Critical gaps and moving forward.** Lenka Munoz, Sydney, Australia

**Thinking big: Towards probing the complete human proteome with chemical probes.** Ingo Hartung, Darmstadt, Germany

## Town Meetings • 6:00 p.m.-8:00 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Sapphire Ballroom - Hilton Bayfront Hotel
**Is Cancer Evolution Key to Understanding and Strategically Applying the Multiple Cancer Early Detection (MECED) Assays?: A Cancer Evolution Working Group Town Hall Meeting**

**Cochairs:** Anna D. Barker, Los Angeles, CA; Jeffrey Townsend, New Haven, CT

**Speaker:**
Vincent L. Cannataro, Boston, MA
Melissa B. Davis, Atlanta, GA
Nicholas E. Navin, Houston, TX

Indigo B - Hilton Bayfront Hotel
**Language Models, Processing, and Deep Learning in Radiation Oncology, the New Frontier: A Radiation Science and Medicine Working Group Town Hall Meeting**

**Chair:** Fei-Fei Liu, Toronto, ON, Canada

**Moderator**: Steven J. Chmura, Chicago, IL

**Speakers:**
Danielle S. Bitterman, Boston, MA
Srinivas Raman, Toronto, ON, Canada
Gilmer Valdes, San Francisco, CA

Sapphire Ballroom - Hilton Bayfront Hotel
**Targeting the Tumor Microenvironment for the Benefit of Cancer Patients: A Tumor Microenvironment Working Group Town Hall**

**Cochairs:** Mikala Egeblad, Baltimore, MD; Edna Cukierman, Philadelphia, PA

**Speakers:**
Janusz Franco-Barraza, Philadelphia, PA
Rebecca Lee, Manchester Cancer Research Centre, United Kingdom
Jan Remsik, Leuven, Belgium

## Professional Advancement Session • 6:30 p.m.-8:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Grand Hall B - Manchester Grand Hyatt San Diego
**Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career**

**Cochairs:** Kathleen W. Scotto, New Brunswick, NJ; Gerardo Colon-Otero, Jacksonville, FL; Sheila Kumari Singh, Hamilton, ON, Canada; Francesco Caiazza, San Francisco, CA

# Wednesday, April 10, 2024

**CME** **Plenary Session** • 8:00 a.m.-10:00 a.m.

Ballroom 20, Convention Center
**AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design**

**Chair:** Vivek Subbiah, Nashville, TN

**Introduction.** Vivek Subbiah, Nashville, TN

**AI in medical imaging, data science, and health disparities.** Maryellen L. Giger, Chicago, IL

**Integrating AI, radiology, and pathology for affordable and equitable precision medicine.** Anant Madabhushi, Atlanta, GA

**AI for precision drug development and discovery: Towards an end to end data-driven approach.** Thomas Clozel, Geneva, Switzerland

**Pan-tumor biomarker development and HRDsig.** Mia A. Levy, Cambridge, MA

**Wrap-up and opportunities for the future.** Vivek Subbiah, Nashville, TN

## Poster Sessions • 9:00 a.m.–12:30 p.m.
**NOT ELIGIBLE FOR CME CREDIT**

Halls A-F, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App

**Immunology**
Section 1      Immune Modulation by Viruses, Bacteria, Radiation, and Other Modalities
Section 2      Microbiome, Inflammation, and Cancer
Section 3      Targeted Immune Cell Engagers
Section 4      Vaccines, Antigens, and Antigen Presentation 2

**Tumor Biology**
Section 6        3D and Tissue Recombinant Models of Cancer
Section 7        Chemokines and Cytokines in Cancer
Section 8        Gene Expression Regulation in the Tumor Microenvironment
Section 9        Immune Cells in the Tumor Microenvironment 2
Section 10       Preclinical Studies of Cancer
Section 11       Tumor Evolution at Single Cell Resolution

**Molecular/Cellular Biology and Genetics**
Section 13       Cancer Cell Communication with the Tumor Microenvironment
Section 14       Elucidating Mechanisms of Oncogenic Action
Section 15       Epigenetic Profiling and Technology
Section 16       Genomics and Immunooncology
Section 17       Mitochondrial Function 1
Section 18       Modifications and Signaling to Cancer Drivers

**Chemistry**
Section 20       Proteomics and Mass Spectrometry 2

**Experimental and Molecular Therapeutics**
Section 22       DNA Damage and Repair
Section 23       Novel Antitumor Agents 6
Section 24       Pharmacology and Pharmacogenetics
Section 25       Reversal of Drug Resistance 2
Section 26       Targeted, Combination, and Differentiation Therapies
Section 27       Vector Systems, Oncolytic Virotherapy, and Gene Therapy
Section 28       YAP/TAZ/TEAD Modulators
Section 54       Late-Breaking Research: Experimental and Molecular Therapeutics 4

**Prevention / Early Detection / Interception**
Section 30       Secondary and Tertiary Cancer Prevention Studies and Patient Communication
                 Decision Making

**Population Sciences**
Section 31       Genetic Epidemiology 2: Family Studies, Pathway Analysis, and Functional Genetics

**Bioinformatics / Computational Biology / Systems Biology / Convergent Science**
Section 33       Application of Bioinformatics to Cancer Biology 5
Section 34       Artificial Intelligence and Machine/Deep Learning 4
Section 35       New Software Tools for Data Analysis
Section 51       Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology,
                 and Convergent Science 3

**Clinical Research**
Section 39       Biologic and Behavioral Effects of Cancer and Oncology Treatment
Section 40       Cancer Immunity and Inflammation
Section 41       Circulating Tumor Cells 2
Section 42       Immune Checkpoint Inhibitor Therapy
Section 43       Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and
                 Gene Expression
Section 44       Other Targets
Section 45       Predictive Biomarkers 7
Section 46       Prognostic Biomarkers 2
Section 52       Late-Breaking Research: Clinical Research 3

## NCI-NIH-Sponsored Session • 10:15 a.m.-11:15 a.m.
**NOT ELIGIBLE FOR CME CREDIT**

Room 2, Convention Center
**NCI Artificial Intelligence (AI) Programs and Resources for Advancing Cancer Research**

**Moderator**: Jennifer Couch, Rockville, MD

**Introduction.** Jennifer Couch, Rockville, MD

**Opportunities for advancing cancer research with AI.** Juli Klemm, Rockville, MD

**FAIR resources to democratize cancer AI research.** Emily J. Greenspan, Bethesda, MD

**Towards a learning, sharing community to support safe and effective AI research in oncology.** Christopher Gibbons, Houston, TX

## CME Advances in Hematologic Malignancies • 10:15 a.m.-11:45 a.m.

Room 33, Convention Center
**Understanding the Mechanisms of Resistance to Immunotherapeutic Approaches in Multiple Myeloma**

**Chair:** Paola Neri, Calgary, AB, Canada

**Chair Introduction.** Paola Neri, Calgary, AB, Canada

**Causes of resistance to immunomodulatory drugs in myeloma.** Bruno Paiva, Pamplona, Spain

**Mechanisms of resistance to CAR-T therapies in myeloma.** Eric L. Smith, Boston, MA

**Escape mechanisms associated to T-cell engagers in myeloma.** Paola Neri, Calgary, AB, Canada

## CME Advances in Organ Site Research • 10:15 a.m.-11:45 a.m.

Room 15, Convention Center
**Androgen Receptor as a Pro-Differentiation and Oncogenic Transcription Factor in Prostate Cancer**

**Chair:** Remi M. Adelaiye-Ogala, Buffalo, NY

**Chair Introduction.** Remi M. Adelaiye-Ogala, Buffalo, NY

**Rapid evolution of AR gene alterations in castration-resistant prostate cancer.** Scott M. Dehm, Minneapolis, MN

**NG09   NSD2 is a druggable subunit of the AR neo-enhanceosome in prostate cancer.** Abhijit Parolia, Ann Arbor, MI

**Emerging role of MECOM on AR activity in treatment-resistant prostate cancer.** Remi M. Adelaiye-Ogala, Buffalo, NY

## CME Advances in Prevention Research • 10:15 a.m.-11:45 a.m.

Room 29, Convention Center
**Application of Precision Medicine to Cancer Prevention**

**Chair:** Adetunji T. Toriola, St. Louis, MO

**Chair Introduction.** Adetunji T. Toriola, St. Louis, MO

**The promise of RANKL inhibition in breast cancer prevention in premenopausal women with dense breasts.** Adetunji T. Toriola, St. Louis, MO

**Novel cancer chemoprevention strategies for women carrying pathogenic variants in the BRCA1 or BRCA2 gene.** Geoffrey J. Lindeman, Parkville VIC, Australia

**Tamoxifen and breast cancer prevention.** Marike A. Gabrielson, Stockholm, Sweden

**Progress and challenges in precision medicine for lung cancer prevention.** Meredith A. Tennis, Aurora, CO

## CME Major Symposia • 10:15 a.m.-11:45 a.m.

Room 17, Convention Center
**Biology and Treatment Strategies for IDH-mutant Cancers**

**Chair:** Daniel Schramek, Toronto, ON, Canada

**Introduction.** Daniel Schramek, Toronto, ON, Canada

**SY16-01   What IDH mouse models have taught us about hematological diseases, from leukemia to T cell lymphoma.** Julie Leca, Lyon, France

**The somatic and germline alterations associated with the development and progression of IDH-mutant gliomas.** Robert Brian Jenkins, Rochester, MN

**Elucidating the genetic alterations that predispose to the development and malignant progression of IDH-mutant glioma.** Daniel Schramek, Toronto, ON, Canada

Ballroom 6 B, Convention Center
**Cancer Metabolism Across Scales: From Organelles to Organisms**

**Chair:** Alec C. Kimmelman, New York, NY

**Introduction.** Alec C. Kimmelman, New York, NY

**Identifying metabolic dependencies in pancreatic cancer.** Alec C. Kimmelman, New York, NY

**SY35-02   Spatial mapping of mitochondrial networks in lung cancer.** David B. Shackelford, Los Angeles, CA

**Lysosome dependent metabolic adaptation in pancreatic cancer.** Rushika M. Perera, San Francisco, CA

Room 31, Convention Center
**Cellular Competition in Premalignancy and Cancer**

**Chair:** Eugenia Piddini, Bristol, United Kingdom

**Introduction.** Eugenia Piddini, Bristol, United Kingdom

**SY07-01   p53-mediated stem cell competition: Insights into mechanisms of clonal dominance.** Eugenia Piddini, Bristol, United Kingdom

**SY07-02   Cell competition vs cell cooperation: Unlocking oncogenic potential of mutant clones in the gut.** Sanne van Neerven, Cambridge, United Kingdom

**SY07-03   Cell competition shapes metastatic latency and relapse.** Srinivas Malladi, Dallas, TX

Room 14, Convention Center
**Dharma Master Jiantai Symposium in Biomarkers: Genomics-based Predictive Biomarkers for Radiotherapy and Radioimmunotherapy**

**Chair:** Jacob G. Scott, Cleveland, OH

**Introduction.** Jacob G. Scott, Cleveland, OH

**Bringing biology into radiation treatment planning: Genomics, heavy ions, pharmacokinetics and predictive mathematical models.** Jacob G. Scott, Cleveland, OH

**Genetic susceptibility to late bladder toxicity after radiotherapy for prostate cancer: Informing treatment planning and targetable pathways.** Sarah Kerns, Milwaukee, WI

**Biomarkers and correlates to predict response to radiation immunotherapy combination treatment.** Ravi B. Patel, Pittsburgh, PA

Ballroom 6 DE, Convention Center
**Emerging Induced Proximity Therapeutic Modalities**

**Chair:** Ryan Potts, Thousand Oaks, CA

**Introduction.** Ryan Potts, Thousand Oaks, CA

**Next generation drug discovery: Proximity-based therapeutics.** Ryan Potts, Thousand Oaks, CA

**Rewiring cancer drivers to activate pathways of programmed cell death.** Gerald R. Crabtree, Stanford, CA

**Interrogating the druggable proteome with induced proximity.** Fleur Ferguson, LaJolla, CA

Ballroom 6 A, Convention Center
**Engineering Strategies Based on NK, and gd T Cells and Their Receptors, and Macrophages**

**Chair:** Jürgen Kuball, Utrecht, Netherlands

**Introduction.** Jürgen Kuball, Utrecht, Netherlands

**Advancing cancer immunotherapy: The emerging role of engineered NK cells.** Katayoun Rezvani, Houston, TX

**SY45-02  Engineering strategies based on receptors derived from gdT cells.** Jürgen Kuball, Utrecht, Netherlands

**Engineering macrophages for cancer immunotherapy: CARs and beyond.** Michael Klichinsky, Philadelphia, PA

Room 30, Convention Center
**Genomic Instability and Metastasis: Dangerous Liaisons or Two Sides of the Same Coin?**

**Chair:** Phuoc T. Tran, Baltimore, MD

**Introduction.** Phuoc T. Tran, Baltimore, MD

**Chromosomal instability as a driver of cancer metastasis.** Samuel F. Bakhoum, New York, NY

**Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immunotherapy.** Sean Pitroda, Chicago, IL

**Chromosomal instability, cancer progression and treatment resistance.** Samra Turajlic, London, United Kingdom

Room 16, Convention Center
**Interventional Studies during Cancer Treatment to Improve Symptoms and Outcomes**

**Chair:** Jane C. Figueiredo, Los Angeles, CA

**Introduction.** Jane C. Figueiredo, Los Angeles, CA

**Exercise to increase treatment efficacy and reduce toxicity in early breast cancer.** Jennifer Ligibel, Boston, MA

**Methodological considerations: Examples from the FORCE trial of resistance training to reduce chemotoxicity in colon cancer.** Elizabeth M. Cespedes Feliciano, Oakland, CA

**Reducing toxicity and improving efficacy during treatment for cancer: Does what you eat or when you eat matter?** Jane C. Figueiredo, Los Angeles, CA

Ballroom 6 CF, Convention Center
**Novel Immune Checkpoints: Beyond PD1 and CTLA4**

**Chair:** J. Silvio Gutkind, La Jolla, CA

**Introduction.** J. Silvio Gutkind, La Jolla, CA

**Reimagining checkpoints and cancer immunotherapy.** Ira Mellman, South San Francisco, CA

**Harnessing B cells and tertiary lymphoid structures for improved immunotherapeutics.** Tullia C. Bruno, Pittsburgh, PA

**SY39-03   Illuminating the tumor immune GPCRome: Novel immunotherapy targets.** J. Silvio Gutkind, La Jolla, CA

Room 28, Convention Center
**Tumor Microbiome**

**Chair:** Marlies Meisel, Pittsburgh, PA

**Introduction.** Marlies Meisel, Pittsburgh, PA

**Exploring pro- and antitumor mechanisms of intratumoral microbes.** Marlies Meisel, Pittsburgh, PA

**Robustness of cancer microbiome signals over a broad range of methodological variation and their biological correlates.** Gregory Sepich-Poore, San Diego, CA

**Function of tumor resident microbes.** Florencia McAllister, Houston, TX

# **CME** Plenary Session • 12:15 p.m.-1:30 p.m.

Ballroom 20, Convention Center
**AACR Annual Meeting 2024 Highlights: Vision for the Future**

**Cochairs:** Keith T. Flaherty, Boston, MA; Christina Curtis, Stanford, CA

**Introductions.** Keith T. Flaherty, Boston, MA; Christina Curtis, Stanford, CA

**Basic cancer science and translational research.** Mikala Egeblad, Baltimore, MD

**Prevention, early detection, population sciences, and disparities research.** Melissa A. Simon, Chicago, IL

**Clinical research and clinical trials.** Ryan B. Corcoran, Boston, MA